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Angiogenesis is the formation of new blood vessels from pre-existing ones. 
Unregulated angiogenesis is associated with several diseases such as diabetic 
retinopathy and tumour growth. Many signal transduction pathways have been 
implicated in the regulation of angiogenesis such as p38 mitogen-activated 
protein kinase (MAPK), phosphatidylinositol-3 kinase (PI3K), extracellular 
signal-related kinase 1/2 (Erk1/2) and of particular interest the 
calcineurin/nuclear factor of activated T-cell (NFAT) pathway. Inhibition of 
calcineurin activity by the drug cyclopsorin A (CsA) has been shown to inhibit 
processes required for successful angiogenesis such as in vitro cell migration, 
tube formation and additionally attenuates corneal angiogenesis in vivo.  CsA is 
associated with severe side effects and therefore the identification of an 
endogenous regulator of this pathway would be beneficial. One possibility is the
plasma membrane calcium ATPases (PMCAs). These high affinity calcium 
extrusion pumps have been shown to interact with calcineurin in mammalian 
cells and cardiomyocytes and down-regulate the calcineurin/NFAT pathway. 
This is hypothesised to be due to the interaction between the two proteins which
maintains calcineurin in a low calcium micro-environment generated by the 
calcium removal function of the pump. Interestingly, PMCA4 has been shown to
interact with calcineurin in endothelial cells. 
The aim of our study was to further our understanding of PMCA4s regulation of 
the calcineurin/NFAT pathway specifically in endothelial cells and establish if 
PMCA4 has a role in the regulation of angiogenesis. ‘Gain of function’ by 
adenoviral over-expression of PMCA4 and ‘loss of function’ by either si-RNA 
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mediated knockdown of PMCA4 or isolation of PMCA4-/- MLEC were used as 
models. Over-expression of PMCA4 in HUVEC resulted in inhibition of the 
calcineurin/NFAT pathway with the opposite result occurring in the case of the 
knockout of PMCA4, identifying PMCA4 as a negative-regulator of the 
calcineurin/NFAT pathway in endothelial cells. Over-expression of PMCA4 
significantly attenuated VEGF-induced protein and mRNA expression of the 
pro-angiogenic proteins RCAN1.4 and Cox-2, endothelial cell migration and in 
vitro and in vivo tube formation with the opposite result occurring in knockdown 
or knockout studies, confirming PMCA4 as a down-regulator of angiogenesis. 
Interestingly, over-expression or knockdown of PMCA4 had no effect on VEGF-
induced HUVEC proliferation or Erk1/2 phopshorylation proposing PMCA4 may 
be a potential inhibitor of angiogenesis without compromising cell survival.
Disruption of the interaction between PMCA4 and calcineurin by generation and
ectopic expression of an adenovirus encoding the region of PMCA4 that 
interacts with calcineurin (428-651) (Ad-ID4) resulted in an increase in NFAT 
activity, RCAN1.4 protein expression and in vitro tube formation. These results 
identify the mechanism of PMCA4s inhibitory effect of the calcineurin/NFAT 
pathway and consequently angiogenesis is a result of the interaction between 
the two proteins.
The novel findings of this study establish PMCA4 as a negative-regulator of the 
calcineurin/NFAT pathway in endothelial cells and angiogenesis. These results 
are far reaching and highlight a potential role for PMCA4 as a therapeutic target
in a variety of diseases that are associated with pathological angiogenesis. 
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1. CHAPTER ONE
       Introduction
1
1.0 Introduction
A plethora of diseases involve unregulated angiogenesis for progression 
(Liekens et al, 2001; Carmeliet, 2005). Inhibition of angiogenesis by down-
regulation of the activity of pro-angiogenic molecules, such as vascular 
endothelial growth factor (VEGF), has been targeted as a treatment in a number
of pathologies such as tumour growth (Willet et al, 2004; Hurwitz et al, 2004) 
and retinopathies (Gragoudas et al, 2004; Rosenfeld et al, 2006). Successful 
angiogenesis requires several events (Liekens et al, 2001; Carmeliet, 2005). 
These are regulated by a variety of cellular signalling pathways that are 
activated in response to pro-angiogenic proteins, such as VEGF (reviewed in 
Takahashi and Shibuya, 2005), one of which is the calcineurin/ nuclear factor of
activated T cells (NFAT) signal transduction pathway (Hernández et al, 2001). 
Inhibition of calcineurin and consequently this pathway, by the drug cyclosporin 
A (CsA), results in down-regulation of angiogenesis both in vitro and in vivo 
(Hernández et al, 2001). However, several adverse effects have been reported 
with CsA treatment (Matrínez-Martínez and Redondo, 2004). Endogenous 
regulators of the calcineurin/NFAT pathway have also been identified including 
plasma membrane calcium ATPases (PMCAs) (Buch et al, 2005; Holton et al, 
2007; Wu et al, 2009). These calcium extrusion pumps have been reported to 
regulate the activity of a variety of interacting partner proteins (reviewed in Di 
Leva et al, 2008). Specifically, PMCA4 down-regulates calcineurin activity in 
HEK293 cells and cardiomyocytes (Buch et al, 2005; Wu et al, 2009). However, 
the role of PMCAs in the regulation of angiogenesis is unknown. An introduction
to angiogenesis, the calcineurin/NFAT pathway and PMCAs will be discussed 
further in this chapter. 
2
1.1 Angiogenesis
Angiogenesis is defined as the formation of blood vessels from pre-existing 
ones. It occurs both physiologically, during processes such as development and
wound healing where it is tightly regulated and pathologically, (Liekens et al, 
2001) being associated with over 70 diseases (Carmeliet, 2005) such as 
diabetic retinopathy, rheumatoid arthritis and tumour growth, where this process
becomes unregulated (Liekens et al, 2001). Alterations in the angiogenic 
phenotype, for example to pro-angiogenic or anti-angiogenic, are referred to as 
the ‘angiogenic switch’. This switch is turned on when pro-angiogenic signals 
such as hypoxia and pro-angiogenic growth factors exceed anti-angiogenic 
signals and is turned off in the reverse conditions (Bergers and Benjamin, 
2003). A multitude of pro- and anti-angiogenic factors have been identified to 
date (Table 1.1). Among them, vascular endothelial growth factor (VEGF) has 
emerged as a key regulator of both physiological and pathological angiogenesis
(Takahashi and Shibuya, 2005). 
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Successful embryonic development requires the formation of the vasculature for
the delivery of oxygen and nutrients required for growth (Patel-Hett and 
D’Amore, 2011). Vascularisation of the embryo occurs initially via a process 
termed vasculogenesis which generates the primary vascular network. 
Angiogenesis then modifies this initial network and extends from it by either 
intussusceptive or sprouting angiogenesis. Intussusception divides a pre-
existing vessel lumen into two by insertion of tissue. In comparison, sprouting 
involves endothelial cell migration, tube formation and proliferation and will be 
the focus of our study (Patan, 2000). In the embryo, angiogenesis is initiated by 
E9.5 days (Patel-Hett and D’Amore, 2011). Inhibition of angiogenesis in vivo 
prevents embryo growth due to attenuation of vascular formation and yolk sac 
development (Klauber et al, 1997). Additionally, the pro-angiogenic factor VEGF
has been identified as an essential signalling molecule in embryonic 
development as knockout of this protein leads to embryonic lethality (Carmeliet 
et al, 1996; Ferrara et al, 1996). 
1.1.1b Wound Healing
Wound healing is comprised of four sections; haemostasis, inflammation, 
proliferation and matrix formation and remodelling. Angiogenesis occurs in the 
proliferation phase (Greaves et al, 2013) which is between days 3 and 20 after 
wound occurrence (Bauer et al, 2005) and is essential for the delivery of oxygen
and nutrients to the wounded area, the restoration of capillaries that have been 
injured (Greaves et al, 2013) and the removal of debris from the site of injury 
(Nissen et al, 1998). Keratinocytes, platelets, macrophages, neutrophiles, 
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endothelial cells, fibroblasts and smooth muscle cells are all a source of VEGF 
in wound sites (Greaves et al, 2013) with the most significant signal of VEGF 
being between 3 and 7 days after initial wound occurrence (Nissen et al, 1998). 
Endothelial cells migrate into the wound site via tips of capillaries towards the 
VEGF signal which is produced due to the hypoxic conditions found in a wound 
(Greaves et al, 2013). 
1.1.1c Menstrual Cycle
The menstrual cycle is divided into three main stages; the menstruation phase, 
the proliferative phase and the secretory phase. Angiogenesis occurs in all 
three stages for the restoration of the remaining layer of the endometrium, the 
development and thickening of the endometrium and the growth and coiling of 
spiral arterioles to supply the functional layer of the endometrium respectively. 
(Demir et al, 2010; Maas et al, 2001; Shifren et al, 1996). Interestingly, the 
angiogenic potential, as measured by the vascular density index (VDI) was 
shown to be increased in human endometrial fragments from early proliferative 
and early and late secretory phases, suggesting a requirement for angiogenesis
at these specific time points in the menstrual cycle which correspond to periods 
of vessel growth (Maas et al, 2001). Furthermore, VEGF mRNA expression in 
human endometrium increased throughout the mid and late proliferative and 
secretory phases compared to the early proliferative phase, with the greatest 
expression detected in the secretory phase which is associated with the highest
angiogenic activity of the endometrium (Shifren et al, 1996).
1.1.2 Pathological Angiogenesis
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Pathological angiogenesis is the result of unregulated angiogenesis which is 
associated with a variety of diseases (Liekens et al, 2001). This can occur due 
to either insufficient or excessive angiogenesis (Carmeliet, 2005).
1.1.2a Insufficient Angiogenesis
1.1.2a(i) Limb Ischemia
Critical limb ischemia (CLI) is associated with peripheral artery disease (PAD) 
(Annex, 2013). It is the result of occlusion of arteries in the lower limbs, for 
example due to atherosclerosis, that impairs blood flow to the lower extremities 
consequently causing limb pain, ulcers, gangrene and in severe cases 
amputation (Annex, 2013). Therapeutic angiogenesis has been shown to 
alleviate the adverse effects of CLI as seen by an increase in collateral blood 
vessel formation and ulcer healing in CLI patients treated with intramuscular 
injection of plasmid DNA encoding VEGF-A165 (Baumgartner et al, 1998).
Diabetes mellitus has been reported to be a risk factor of CLI, (Annex, 2013). In 
a non-obese diabetic (NOD) limb ischemia mouse model, that is representative 
of type I (insulin dependent) diabetes, angiogenesis was shown to be reduced 
as a decrease in blood flow and capillary density were observed (Rivard et al, 
1999). Furthermore, wound healing is attenuated in diabetic mice compared to 
healthy mice, which was suggested to be due to a reduction in VEGF 
expression which was shown to be down-regulated in the phase of wound 
healing that requires angiogenesis (Frank et al, 1995).
1.1.2b Excessive Angiogenesis
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1.1.2b(i) Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is associated with two stages; a highly inflammatory 
phase and a vascular phase (Marrelli et al, 2011) with the severity of the 
disease positively correlated with increasing levels of VEGF (Sone et al, 
2001b). In RA there is hyperplasia of the synovium resulting in an increase in 
mass (Maruotti et al, 2006) generating a hypoxic environment that leads to an 
increase in VEGF expression and a concomitant up-regulation of angiogenesis 
(Paleolog, 2002). Synovial fluid and inflammation is also increased and 
consequently leads to joint pain and swelling (Maruotti et al, 2006). A highly 
vascularised pannus is formed that damages cartilage and bone and leads to 
joint destruction (Maruotti et al, 2006; Paleolog, 2002). Angiogenesis not only 
transports oxygen and nutrients required for the proliferation of synovial cells, 
but also localises inflammatory cells leading to inflammation of the synovium 
(Marrelli et al, 2011).
1.1.2b(ii) Psoriasis
Psoriasis is a chronic inflammatory disorder of the skin resulting in a 
hyperplastic epidermis, increased angiogenesis, generation of an immune 
response and localisation of inflammatory cells such as macrophages to this 
site (Singh et al, 2013). In particular microvessels of the papillary dermis have 
increased permeability, are elongated and dilated. VEGF and VEGF receptors 
VEGFR-1 and 2 were shown to be over-expressed in biopsies of psoriatic skin 
compared to control patients especially in the hyperplastic epidermis. It is 
proposed angiogenesis is augmented in this condition to cope with the 
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increased demand of oxygen and nutrients at hyperplastic sites (Detmar et al, 
1994).
1.1.2b(iii) Retinopathies 
Angiogenesis has been implicated in the progression of a number of 
retinopathies. An increase in VEGF levels in the ocular fluid has been reported 
in retinopathies with neovascularisation. Furthermore, treatments that reduce 
neovascularisation such as photocoagulation also reduce levels of VEGF (Aiello
et al, 1994).
Neovascular (wet) age-related macular degeneration (AMD) is most prevalent in
the elderly and causes irreversible sight loss (Zhou and Wang, 2006). Choroidal
neovascularisation in wet AMD is the result of abnormal blood vessel growth 
into the retina (Kourlas and Abrams, 2007; Zhou and Wang, 2006) that results 
in leaking and haemorrhaging of the retina and potentially retinal pigment 
epithelium (RPE) detachment (Kourlas and Abrams, 2007). Specifically in rats, 
increases in choroidal blood vessel growth, vascular leakage and retina 
degeneration were observed in the presence of ectopic expression of VEGF in 
the RPE (Spilsbury et al, 2000). 
Diabetic retinopathy is a severe complication associated with diabetes. 
Proliferative diabetic retinopathy (PDR) displays as macular ischemia and 
oedema and neovascularisation of the retina resulting in haemorrhage, 
glaucoma and in severe cases retinal detachment and vision loss (Cheung et al,
2010). VEGF expression is increased in retinal endothelial cells and pericytes 
due to hypoxic conditions within the eye, resulting in an increase in 
angiogenesis and enhancement of the permeability of capillaries (Cheung et al, 
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2010). Specifically, in patients with PDR, levels of VEGF in the vitreous have 
been reported to be increased in comparison to non-PDR patients (Adamis et 
al, 1994).
1.1.2b(iv) Endometriosis
Endometriosis is the presence and growth of the endometrium at locations 
outside of the uterus such as the ovaries and abdominal cavity. It occurs when 
the lining of the uterus (endometrium) sheds during menstruation (Hull et al, 
2003). Angiogenesis at these ectopic sites leads to the development of a 
vascular supply and growth of these lesions which results in a pathological 
phenotype (Hull et al, 2003). Levels of VEGF expression in the peritoneal fluid 
of women correlate with the severity of the disease (Shifren et al, 1996). 
1.1.2b(v) Tumour Angiogenesis
When a tumour reaches 1-2mm it requires an enhanced supply of nutrients 
(Bergers and Benjamin, 2003). Angiogenesis generates new vessels to supply 
the tumour with oxygen and nutrients to maintain its survival (Papetti and 
Herman, 2002) and is involved in the metastatic spread of tumours (Jain, 2005).
Pathological tumour angiogenesis differs from physiological angiogenesis as 
the blood vessels formed are abnormal. Tumour vessels are leaky, 
disorganised (Jain, 2005), dilated and often have dead ends resulting in a 
reduced blood flow (Bergers and Benjamin, 2003). Pericyte attachment is 
significantly reduced resulting in disruption of vessel diameter (Bergers and 
Benjamin, 2003). Growth and proliferation of the tumours results in additional 
pressure onto the vasculature which constricts them, consequently inhibiting 
blood flow into tumours and increasing the hypoxic environment (Jain, 2005). 
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Furthermore, an increase in VEGF expression is associated with augmentation 
of microvessel density and a decrease in the relapse free survival rate of 
patients compared to tumours with less VEGF (Toi et al, 1994).
1.1.3 Processes Required for Successful Angiogenesis
Angiogenesis is a highly complex process (Liekens et al, 2001) consisting of 
several events such as basement membrane break down, migration and tube 
formation (Fig. 1.1.1) (Carmeliet, 2000). 
1.1.3a Basement Membrane Degradation
In response to pro-angiogenic factors, pericytes or smooth muscle cells are 
removed from the existing vessel (Papetti and Herman, 2002) which results in 
their destabilisation (Carmeliet, 2000), allowing endothelial cells to respond to 
environmental factors (Liekens et al, 2001). In an environment favouring 
angiogenesis initiation, endothelial cells release proteases such as plasmin and 
matrix metalloproteinases (MMPs) in response to pro-angiogenic signals to 
degrade the basement membrane. (Liekens et al, 2001). 
1.1.3b Cell Migration and Proliferation
The degradation of the basement membrane allows the migration of endothelial 
cells out of the existing blood vessel into the surrounding tissue (Fig 1.1.1) and 
releases pro-angiogenic factors associated to the extracellular matrix (ECM) 
which can activate the proliferation of endothelial cells (Liekens et al, 2001; 
Conway et al, 2001). The loss of cell-cell and cell-ECM interactions is also 
required for the successful migration of endothelial cells across the opened 
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basement membrane. Proliferating cells follow the migrating cells to form solid 
tubes (Liekens et al, 2001). 
1.1.3c Tube Formation
Functional tubes are generated by the formation of a lumen in the migrated 
endothelial cells that have formed tubular like structures. This process occurs 
by the thinning of endothelial cells and involves a variety of growth factors and 
proteins (Conway et al, 2001). Even though new blood vessels have been 
generated they are still termed ‘immature’ as they require stabilisation via 
interaction with the ECM (Liekens et al, 2001) or the recruitment of pericyte or 
smooth muscle cells to the vessel wall (Carmeliet, 2000).
1.1.3d Recruitment of Pericyte and Smooth Muscle Cells
The final stage of angiogenesis is the recruitment of pericytes or smooth muscle
cells to the newly formed blood vessel to construct a mature, functional vessel 
(Fig 1.1.1) (Carmeliet, 2000). These peri-endothelial cells regulate the vessel 
diameter and increase the contacts between endothelial cells. They play a part 
in the formation of the basement membrane and generate proteins of the ECM 
(Bauer et al, 2005). Additionally, they also act to prevent any further cell 
proliferation, migration or vascular permeability, regulate blood flow and inhibit 
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Fig. 1.1.1 Mechanisms required for successful angiogenesis (adapted from 
Nguyen et al, 2001; Bergers and Benjamin, 2003). The first step of angiogenesis 
involves the removal of pericytes or smooth muscle cells from the vessel. In response 
to a pro-angiogenic stimulus, such as VEGF, endothelial cells release proteases that 
degrade the basement membrane allowing endothelial cell migration towards the signal
along with cell proliferation. Tubes are formed when the migrated endothelial cells 
develop a lumen and functional vessels occur with the recruitment of pericyte or 
smooth muscle cells which enhance the stability of the vessel.
1.1.4 Activators of Angiogenesis
There are a plethora of pro-angiogenic molecules (Table 1.1) that act directly on
endothelial cells or on other target cells to initiate and sustain angiogenesis 
(Liekens et al, 2001). Of particular interest is VEGF which is a potent inducer of 
angiogenesis (Ferrara et al, 2003) and for that reason it was selected as a 
stimulator of angiogenesis in our experiments and will be more extensively 
reviewed here.
1.1.4a The Vascular Endothelial Growth Factor Protein 
Family
VEGF represents a protein family that includes several proteins such as VEGF-
A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, svVEGF (snake venom VEGF) and 
PlGF (placental growth factor). They vary in their tissue distribution, interaction 
with receptor tyrosine kinases and in their overall effect during development and
processes such as angiogenesis. Of particular interest is VEGF-A which acts on
endothelial cells and is implicated in both physiological and pathological 
angiogenesis (Takahashi and Shibuya, 2005). 
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1.1.4a(i) VEGF-A
VEGF-A, located at chromosomal position 6p21.3, is composed of 7 introns and
8 exons. Alternative splicing generates nine isoforms (Fig. 1.1.2) including; 
VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-A165, VEGF-A183, VEGF-
A189, VEGF-A206 and also the anti-angiogenic isoform VEGF-A165b which 
competes for binding to the receptor. The isoform number denotes the number 
of amino acids (Ferrara et al, 2003).  VEGF-A165 is classed as the predominant 
isoform (Liekens et al, 2001). This splice variant is the result of the removal of 
residues within exon 6 (Fig. 1.1.2) (Ferrara et al, 2003). It binds to and signals 
through the VEGF receptor tyrosine kinases VEGFR-1 and VEGFR-2 
(Takahashi and Shibuya, 2005). In addition to its pro-angiogenic activity, 
VEGF165 has also been reported to increase vascular permeability, induce 
vessel dilation and act as an inhibitor of apoptosis (Ferrara et al, 2003).
In embryonic stem cells, inactivation of one or both alleles of VEGF-A, results in
abnormal blood vessel development and embryonic fatality at approximately 
10.5 days after coitum respectively. Loss of VEGF prevents correct 
vasculogenesis, angiogenesis and lumen formation (Carmeliet et al, 1996). 
Likewise, Ferrara et al, 1996 reported heterozygous knockout of VEGF-A 
resulted in embryonic lethality around days 11-12 with an increase in apoptosis 
at day E11.5, insufficient blood supply to the yolk sak and abnormalities in 
development of the brain, heart and vasculature of other organs and tissues 
(Ferrara et al, 1996). 
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Fig.1.1.2 Schematic diagram of the VEGF-A splice variants (adapted from 
Takahashi and Shibuya, 2005). VEGF-A is composed of seven introns and eight 
exons. Alternative splicing of this primary transcript generates nine isoforms; VEGF-
A121, VEGF-A145, VEGF-A148, VEGF-A162, VEGF-A165, VEGF-A183, VEGF-A189, VEGF-A206 
and also the anti-angiogenic isoform VEGF-A165b. The predominant isoform and the one
implicated in the stimulation of angiogenesis is VEGF-A165 which has exon 6 removed.
1.1.4b VEGF Receptors 
The VEGF receptors (VEGFR) are predominantly found on endothelial cells 
(Takahashi and Shibuya, 2005). Two main receptors are involved in VEGF-A 
signalling; VEGFR-1(Flt-1) and VEGFR-2 (Flk-1/KDR in mouse and human 
respectively) whose structures consist of an extracellular domain containing 
seven immunoglobulin (Ig) like domains, one transmembrane domain and a 
cytoplasmic tyrosine kinase domain (Takahashi and Shibuya, 2005; Ferrara et 
al, 2003). They are activated in response to VEGF binding which results in 
receptor dimerisation and auto-phosphorylation (Schlessinger, 2000). 
1.1.4b(i) VEGFR-1 (Flt-1)
The VEGFR-1 is a 180 kDa protein. Interestingly, it has a higher affinity for 
VEGF-A by up to 10 fold compared to VEGFR-2 although VEGFR-2 is the main 
receptor involved in angiogenic processes (Takahashi and Shibuya, 2005). It is 
hypothesised that VEGFR-1 acts as a ‘decoy receptor’ preventing VEGF from 
binding and signalling through VEGFR-2 (Ferrara et al, 2003) although it has 
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been shown a monoclonal antibody against VEGFR-1 (KM1750) inhibits 
receptor binding to VEGF and down-regulates VEGF-induced migration of 
human umbilibal vein endothelial cells (HUVEC) (Kanno et al, 2000). 
The role of VEGFR-1has been identified by use of knockout studies. Mutation of
the Flt-1 gene in the mouse embryo does not affect the formation or proliferation
of endothelial cells but does affect their ability to form functional channels 
resulting in embryonic death at roughly E8.5 days. The yolk sac contains no 
regulated vascular network and disrupted blood island structures are observed. 
Therefore this receptor is essential for vascularisation of the embryo (Fong et al,
1995).
1.1.4b(ii) VEGFR-2 (KDR/Flk-1)
The VEGFR-2 is a 200-230 kDa protein and is proposed to be the main 
receptor involved in VEGF-induced angiogenesis (Takahashi and Shibuya, 
2005). Binding of VEGF-A to VEGFR-2 results in migration of HUVEC, DNA 
synthesis and extracellular signal-related kinase (Erk) activation (Kanno et al, 
2000). 
Interestingly, in the case of the knockout of Flk-1 a similar phenotype was 
observed to that seen for Flt-1 in that there was no organised blood vessels in 
the yolk sac or blood island formation and embryonic death occurred between 
days E8.5-9.5. Additionally, an increase in necrosis is observed and endothelial 
cells do not form correctly. Therefore, Flk-1 is also essential for vascularisation 
of the embryo in early development (Shalaby et al, 1995).
1.1.5 Anti-Angiogenic Therapies
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Given the relevance of VEGF in the angiogenic processes associated to human
diseases, it is not surprising that several therapeutic strategies have been 
developed to suppress the action of VEGF on these pathologies. This can be 
the result of preventing the VEGF/VEGFR interaction or by attenuating receptor 
activation. All have potential therapeutic benefits but are also associated with 
adverse effects on the patient (Gotink and Verheul, 2010; Kamba and 




Bevacizumab was the first anti-angiogenic drug to be used therapeutically (Shih
and Lindley, 2006). It was approved by the Food and Drug Administration (FDA)
in 2004 for metastatic colorectal cancer treatment. It is a humanised monoclonal
antibody and has a half-life of 17-21 days (Ferrara et al, 2004). It binds to all 
isoforms of VEGF-A and inhibits its activity by preventing VEGF interacting with 
its receptors, VEGFR-1 and VEGFR-2 (Shih and Lindley, 2006). Bevacizumab 
has been associated with several side effects including impaired wound healing 
and proteinuria, with the most severe side effect being hypertension (Shih and 
Lindley, 2006; Hurwitz et al, 2004). Hypertension is thought to be the result of 
attenuation of nitric oxide (NO) production via endothelial nitric oxide synthase 
(eNOS) due to VEGF inhibition causing vasoconstriction and consequently an 
increase in blood pressure (Kamba and McDonald, 2007). It has been proposed
the long half-life of bevacizumab may potentiate the adverse side effects 
associated with this therapy (Pieramici and Rabena, 2008). Treatment of 
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patients presenting rectal carcinomas using bevacizumab combined with 5-
fluorouracil and radiation therapy resulted in a reduction in blood volume, 
interstitial fluid pressure and micro-vascular density of tumours (Willet et al, 
2004). Co-treatment of bevacizumab with the chemotherapeutic agents 
irinotecan, fluorouracil and leucovorin (IFL) increased the median survival time 
of patients with metastatic colorectal cancer by up to 4.7 months compared to 
IFL treatment alone (Hurwitz et al, 2004).
 
1.1.5a(ii) Pegaptanib (Macugen®, EYE001, NX1838)
Pegaptanib is an RNA aptamer composed of 28 bases (Zhou and Wang, 2006) 
that binds and inhibits the function of VEGF-A165 by preventing its interaction 
with VEGFR-2 (Pieramici and Rabena, 2008). It was approved by the FDA in 
2004 for the treatment of wet AMD. This inhibitor is engineered to bind VEGF-
A165 with high affinity (Zhou and Wang, 2006) and is more stable due to 
resilience against nucleases (Gragoudas et al, 2004). Interestingly, in a rat 
model of proliferative retinopathy, pegaptanib treatment which inhibits rat 
VEGF-A164 (the equivalent isoform to human VEGF-A165) attenuated pathological
but not physiological neovascularisation, whereas inhibition of all VEGF 
isoforms reduced neovascularisation in both cases highlighting an 
advantageous role of isoform specific inhibition (Ishida et al, 2003). Pegaptanib 
treatment in patients displaying AMD resulted in reduced vessel permeability, 
reduced leakage, neovascularisation and a decrease in the size of the lesion 
(Gragoudas et al, 2004). Additionally, pegaptanib attenuated the loss of visual 
acuity and in some cases maintained or increased the visual acuity of patients 
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with AMD compared to those receiving sham injections (Gragoudas et al, 2004).
It has been proposed its specificity for VEGF-A165 compared to all VEGF-A 
isoforms results in reduced efficacy of this treatment (Pieramici and Rabena, 
2008) although side effects associated to this drug are highly reduced (Zhou 
and Wang, 2006). In fact, the majority of adverse effects are associated with the
injection process rather than the drug itself, for example endophthalmitis, an 
intraocular infection that can lead to vision loss, occurred in a number of 
patients (Gragoudas et al, 2004). 
1.1.5a(iii) Ranibizumab (Lucentis®) 
Ranibizumab is a 48 kDa humanised monoclonal antibody also used for the 
treatment of AMD that was approved by the FDA in 2006. Unlike pegaptanib it 
binds all isoforms of VEGF-A, inhibiting their activity by blocking the 
VEGF/VEGFR interaction and the initiation of intracellular signalling (Kourlas 
and Abrams, 2007). It is generated using the Fab fragment from bevacizumab 
and has an approximately 20 times increase in VEGF binding affinity compared 
to bevacizumab (Pieramici and Rabena, 2008). Additionally, ranibizumab is 
smaller in size compared to bevacizumab and therefore penetrates better in 
tissue (Pieramici and Rabena, 2008). Clinical trials of ranibizumab for the 
treatment of neovascular AMD resulted in a reduction of the loss of visual acuity
compared to the sham treated control patients. Interestingly, visual acuity was 
shown to be increased in patients treated with ranibizumab for 1 year which was
associated with reduced growth and leakage from choroidal neovascularisation.
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Few adverse effects were observed in the ranibizumab treated group compared
to sham with the most severe being endophthalmitis (Rosenfeld et al, 2006). 
1.1.5a(iv) VEGF-Trap
VEGF-Trap also acts as an inhibitor of VEGF by preventing its interaction with 
VEGFR. It has the highest affinity for VEGF out of the inhibitors (Chang et al, 
2012; Holash et al, 2002) as it is composed of the second and third Ig domains 
of VEGFR-1 and VEGFR-2 respectively (which are the regions of the receptor 
involved in VEGF binding in each case) combined with a human IgG Fc 
fragment and therefore acts as a decoy receptor (Holash et al, 2002). Due to its 
small size it is proposed to improve its penetration in tissues (Pieramici and 
Rabena, 2008). It interacts with all isoforms of VEGF-A and additionally 
placental growth factor (PlGF) -1 and 2, suggesting it has the potential to be a 
strong anti-angiogenic molecule by inhibiting two stimulators of angiogenesis. 
Additionally, VEGF-Trap has been shown to have a long half-life after injection 
into the eye (Chang et al, 2012). VEGF- Trap treatment in patients with 
neovascular AMD results in reduced lesion size and choroidal 
neovascularisation and significantly improves visual acuity. Adverse effects 
observed are conjunctival hemorrhage associated with the injection procedure 
and increases in intraocular pressure and uveitis. Systemic side effects such as 
bronchitis and infection of the upper respiratory and urinary tract were also 
reported (Heier et al, 2011). It is proposed the high affinity of VEGF-Trap for 
VEGF will result advantageously in longer intervals between required 
treatments and therefore may reduce adverse effects associated with the 
administration of this treatment (Heier et al, 2011).
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1.1.5b VEGFR Inhibitors
VEGFR inhibitors can either be monoclonal antibodies (Casanovas et al, 2005) 
which bind to the surface of the receptor or receptor tyrosine kinase inhibitors 
such as small molecule inhibitors, which can pass through the membrane and 
bind to cytosolic regions of the receptor, either at the ATP binding site or near to
it, preventing both ATP binding and activation of signalling (Gotink and Verheul, 
2010).
1.1.5b(i) Sunitinib (Sutent®, SU11248)
Sunitinib was FDA approved in 2006 (Faivre et al, 2007). It is a small molecule 
inhibitor that binds directly to the ATP binding site inhibiting ATP interaction and
preventing receptor activation (Gotink and Verheul, 2010). It inhibits VEGFR-1,2
and 3 and additionally the platelet-derived growth factor receptor (PDGFR) 
(Faivre et al, 2007). Administration of sunitinib has been reported to reduce 
significantly the growth and microvessel density of several kinds of tumours in 
animal models of cancer or clinical trials of human patients (Mendel et al, 2003; 
Motzer et al, 2006). Unfortunately, this molecule is associated with a number of 
side effects including, diarrhea, vomiting, fatigue, hypertension and hand-foot 
syndrome (delicate skin on the hands and feet that can blister and peel in 
severe cases) although it was reported these were manageable and ended 
upon completion of treatment (Faivre et al, 2007). Additionally, due to being a 
small molecule inhibitor it has a short half-life and therefore it is proposed the 
rate of recovery of adverse effects will be quicker (Kamba and McDonald, 
2007).
1.1.5b(ii) Sorafenib (Nexavar®, Bay 43-9006)
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Sorafenib, approved in 2005 by the FDA for the treatment of renal cell 
carcinoma (RCC) (Wilhelm et al, 2006), is a small molecule inhibitor that binds 
to the intracellular region of the VEGFR. It binds at a site next to the ATP 
binding site altering its conformation and preventing receptor interaction with 
ATP and signal transduction activation (Gotink and Verheul, 2010; Wilhelm et 
al, 2006). As in the case of other receptor inhibitors, animal models and clinical 
trials in human patients have demonstrated the efficiency of sorafenib in 
reduction of tumour growth and microvessel density (Wilhelm et al, 2004; Ratain
et al, 2006). Side effects were observed such as fatigue, hand-foot syndrome 
and diarrhea which could be alleviated by dose reduction. The most severe side
effect was hypertension which could be controlled by the use of anti-
hypertensive drugs (Ratain et al, 2006). As sorafenib is also a small molecule 
inhibitor it is suggested the recovery rate of adverse effects will be faster due to 
a shorter half-life as proposed for sunitinib (Kamba and McDonald, 2007).
1.1.5b(iii) IMC-1121b (Ramucirumab) 
The monoclonal antibody ramucirumab is an anti-VEGFR antibody. It binds to 
VEGFR-2 preventing all isoforms of VEGF interacting with this receptor 
(Spratlin et al, 2010). Ramucirumab treatment of patients with advanced solid 
malignancies resulted in reduced perfusion and vascularity of tumours although 
adverse effects such as hypertension, proteinuria, abdominal pain, headaches, 
deep vein thrombosis (DVT) and vomiting were observed (Spratlin et al, 2010).  
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1.1.6 Problems Derived From Current Anti-Angiogenic Therapies
1.1.6a Resistance to Angiogenic Inhibitors
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 It was initially thought that anti-angiogenic inhibitors would result in reduced 
resistance to treatment as they act on the genetically stable endothelial cells 
rather than tumour cells which can readily mutate and adapt to therapy (Rosen, 
2000). However, it has been shown in a mouse model of islet cell 
carcinogenesis, prolonged inhibiton of VEGFR-2 signalling results in an 
increase in the expression of pro-angiogenic proteins such as fibroblast growth 
factor (FGF) and loss of intital regression of tumour growth suggesting 
resistance to angiogenic inhibitors can occur due to an increase in pro-
angiogenic molecules and signalling via alternative pathways (Casanovas et al, 
2005). Additionally, some treatments may lead to an increase in expression of 
both VEGF and its receptors, therefore upon the termination of the anti-
angiogenic treatment, tumour growth can reoccur as angiogenesis will be 
activated once again (Verheul and Pinedo, 2007).
1.1.6b Combined Therapy
Originally chemotherapy and radiotherapy were the main treatments for 
tumours. However, severe side effects were seen with these treatments as they
do not differentiate between tumoural and non-tumoural cells (Wilhelm et al, 
2006). Due to this, combination therapy of these treatments with anti-angiogenic
compounds was proposed. It is hypothesised drug delivery to the tumour will be
improved in the presence of angiogenic inhibitors as the interstitial pressure 
within the tumour will be reduced and the vasculature will return to a normalized
state that is no longer permeable. Both the tumoural cells and the endothelial 
cells that respond to the pro-angiogenic signals released from the tumour are 
targeted in this form of treatment by chemotherapy/radiotherapy and anti-
angiogenic compounds respectively (Jain, 2001). The benefit of combined 
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therapy has now been shown in the treatment of metastatic colorectal cancer. In
patients treated with the IFL, the addition of bevacizumab resulted in an 
increase in the median overall survival, the median length of progression free 
survival and the one year survival rate which correlated with a reduction of up to
34% of the likelihood of death compared to the placebo group (Hurwitz et al, 
2004). 
1.1.7 VEGF Signalling Pathways in Angiogenesis
VEGF signals through a variety of cellular pathways involved in various aspects 
of angiogenic processes and is therefore a very diverse stimulus (Fig. 1.1.3) 
(Takahashi and Shibuya, 2005). 
1.1.7a p38 Mitogen-Activated Protein Kinase (MAPK)
There are four isoforms of the p38 MAPK including β, α, γ and δ which belong 
to the MAPK family. This protein becomes activated when phosphorylated by 
MAP/Erk Kinase Kinase (MEK) 3 and 6 (McMullen et al, 2005). The 
predominant isoform activated in endothelial cells in response to MEK6 
activation was found to be p38α (McMullen et al, 2005). Furthermore, p38 
MAPK phosphorylation and activation was shown to be upregulated in HUVEC 
in response to VEGF-stimulation and its activity was shown to inhibit endothelial
cell proliferation (Yu and Sato, 1999) via inhibiton of Erk activity and increased 
cell migration via activation of its substrate, heat shock protein 27 (Hsp27) (Fig. 
1.1.3) (McMullen et al, 2005). 
1.1.7b Extracellular Signal-Related Kinase (Erk) Pathway
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Erk1/2 is a serine/threonine kinase also known as p44/p42 MAPK. This 
signalling pathway is a kinase cascade (Meloche and Pouysségur, 2007). 
Initially, Ras is activated by receptor stimulation and phosphorylates the MAP 
kinase kinase kinase (MAPKKK) Raf. Raf then activates the MAP kinase kinase
(MAPKK) MEK1/2 which consequently phosphorylates threonine and tyrosine 
residues on the MAP kinase (MAPK) Erk1/2 and increases its activity (Meloche 
and Pouysségur, 2007). Specifically, phosphorylation and activation of Erk1/2 
by VEGF has been reported to promote HUVEC proliferation (Yu and Sato, 
1999; Meadows et al, 2001) and cell survival of Human Dermal Microvascular 
Endothelial Cells (HDMEC) by preventing apoptosis (Fig. 1.1.3) (Gupta et al, 
1999). 
1.1.7c Phosphatidylinositol-3 Kinase (PI3K)
The PI3K pathway is involved in the activation of p70 S6 kinase and 
consequently the proliferation of HUVEC in response to VEGF-signalling (Yu 
and Sato, 1999). Additonally, the serine/threonine kinase Akt is also activated 
by PI3K in VEGF-induced HUVEC which enhances cell survival (Fujio and 
Walsh, 1999) (Fig. 1.1.3).
1.1.7d Phospholipase C-γ (PLC-γ)
VEGF stimulation of VEGFR-2 activates PLC-γ activity which in turn results in 
the production of Inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) 
from the hydrolysis of phosphatidylinositol (4,5)-bisphosphate (PIP2) (Holmes et
al, 2010). DAG and IP3 activate the protein kinase C (PKC) (Holmes et al, 2010)
and the calcineurin/nuclear factor of activated T-cells (NFAT) pathways 
respectively (Crabtree and Olson, 2002).
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1.1.7d(i) Protein Kinase C (PKC)
Stimulation of bovine aortic endothelial cells (BAEC) with VEGF has been 
reported to increase PKC activity which is accompanied by a shift in its 
localisation from the cytosol to the membrane. VEGF-dependent activation of 
PKC signalling has been shown to play a role in endothelial cell proliferation 
and survival (Xia et al, 1996) (Fig. 1.1.3).
1.1.7d(ii) Calcineurin/NFAT 
Calcineurin is a serine/threonine protein phosphatase that is activated by 
calmodulin in a calcium dependent manner (Li et al, 2011). Activated calcineurin
consequently dephosphorylates NFAT resulting in its translocation from the 
cytoplasm to the nucleus where it binds to DNA and activates the transcription 
of target genes (Crabtree and Olson, 2002). The calcineurin/NFAT pathway has
been shown to regulate angiogenesis in endothelial cells in response to VEGF-
stimulation (Hernández et al, 2001) (Fig. 1.1.3) and will be discussed 
extensively in section 1.2.6. 
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Fig. 1.1.3 VEGF-induced signalling pathways involved in angiogenesis (adapted 
from Takahashi and Shibuya, 2005). VEGF/VEGFR interaction stimulates a variety of
signalling pathways required for successful angiogenesis including the 
phosphatidylinositol-3 kinase (PI3K) pathway that activates both Akt and P70 S6 
kinase required for cell survival and proliferation respectively. The phospholipase C-γ 
(PLCγ) pathway activates the production of Inositol 1,4,5-trisphosphate (IP3) and 
Diacylglycerol (DAG) which stimulate the calcineurin/nuclear factor of activated T cell 
(NFAT) pathway and protein kinase C (PKC) pathway respectively consequently 
increasing gene transcription and proliferation. Erk1/2, required for cell proliferation, is 
activated via the Ras/Raf/MEK pathway is also activated by PKC but is inhibited by p38
mitogen activated protein kinase (p38MAPK). P38MAPK as well as inhibiting cell 
proliferation has been reported to increase cell migration.
1.2 The Calcineurin/NFAT Pathway
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The calcineurin/NFAT pathway converts calcium signalling into the expression 
of target genes (Li et al, 2011) which are required in a variety of cellular events 
such as the immune response (Crabtree and Olson, 2002) and angiogenesis 
(Iizuka et al, 2004; Hernández et al, 2001). Specifically, activation of this 
signalling pathway in HUVEC has been shown to occur in response to VEGF-
signalling (Armesilla et al, 1999).
1.2.1 Calcineurin
Calcineurin (Cn), also referred to as protein phosphatase2B (PP-2B), is a 
serine/threonine phosphatase of approximately 80 kDa (Klee et al, 1998) that 
has been shown to have an important role in diverse biological processes such 
as regulation of the immune response (Clipstone and Crabtree, 1992), 
apoptosis (Klee et al, 1998) and angiogenesis (Hernández et al, 2001).
Calcineurin is a heterodimer composed of a catalytic A and a regulatory B 
subunit of approximately 60 kDa and 20 kDa respectively. The A subunit is 
further subdivided into a catalytic domain and a regulatory region which is 
composed of a calcineurin B binding region, calmodulin binding domain and an 
auto-inhibitory domain running from N-terminal to C-terminal respectively (Fig. 
1.2.1) (Li et al, 2011).  
Calcineurin A (Cn A) is encoded by three genes which generates three 
isoforms; Cn Aα, Cn Aβ and Cn Aγ. They vary in their tissue distribution with Aα
and Aβ isoforms being present in the brain and lympocytes while Cn Aγ is 
tissue specific being localised to the testis (Matrínez-Martínez and Redondo, 
2004). In comparison, Cn B is encoded by two genes (Graef et al, 2001) 
generating the isoforms Cn B1 and Cn B2, with isoform B1 being ubiquitously 
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expressed whereas B2 expression is restricted to the testis (Musson et al, 
2012).
Calcineurin is activated by both calcium and calcium/calmodulin (Li et al, 2011). 
The regulatory B subunit of calcineurin contains four EF hand motifs; two with 
high affinity and two with low affinity for calcium (Fig. 1.2.1). The high affinity 
sites are generally constantly occupied by a calcium ion and have been 
suggested to have a role in the maintenance of the structure of calcineurin. In 
comparison the low affinity sites acts as sensors for the concentration of 
calcium in the surrounding environment (Li et al, 2011). When the calcium 
concentration increases, the low affinity calcium sites become occupied and 
calcineurin is partially activated. These low affinity sites also induce a 
conformational change in the calcineurin A subunit that opens up the calmodulin
binding domain (Yang and Klee, 2000). Calmodulin binding is proposed to 
displace the auto-inhibitory domain (Tokoyoda et al, 2000) and increases the 
activity of calcineurin up to 20 fold (Klee et al, 1998). 
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Fig. 1.2.1 Structure of the human calcineurin A and B subunits (adapted from Li 
et al, 2011; Klee et al, 1998).  Calcineurin is composed of a catalytic A and regulatory 
B subunit. The A subunit (numbered according to human calcineurin Aα) is divided into 
four regions; the N-terminal region, the catalytic domain, the regulatory domain and the
C-terminal region. The regulatory domain of subunit A contains the calcineurin B (Cn B)
binding region which interacts with the calcineurin B subunit, the calmodulin binding 
region which interacts with calmodulin resulting in activation of calcineurin upon 
displacement of the auto-inhibitory peptide that is also found in this region. The 
calcineurin B subunit contains 4 sites for calcium binding numbered 1-4. Two of these 
have high affinity for calcium and the other two have low affinity and act as sensors for 
calcium concentration in the surrounding environment. 
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1.2.2 Calcineurin Knockout and Mutational Studies
Calcineurin Aα-/- mice have revealed a role for calcineurin in T-cell signalling 
and therefore the immune response. T-cell proliferation in response to antigen 
stimulation in knockout mice was reduced whereas proliferation in response to 
mitogen stimulation, such as Phorbol-12 Myristate 13-Acetate (PMA) and 
ionomycin was unaffected. Additionally, in vitro re-stimulation of T-cells from 
knockout mice secreted less IL-2, IL-4 and IFN-γ than the wild-type. 
Interestingly, NFAT nuclear localisation was unaffected in response to mitogen 
stimulation (Zhang et al, 1996). In comparison, calcineurin Aβ-/- mice have 
reduced translocation of NFAT to the nucleus compared to the wild-type. Loss 
of Cn Aβ also resulted in a decrease in the proliferation and number of T-cells. 
The production of cytokines such as IL-4, IFN-γ and IL-2 was also down-
regulated in response to mitogen stimulation in Cn Aβ-/- mice (Bueno et al, 
2002).
Mutation of the Cn B gene in mice prevents activation of Cn A and consequently
leads to embryonic lethality at days E10.5-E11.5. Calcineurin signalling was 
shown to be required between days E7.5-E8.5. In Cn B-/- mice, initial 
vascularisation occurs but fails to develop into organised structures to that seen
in the wild-type. Angiogenesis of the yolk sac is reduced in addition to a 
decrease in the recruitment of smooth muscle cells to the aorta. Furthermore, 
VEGF-A was shown to be over-expressed in Cn B-/- embryos. Therefore, Cn B 
is required for the correct patterning of the vasculature which is proposed to 
occur through negative-regulation of VEGF-A expression (Graef et al, 2001). 
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Moreover, B-cell specific knockout of Cn B1 inhibits dephosphorylation of 
NFAT, in response to PMA and Ionomycin stimulation, and consequently 
calcineurin activity which downregulates the transcription of NFAT-dependent 
target genes. Cn B1-/- B-cells were also shown to have reduced proliferation and
increased IgM levels in response to T-cell-independent antigen signalling 
compared to the wild-type (Winslow et al, 2006).
1.2.3 Nuclear Factor of Activated T Cells (NFAT)
NFAT is an approximately 120 kDa protein (Ruff and Leach, 1995) that is 
activated by calcineurin and initiates the transcription of target genes (Crabtree 
and Olson, 2002) such as those required for angiogenesis (Iizuka et al, 2004; 
Hernández et al, 2001). 
NFAT consists of a transactivation domain, a NFAT homology region (NHR) 
(also referred to as the regulatory region), a DNA binding domain (also termed 
the Rel homology region (RHR)) and a C-terminal domain, running from N-
terminal to C-terminal respectively (Fig. 1.2.2) (Mancini and Toker, 2009; Li et 
al, 2011). Both the NHR and DNA binding domain, consist of approximately 300
residues each and are conserved among NFAT isoforms (Rao et al, 1997). 
Within the NHR of NFAT, three conserved serine/proline (SP) repeats (SP1, 
SP2 and SP3) (Mancini and Toker, 2009; Hogan et al, 2003 ) which each have 
the sequence, SPXXSPXXSPXXXXXD/ED/E, where X is any amino acid 
(Crabtree, 1999) and a conserved serine rich region (SRR1) are found (Beals et
al, 1997). They contain the 13 serine residues which become dephosphorylated
in response to calcineurin activation which is required for NFAT localisation to 
the nucleus (Fig. 1.2.2) (Hogan et al, 2003; Beals et al, 1997).  
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There are five main isoforms of human NFAT that are ubiquitously expressed 
(additional nomenclature that each isoform is known as is shown in brackets); 
NFAT1 (NFATc2, NFATp), NFAT2 (NFATc1, NFATc), NFAT3 (NFATc4), 
NFAT4 (NFATc3, NFATx) and NFAT5 (tonicity-responsive enhancer-binding 
protein (TonEBP) and osmotic response element binding protein (OREBP)). Of 
particular interest is isoforms NFAT1-4 which are regulated by calcium (Mancini 
and Toker, 2009).
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Fig. 1.2.2 Schematic diagram of the structure of NFAT and its domains (adapted 
from Mancini and Toker, 2009; Li et al, 2011; Rao et al, 1997). NFAT is composed of
four domains; the transactivation domain, the NFAT homology region (NHR) (also 
known as the regulatory region), the DNA binding domain (also known as the Rel 
homology domain) and the C-terminal region. Both the NHR and the DNA binding 
domain are highly conserved amongst the isoforms. The NHR contains two calcineurin 
binding domains (Cn BD) PxIxIT and LxVP at its N and C-terminals respectively. Two 
serine rich regions (SRR) and three serine/proline (SP) repeats are also present here 
and are highly conserved. These contain 13 serine residues (represented as red 
circles) which become dephosphorylated by calcineurin to allow NFAT localisation to 
the nucleus and activation of the transcription of target genes. Two nuclear localisation 
sequences (NLS) are also present, one in the NHR and one in the DNA binding domain





NFAT1-/- mice have a decrease in the cross sectional area of myofibers, but not 
the overall number, resulting in a reduced muscle size compared to the wild-
type, demonstrating a role for NFAT1 in the regulation and growth of skeletal 
muscle (Horsley et al, 2001).
Additionally, NFAT1 is involved in the regulation of the immune response. 
NFAT1-/- mice have splenomegaly and hyperproliferation of both B and T-cells 
due to a reduction of CD40 and Fas ligand. The production of IL-4 is also 
reduced at early time points but increased at later time points compared to the 
wild-type (Hodge et al, 1996). 
1.2.4b NFAT2
NFAT2 has been implicated in the regulation of heart development specifically 
in valve formation. NFAT2-/- mice are embryonic lethal at E14.5 days due to lack
of development of the cardiac valves and septa but begin to show cardiac 
defects around E12.5, such as a reduction in chamber size in addition to the 
aortic sac having both thicker walls and a thinner lumen compared to the wild-
type. Additionally, at E13.5 slower development of semilunar valves is observed
(De la Pompa et al, 1998). A similar result was seen in a study by Ranger et al, 
1998 that also studied NFAT2-/- mice. Congestive heart failure caused 
embryonic lethality between days E13.5-17.5 as a result of the loss of aortic and
pulmonary valve formation (Ranger et al, 1998a).
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1.2.4c NFAT3
Disruption of the NFAT3 gene to generate NFAT3-/- knockout mice had no effect
on embryonic development. However, when this was combined with NFAT4-/- 
mice, embryonic development defects began to be observed around E10.5 
days, such as a less vascularised yolk sac and development compared to the 
wild-type, with lethality occurring around E11.5 due to formation of dysfunctional
vessels. These isoforms of NFAT are also required for recruitment of smooth 
muscle cells to the vessels to enhance stability (Graef et al, 2001).
1.2.4d NFAT4
NFAT4, as well as having a role in the stabilisation of the vasculature and 
functionality of vessels in the developing heart (see above) (Graef et al, 2001), 
has also been implicated in the regulation of skeletal muscle growth as at E17.5
days a smaller cross sectional area of muscle was observed in NFAT4-/- mice. A
reduction in the size of both fast and slow muscles resulting in an overall 
decrease in muscle mass compared to wild-type was also seen and shown to 
be a consequence of a decrease in myofibre number as a result of abnormal 
development, leading to a reduced number of primary myofibres (Kegley et al, 
2001). 
Additionally, NFAT4-/- mice have a reduced number of mature single positive 
thymocytes which is thought to occur due to an increase in apoptosis of double 
positive thymocytes as a result of a decrease in Bcl-2 protein expression. 
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Therefore, NFAT4 has a protective role against apoptosis in the formation of 
single positive thymocytes (Oukka et al, 1998).
Transgenic mice containing a double knockout (DKO) of NFAT1 and 4 were 
shown to have a role in the negative regulation of the immune response. At 
seven weeks of age, DKO mice have an increase in mast and eosinophil cells in
the spleen and lymph nodes and display spleenomegaly and lymphadenopathy 
which was thought to be the result of a 2-3 fold increase in proliferation of 
spleenocytes and lymph node cells. An increase in T-cell proliferation was also 
observed which was suggested to be the result of Fas ligand transcription 
inhibition. The cytokines IL-4, IL-5, IL-6 and IL-10 were also upregulated in DKO
mice compared to the wild-type. It was proposed NFAT1 and 4 act as regulators
of the threshold at which T-cells can be activated and in their absence this 
threshold is lower, resulting in greater T-cell activation and responses such as 
hyperproliferation (Ranger et al, 1998b).
1.2.5 Mechanism of NFAT Translocation From the Cytoplasm to the 
Nucleus
Calcineurin has been shown to be required for successful NFAT nuclear 
localisation and the consequent transcription of target genes (Beals et al, 1997; 
Shibasaki et al, 1996; Rao et al, 1997). Binding of a stimulus to a receptor such 
as VEGF to VEGFR initiates the PLC signalling pathway (Mancini and Toker, 
2009) which stimulates the release of intracellular stores of calcium from the 
endoplasmic reticulum (ER) in response to IP3 signalling (Fig. 1.2.3) (Crabtree 
and Olson, 2002). However, stimulation of NFAT for its nuclear translocation 
requires a prolonged calcium signal (Timmerman et al, 1996). The sustained 
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calcium levels in the cytosol are achieved by the activation of the calcium-
release activated calcium channels (CRAC). The increase in cytosolic calcium 
results in calcium interaction with calmodulin and consequently initiates 
calcineurin activity (Mancini and Toker, 2009). Activated calcineurin interacts 
with the N-terminal region of NFAT (Luo et al, 1996) at two distinct regions, one 
N-terminal and one C-terminal, of the regulatory region of NFAT denoted PxIxIT
and LxVP respectively (Fig. 1.2.2) (Li et al, 2011). PxIxIT is highly conserved 
among NFAT proteins whereas LxVP was originally identified in NFAT 2 and 4 
only (Hogan et al, 2003). 
Both the critical serine residues in the SP repeats and SRR have been shown to
be essential for NFAT2 nuclear localisation. Two nuclear localisation sequences
(NLS) between residues 265-267 (KRK) and 682-685 (KRKK) have also been 
reported to be involved in this process. It was shown calcineurin 
dephosphorylates the serine residues, which is proposed to expose the nuclear 
localisation sequences and induce concomitant NFAT nuclear translocation 
(Beals et al, 1997).
Interestingly, NFAT4 and calcineurin were shown to interact and additionally co-
localise to the nucleus in response to ionophore stimulation. It has been 
proposed calcineurin binding to NFAT exposes the NLS and due to the 
interaction with NFAT co-translocates to the nucleus sustaining NFAT activity 
during calcium signalling (Fig. 1.2.3) (Shibasaki et al, 1996).
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Fig. 1.2.3 Diagram of the calcineurin/NFAT signalling pathway (adapted from 
Mancini and Toker, 2009; Rao et al, 1997). In response to VEGF binding to its 
receptor, phospholipase C-γ (PLCγ) is activated and stimulates the production of 
inositol trisphosphate (IP3). This increases the intracellular levels of calcium as it is 
released from the endoplasmic reticulum and stimulates the sustained increase in 
cytosolic calcium via opening of the calcium-release activated calcium channel 
(CRAC). This activates calmodulin (CaM) which binds to calcineurin (Cn) and initiates 
its binding to NFAT. This interaction results in dephopshoyrlation of critical serine 
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residues within NFAT which activates it and allows its translocation to the nucleus in 
conjunction with calcineurin. Once in the nucleus it binds to DNA. 
1.2.6 The Calcineurin/NFAT Pathway in Biological Processes
The calcineurin/NFAT pathway has been implicated in biological processes 
such as skeletal and cardiac development, apoptosis and the immune response
however these topics are out of the scope of this research (for a review see 
Crabtree and Olson, 2002; Klee et al, 1998). In this study we will focus on the 
role of the calcineurin/NFAT pathway in angiogenesis.
Successful angiogenesis requires, cell migration, tube formation and 
proliferation (Carmeliet, 2000; Liekens et al, 2001). A study by Hernández et al, 
2001 identified a role for the calcineurin/NFAT pathway in angiogenesis as 
inhibition of calcineurin by Cyclosporin A (CsA) was shown to attenuate VEGF- 
induced endothelial cell migration, in vitro tubular morphogenesis and an in vivo
mouse model of corneal angiogenesis. However, calcineurin did not regulate 
cellular proliferation in response to VEGF-signalling (Hernández et al, 2001).
Interestingly the expression of two pro-angiogenic proteins; regulator of 
calcineurin 1.4 (RCAN1.4) and Cyclooxygenase-2 (Cox-2) have been reported 
to be regulated by the calcineurin/NFAT pathway. RCAN1.4 and Cox-2 have 
been shown to contain 15 and 2 NFAT binding sites in their promoters 
respectively (Yang et al, 2000; Hernández et al, 2001). Additionally, VEGF 
stimulation of endothelial cells enhances their expression which is inhibited in 
the presence of CsA showing a calcineurin dependent mechanism of 
expression (Holmes et al, 2010; Iizuka et al, 2004; Hernández et al, 2001).
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The pro-angiogenic proteins RCAN1.4 and Cox-2 have also been implicated in 
angiogenic processes (Iizuka et al, 2004; Hernández et al, 2001). For example, 
knockdown of RCAN1.4 has been shown to inhibit endothelial cell migration and
tubular morphogenesis both in vitro and in vivo in response to VEGF-stimulation
but has no effect on proliferation (Holmes et al, 2010; Iizuka et al, 2004). In 
contrast, other studies have demonstrated a negative role for RCAN1.4 
proposing it to be a negative feedback inhibitor of calcineurin activity (see 
section 1.2.7e) (Yao and Duh, 2004) and consequently angiogenesis (Hesser et
al, 2004). For instance, ectopic expression of RCAN attenuated the expression 
of the pro-angiogenic protein Cox-2. Over-expression of RCAN also attenuated 
in vitro and in vivo tube formation and inhibited tumour growth in mice. 
RCAN1.4 also down-regulated VEGF- induced proliferation (Hesser et al, 2004; 
Minami et al, 2004; Qin et al, 2006). The reason for this discrepancy in RCAN’s 
role in the regulation of angiogenesis is still unclear.
Cox-2 has also been implicated in the regulation of angiogenesis as a variety of 
Cox-2 inhibitors have been shown to down-regulate  PMA-induced migration 
and tube formation of endothelial cells (Woods et al, 2003; Daniel et al, 1999). 
Moreover, inhibition of Cox-2 by the inhibitor NS-398 resulted in attenuation of 
VEGF-induced in vitro and in vivo tube formation. Furthermore, the inhibition of 
angiogenesis by either CsA or NS-398 could be reversed with the addition of 
the Cox-2 product Prostaglandin E2 (PGE2) (Hernández et al, 2001). 
Interestingly, PGE2 was shown to upregulate the expression of VEGF in 
endothelial cells (Pai et al, 2001). As previously mentioned, VEGF is a pro-
angiogenic molecule (Takahashi and Shibuya, 2005) and therefore suggests 
Cox-2 is involved in the propagation of angiogenic signalling.
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1.2.7 Inhibitors of the Calcineurin/NFAT Pathway
1.2.7a Cyclosporin A and FK506
Cyclosporin A (CsA) and tacrolimus (FK506) are two immunosuppressive drugs
that interact with the intracellular proteins (immunophilins); cyclophilin A and 
FK506 binding protein (FKBP12) respectively (Li et al, 2011). The inhibitory 
complexes formed bind to the border between the calcineurin A and B subunits 
at similar sites (Klee et al, 1998) preventing its interaction with NFAT, inhibiting 
NFAT dephosphorylation and consequently attenuating its activation (Ruff and 
Leach, 1995; Loh et al, 1996; Fruman et al, 1992). These drugs have been 
used in transplant therapy to prevent transplant rejection (Crabtree and Olson, 
2002) due to inhibition of NFAT activity and consequently reduction of gene 
transcription in immune cells such as T-cells (Li et al, 2011). Additionally, they 
were tested for the treatment of cardiac hypertrophy. Unfortunately the dosage 
required for treatment highly exceeds the amount needed to subdue the 
immune response (Crabtree, 1999) and treatment was associated with 
substantial side effects including kidney damage, renal failure, hypertension, 
diabetes (hyperglycaemia) and gastrointestinal problems (Matrínez-Martínez 
and Redondo, 2004).
1.2.7b Cabin 1/Cain 
Cabin1 (calcineurin binding)/ cain (calcineurin inhibitor) is an approximately 230 
kDa protein that interacts with calcineurin and inhibits its activity (Lai et al, 1998;
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Sun et al, 1998). At the mRNA and protein level it was shown to be localised 
predominantly in the brain and liver. Interestingly, cabin1 and calcineurin were 
shown to co-localise in the brain (Lai et al, 1998). It has been reported 
cabin1/cain inhibits both T-cell activation by downregulation of calcineurin 
phosphatase activity and consequent attenuates NFAT activation (Sun et al, 
1998) and synaptic vesicle endocytosis (Lai et al, 2000).
1.2.7c A-Kinase-Anchoring Protein (AKAP79)
AKAP79 is localised in T-cells and neurones (Kashishian et al, 1998) and has 
been classed as a scaffolding protein that can anchor multiple proteins in a 
complex with the potential of targeting both kinases and phosphatases in 
specific sub-cellular sections to regulate protein and receptor activity 
(Dell’Acqua et al, 2002). Specifically, AKAP79 has been shown to interact with 
Cn A in COS cells and act as an inhibitor of calcineurin activity as over-
expression of AKAP79 in HEK293T cells results in a 95% down-regulation of 
NFAT activation compared to the control in response to PMA and ionophore 
stimulation (Kashishian et al, 1998). In addition, co-expression of calcineurin 
and AKAP79 in COS-7 cells resulted in translocation of calcineurin from the 
cytoplasm to the membrane (Dell’Acqua et al, 2002). Therefore it is proposed 
the down-regulation of NFAT activity observed is a result of the interaction 
between calcineurin and AKAP79 which maintains calcineurin at the membrane 
out of spatial contact with NFAT (Kashishian et al, 1998).  
1.2.7d Calcineurin Homologous Protein (CHP)
The calcineurin homologous protein (CHP) is a calcium binding protein that has 
a high percentage of homology of 65% and 59% to Cn B and CaM respectively. 
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Over-expression of CHP in Jurkat T-cells results in inhibition of PMA and 
ionophore-induced NFAT activity. Interestingly, ectopic expression of CHP in 
HeLa cells prevented nuclear localisation of NFAT in response to PMA and 
ionophore stimulation. Furthermore, CHP was shown to inhibit calcineurin 
phosphatase activity and interact with Cn A. It was therefore proposed CHP 
disrupts the interaction between calcineurin A, calcineurin B and calmodulin 
which consequently attenuates the calcineurin/NFAT signalling pathway (Lin et 
al, 1999).
1.2.7e Regulator of Calcineurin 1 (RCAN1) 
The regulator of calcineurin 1 (RCAN1), also referred to as Down syndrome 
critical region 1 (DSCR1), myocyte-enriched calcineurin interacting protein 1 
(MCIP1), calcipressin 1 and Adapt 78, is composed of 7 exons. The first 4 
exons are alternative with the two main isoforms RCAN1.1 and RCAN1.4 being 
generated with the inclusion of exon 1 or exon 4 respectively (Holmes et al, 
2010). Isoforms are produced via alternative promoter usage. RCAN1.4 
contains 15 NFAT binding sites upstream of exon 4 and its expression is 
activated in response to calcineurin/NFAT signalling whereas RCAN1.1 
expression is not (Yang et al, 2000; Yao and Duh, 2004; Holmes et al, 2010).
RCAN1 was shown to interact with calcineurin and this has been mapped to the
region encompassing nucleotides 338-352 of calcineurin which is located 
between the Cn A catalytic domain and the Cn B binding region (Rothermel et 
al, 2000; Fuentes et al, 2000). RCAN1 was shown to inhibit calcineurin activity 
as seen by a reduction in calcineurin dependent gene transcription or 
attenuation of calcineurin/NFAT dependent promoter activity (including its own) 
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due to prevention of NFAT nuclear localisation (Rothermel et al, 2000; Fuentes 
et al, 2000; Yao and Duh, 2004; Hesser et al, 2004). This downregulation of 
calcineurin activity was shown to be dependent on the interaction between the 
two proteins (Fuentes et al, 2000). It is therefore suggested RCAN1.4 acts as 
negative feedback inhibitor of calcineurin activity (Yao and Duh, 2004).
1.2.7f Plasma Membrane Calcium ATPase (PMCA)
PMCA has been shown to interact with calcineurin in a variety of cells including 
endothelial cells (Holton et al, 2010a), cardiomyocytes (Wu et al, 2009), PC12 
cells (Kosiorek et al, 2011), HEK293 cells (Buch et al, 2005) and breast cancer 
cells (Holton et al, 2007). Transfection of HEK293 cells with a plasmid encoding
PMCA4b has been shown to downregulate NFAT activation by 60% compared 
to the control in response to PMA and calcium ionophore (A23187) stimulation, 
showing PMCA4 is an inhibitor of the calcineurin/NFAT pathway (Buch et al, 
2005). A similar result was observed for the PMCA2b isoform (Holton et al, 
2007).
Given the adverse effects associated with the high concentration requirement of
calcineurin inhibitors such as CsA in clinic (Crabtree, 1999; Matrínez-Martínez 
and Redondo, 2004), research has focused on the identification of endogenous 
down-regulators of the calcineurin/NFAT pathway as future therapeutic targets. 
Therefore in this thesis we have focused on the plasma membrane calcium 
ATPase 4 (PMCA4) as an endogenous inhibitor of calcineurin-dependent 
angigoensis.
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1.3 Plasma Membrane Calcium ATPases (PMCAs)
Plasma membrane calcium ATPases (PMCAs) are membrane proteins involved
in calcium extrusion from the cytoplasm to the external environment. They are a
member of the P-type family of ATPases defined by their ability to become 
phosphorylated during the transportation of calcium (Carafoli and Brini, 2000). 
PMCAs have an approximate MW of 138 kDa and in erythrocytes constitute no 
more than 0.05% of the total membrane protein (Verma et al, 1988).
1.3.1 Mechanism of Calcium Removal
PMCAs exist in two main conformations known as E1 and E2. In the E1 state 
the calcium (Ca2+) binding site faces the cytosol and has a high affinity for 
calcium.  A conserved aspartic acid residue within the PMCA structure 
(Aspartate 672 in human PMCA4) becomes phosphorylated with concomitant 
hydrolysis of an ATP molecule and PMCA converts from the E1 to the E2 
conformation resulting in the exposure of Ca2+ to the extracellular space. In this 
state Ca2+ has a lower affinity for the binding site and is released. 
Dephosphorylation of the Aspartate residue returns the pump to the E1 
conformation ready for the cycle to begin again (Carafoli and Brini, 2000). One 
calcium ion is transported for one ATP molecule hydrolysed and results in the 
intake of a hydrogen ion (H+) (Di Leva et al, 2008).
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1.3.2 Structure of PMCAs
The putative structure of PMCAs consists of ten transmembrane (TM) domains 
with the majority of the protein being cytosolic. The cytosolic portion of the 
pump is further subdivided into four main units: The N-terminus and the first 
intracellular loop between TM2 and TM3 which contains the binding site for 
activatory acidic phospholipids and a splice site (site A) (the transduction 
domain), a large catalytic intracellular loop between TM4 and TM5 which 
contains the ATP binding site and the Aspartate that becomes phosphorylated 
in the calcium removal cycle (the phosphorylation domain), and the C-terminus 
that contains another site for splicing (site C) and a binding domain for 
calmodulin that is involved in auto-inhibition of the pump (the nucleotide binding 


















































































Fig. 1.3.1 The putative structure of PMCAs (adapted from Di Leva et al, 2008; 
Strehler and Zacharias, 2001). PMCAs contain 10 transmembrane domains (TM) with
three main cytosolic domains: The transduction domain containing the N-terminus and 
the first intracellular loop between TM2 and TM3 which includes both splice site A (A) 
and a phospholipid binding domain (PL BD). The phosphorylation domain includes the 
large cytosolic loop between TM4 and TM5 which contains an Aspartate residue 
(conserved in all isoforms) that becomes phosphorylated during the reaction cycle (D). 
The nucleotide binding domain includes the C-terminal tail which contains a calmodulin
binding domain (CaMBD) and splice site C (C). A) When the calmodulin binding 
domain interacts with two sites of the PMCA pump, one located in the first intracellular 
loop and one in the cytosolic loop between TM4 and TM5, the pump is in an inhibited 
state. B) When calmodulin (CaM) binds to the CaMBD it removes the interaction of the 
auto-inhibitory site with the two pump receptor sites and consequently removes the 
auto-inhibition, stimulating pump activity. 
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1.3.3 PMCA Isoforms
There are four main PMCA isoforms: PMCA1, PMCA2, PMCA3 and PMCA4 
encoded by four independent genes ATP2B1, ATP2B2, ATP2B3 and ATP2B4 
respectively (Di Leva et al, 2008). RNA alternative splicing at sites A and C 
generates further isoform diversity (Strehler and Zacharias, 2001). To date 
more than 20 varieties of PMCAs have been reported. 
1.3.3a Splice Site A
At splice site A, different isoforms (denoted w,x,y and z) are generated by the 
inclusion or exclusion of up to 3 exons. The ‘w’ variant contains all three 
additional exons and variant ‘z’ includes no exons (Fig. 1.3.2). For all the PMCA
isoforms insertion of an exon at this site does not affect the reading frame 
(Strehler and Zacharias, 2001). It has been reported that splicing at site A 
regulates PMCA targeting to specific membranes (Chicka and Strehler, 2003).
1.3.3b Splice Site C
Isoforms generated by alternative splicing at site C are labelled a,b,c,d,e and f, 
where variant ‘a’ contains one exon and variant ‘b’ has no inserted exons (Fig. 
1.3.2). Inclusion of exons at this splice site in isoform ‘a’ pumps results in a shift 
in the reading frame leading to the truncation of the C-terminal region of the 
protein. PMCAb variants maintain fully functioning C-terminal regions. Splice 
site C is found within the calmodulin binding region (Fig 1.3.1) thus splicing at 
this site affects the affinity of the pump for calmodulin (Strehler and Zacharias, 
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2001). For example, PMCA4b isoforms have a higher affinity for calcium and 
calmodulin then PMCAa isoforms (Enyedi et al, 1994).
Fig. 1.3.2 Generation of isoform diversity by alternative splicing at splice site A 
and C (adapted from Strehler and Zacharias, 2001). Images not drawn to scale. 
Blue bars represent inserted exons that are equivalent among the isoforms, the 
number inside denotes the size in nucleotides. Purple boxes represent additional exons
not occurring in all isoforms. A) Diagram of potential isoforms at splice site A. All 
isoforms denoted ‘z’ contain no inserted exon, isoforms ‘x’ result from the insertion of 
one exon. Only PMCA2 has additional isoforms due to the insertion of two more exons 
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at this site. B) Isoforms occurring from splicing at site C. All isoforms denoted ‘b’ 
contain no exons, one exon is inserted in ‘a’ isoforms. A greater number of splice 
variants occurs at site C as there are further splice sites within exons (represented by 
dashed line on the exon itself) and additional exons are included in both PMCA2 and 
PMCA3 isoforms.  
1.3.3c Expression of PMCA Isoforms
PMCA1 and PMCA4 are found throughout most tissues and have a wide 
distribution in adults. In comparison PMCA2 and 3 display a more specific 
cellular and tissue distribution. PMCA2 is localised to the brain, cochlear hair 
cells of the inner ear, lactating mammary gland, uterus, kidney and liver. 
PMCA3 is predominantly found in the brain (Strehler and Zacharias, 2001).
1.3.4 PMCA Knockouts
PMCA knockout (-/-) mice have been generated to identify the physiological 
function of PMCA isoforms in vivo (Prasad et al, 2004).
1.3.4a PMCA1
PMCA1-/- mice do not survive past embryonic development suggesting a 
‘housekeeping’ role for PMCA1 (Okunade et al, 2004). Recently, Kobayashi et 
al, 2012 generated a specific knockout of the PMCA1 gene ATP2B1 in vascular 
smooth muscle cells of mice that showed high blood pressure levels. This 
phenotype was associated with an increase in both intracellular calcium levels 
and femoral artery vasoconstriction in response to phenylephrine (PE) 
stimulation. This data highlights a further role for PMCA1 specifically in the 
regulation of blood pressure (Kobayashi et al, 2012).
1.3.4b PMCA2
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The isoform PMCA2w/a is highly expressed within the plasma membrane of the
stereocilia of inner ear hair cells (Carafoli, 2011), highlighting the pivotal role of 
PMCA2 in the auditory system as PMCA2-/- mice are profoundly deaf (Kozel et 
al, 1998). Moreover, ablation of PMCA2 also results in balance impediments 
that are proposed to be linked to the loss of otoconia in the knockout animals 
(Kozel et al, 1998). 
PMCA2b is the predominant isoform expressed in the apical membrane of 
mammary gland cells and its protein expression increases dramatically during 
lactation (up to 100 fold increase) (Reinhardt et al, 2000). PMCA2-/- mice have a
significantly reduced calcium content in their milk (up to 60% less compared to 
wild-type animals) (Reinhardt et al, 2004) suggesting that PMCA2 acts as a 
macro-calcium transporter to enrich milk with calcium during lactation 
(Reinhardt et al, 2000).
PMCA2 is also involved in the regulation of apoptosis in the physiological 
process of mammary gland involution that occurs upon lactation cessation. A 
study using PMCA2 deafwaddler-2J knockout mice, demonstrated that loss of 
PMCA2 on day 18 of pregnancy resulted in an increase in apoptosis of 
mammary epithelial cells. Likewise, ionomycin-induced apoptosis in mammary 
epithelial cells from PMCA2-/- mice is significantly higher than that of wild-type 
cells. These results suggest an apoptosis-protective function for PMCA2 
(VanHouten et al, 2010). 
1.3.4c PMCA3
 A knockout model of PMCA3 has not been created to date.
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1.3.4d PMCA4
PMCA4-/- male mice have been reported to be infertile (Schuh et al, 2004) due 
to a reduction in the motility and directed movement of sperm (Schuh et al, 
2004; Okunade et al, 2004). 
PMCA4 has been shown to have a role in the heart as PMCA4-/- results in an 
increase in cardiac hypertrophy (enlargement of the heart) in response to 
pressure overload by transverse aortic constriction (TAC) compared to the wild-
type. An increase in myocyte surface area and pulmonary edema were also 
observed. Interestingly, hypertrophy as a result of exercise was not altered 
between PMCA4-/- and wild-type mice highlighting a specific role for PMCA4 as 
a down-regulator of pathological hypertrophy (Wu et al, 2009). PMCA4-/- mice 
also have an increase in cardiac contraction in vivo which was proposed to be a
result of a decrease in membrane localised nNOS due to loss of PMCA4 which 
alters microdomain signalling, leading to a decrease in cGMP and 
phosphodiesterase 2 (PDE2) activity, an increase in cAMP and consequently 
phosphorylation of ryanodine receptors and activation of L-type calcium 
channels which increases contraction. Interestingly, the loss of PMCA4 had no 
effect on the rate of overall calcium removal (Mohamed et al, 2011).
PMCA4 has also been implicated in the regulation of osteoclasts and 
consequently bone formation. In vivo studies using PMCA1+/- or PMCA4-/- mice 
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have shown that femurs from 6 week old mice have a lower bone volume and 
decreased mineralization and density compared to wild-type mice (Kim et al, 
2012). Study of trabecular bone sections and osteoclasts derived from 
PMCA1+/- or PMCA4-/- mice confirmed apoptosis was increased with the loss of 
PMCA1or 4 protein suggesting that PMCA1 and 4 also share the apoptosis 
protective function observed for PMCA2 (Kim et al, 2012). 
PMCA4 has been hypothesised to play a specific role in bladder smooth muscle
contraction by regulation of the acetycholine signalling pathway as PMCA4-/- in 
mice bladder smooth muscle cells results in reduced contraction after carbachol
stimulation, however there was no significant difference in general calcium 
clearance compared to the wild-type which is in contrast to that found for 
PMCA1+/- (Liu et al, 2007). 
1.3.5 Regulation of PMCA Activity
PMCA activity is regulated by a variety of mechanisms including modification by
kinases, interaction with proteins, cleavage and self-association which result in 
an alteration of PMCA activity (Di Leva et al, 2008).
1.3.5a Calmodulin
The calmodulin binding domain (CaMBD) interacts with two sites of the PMCA 
pump; one located in the intracellular loop between TM2 and 3 and another in 
the catalytic loop between TM4 and TM5 (Falchetto et al, 1991; Falchetto et al, 
1992) (Fig. 1.3.1). Calmodulin increases the affinity of the ATPase pump for 
calcium and also its activity (Niggli et al, 1981). It is proposed that binding of 
calmodulin to the CaMBD displaces its interactions with the pump consequently 
removing the auto-inhibition (Di Leva et al, 2008). The concept of the CaMBD 
acting as an auto-inhibitory mechanism was confirmed with a mutant PMCA4b 
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pump that lacks the last 120 C-terminal amino acids (PMCA4b (ct120)) and 
therefore no longer contains a CaMBD. PMCA4b (ct120) was shown to be 
constitutively active, calmodulin independent and had 10 times greater activity 
than the wild-type (Enyedi et al, 1993).
1.3.5b Acidic Phospholipids
Binding sites for acidic phospholipids have been located to the intracellular loop 
between TM2 and TM3 and also the CaMBD within the PMCA structure (Di 
Leva et al, 2008). Specifically, the acidic phospholipids; phosphatidylserine and 
phosphatidic acid both increase, up to 4 times, the activity of PMCAs isolated 
from human erythrocytes. Stimulation of the pump with both calmodulin and 
phospholipid is additive and is more pronounced at low concentrations of 
phospholipid suggesting they share a binding site (Brodin et al, 1992).
1.3.5c Oligomerization 
Fluorescence resonance energy transfer (FRET) analysis of PMCAs isolated 
from erythrocytes labelled with either a donor or acceptor fluorophore, showed 
that PMCAs associate and can therefore form oligomers, with the pump activity 
being enhanced by oligomerization (Kosk-Kosicka et al, 1989). It was later 
established that oligomerization of PMCAs occurs via its calmodulin binding 
domain (Vorherr et al, 1991).
1.3.5d Phosphorylation 
PMCAs are phosphorylated by a variety of kinases at various residues within its
structure (Di Leva et al, 2008).
Cyclic AMP (CAMP)-dependent protein kinase, protein kinase A (PKA), directly 
phosphorylates PMCAs from both sarcolemmal and erythrocyte membranes 
which consequently increases ATPase activity (Neyses et al, 1985). 
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Protein kinase C (PKC) also activates the calcium transport activity of PMCAs 
by phosphorylating a threonine residue located in the CaMBD and thus 
preventing the auto-inhibitory conformation of the pump (Wang et al, 1991; 
Hofmann et al, 1994).
In some cases PMCA phosphorylation inhibits the function of the pump. For 
example, phosphorylation of tyrosine 1176 of PMCA4b by activated pp60src 
kinase turns off the activity of the pump by up to 75% (Dean et al, 1997). 
1.3.5e Calpain Cleavage
Calpain is a calcium dependent endopeptidase known to act on a number of 
proteins. It has been reported to digest the C-terminal region of PMCAs. This 
cleavage results in the formation of an approximately 124 kDa version of the 
pump that lacks the auto-inhibitory domain and is constitutively active (James et
al, 1989).  
1.3.6 PMCA Membrane Localisation in Relation to Involvement in 
Signalling Pathways
1.3.6a Lipid Rafts
Lipid rafts are specialised membrane domains characterised by high levels of 
cholesterol and sphingolipids. Rafts cluster together bringing various molecules 
into close proximity and allow the possibility of modification of these proteins 
which has the potential to initiate signalling pathways (Simons and Toomre, 
2000). In pig cerebellum synaptic plasma membrane, PMCAs localise to lipid 
rafts in an isoform dependent manner. PMCA4 is found within the lipid raft 
density fraction whereas PMCA1, 2 and 3 are not (Sepúlveda et al, 2006).
1.3.6b Caveolae
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Caveolae are membrane invaginations that are implicated in the regulation of 
cellular signalling pathways (Simons and Toomre, 2000). PMCAs are reported 
to localise to caveolae in plasma membranes in a variety of cells, including 
endothelial cells, suggesting that targeted localisation of PMCA proteins may 
lead to more significant changes in calcium concentration in defined regions of 
the cytosol (Fujimoto, 1993). PMCA4b but not PMCA4a localisation to caveolae 
is dependent on caveolin-1, a protein essential for correct caveolae formation. 
In bovine tracheal smooth muscle, disruption of caveolae formation also 
decreases the calcium extrusion properties of PMCA4, suggesting caveolae are
required for the correct functioning of PMCA (El-Yazbi et al, 2008). 
1.3.7 PMCA Interacting Partner Proteins
A variety of cytoplasmic cellular proteins have been demonstrated to interact 
with PMCAs. These interactions occur at various positions of the PMCA 
structure (Fig. 1.3.3) and have a variety of effects on the activity of both PMCA 
and the partner protein (Di Leva et al, 2008) which consequently regulates their 
corresponding signalling pathways. This is in agreement with the localisation of 
PMCAs in membrane micro-domains specialised in signal transduction such as 
caveolae (Holton et al, 2010b). Whether the interaction with these proteins is 
dependent on caveolae localisation is not known at present.
1.3.7a Protein Interaction With the N-Terminal Region of PMCA
The N-terminal domain of the PMCA pumps is the most variable portion of the 
protein between the four isoforms, with roughly 50% amino acid similarity. Only 
one partner protein, the small acidic protein 14-3-3ϵ, has been identified to date 
to interact with this region (Fig. 1.3.3) (Rimessi et al, 2005). There are several 
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known isoforms of the small acidic protein 14-3-3 including β, η, ζ, σ, θ, ϵ and γ 
that have been implicated in the regulation of cellular signalling pathways, 
localisation of molecules and processes such as apoptosis (Linde et al, 2008). 
PMCAs interact with 14-3-3ϵ in an isoform dependent manner. PMCA1, 3 and 4
have been shown to interact with 14-3-3ϵ whereas PMCA2 does not (Rimessi 
et al, 2005; Linde et al, 2008). Studies on the functional consequences of the 
interaction PMCA/14-3-3ϵ have shown that co-expression of the two proteins 
leads to inhibition of the calcium extrusion properties of PMCAs highlighting 14-
3-3ε as a down-regulator of PMCA pump activity (Linde et al, 2008).
1.3.7b Protein Interaction With the Catalytic Core of PMCA 
Unlike the N-terminal region of PMCA pumps, the large intracellular loop 
between TM4 and TM5 involved in calcium removal has high similarity in its 
amino acid sequence (up to 80%) among the isoforms (Buch et al, 2005). A 
number of interactions with partner proteins have been mapped to this domain 
of PMCAs (Fig. 1.3.3) (Di Leva et al, 2008).
1.3.7b(i) Ras-Associated Factor 1 (RASSF1)
RASSF1 is a tumour suppressor protein that is implicated in Ras signalling 
pathways, in particular Ras-mediated apoptosis (Vos et al, 2000). The Ras 
signalling pathway also regulates Erk activity and consequently cell proliferation
(Force and Bonventre, 1998). RASSF1 proteins are expressed ubiquitously and
have multiple splice variants with the major isoforms RASSF1A and 1C, which 
have both been reported to interact with PMCA4b in HEK293 cells,  specifically 
via amino acids 652-748 of PMCA4b (Armesilla et al, 2004). Additionally, in rat 
neonatal cardiomyocytes both endogenous PMCA4 and RASSF1 proteins co-
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localise to the membrane further confirming the PMCA4/RASSF1A interaction. 
The interaction of the two proteins results in down-regulation of the epidermal 
growth factor (EGF)-mediated activation of Erk, suggesting that PMCA acts as a
negative regulator of  Ras-mediated signalling pathways via an interaction 
dependent mechanism with RASSF1 (Armesilla et al, 2004). 
1.3.7b(ii) Endothelial Nitric Oxide Synthase (eNOS/NOS III)
eNOS is a calcium/calmodulin dependent enzyme that catalyses the production 
of NO from L-arginine and molecular oxygen (Förstermann and Sessa, 2012). 
eNOS plays a fundamental role in the regulation of critical vascular responses 
including dilation of blood vessels, protection from atherosclerosis and 
regulation of blood pressure (Förstermann and Sessa, 2012). Endogenous 
PMCA1, 2 and 4 have been demonstrated to interact with eNOS in human 
endothelial cells (Holton et al, 2010a). This interaction occurs via the large 
catalytic loop of PMCAs. The PMCA/eNOS interaction results in an increase in 
the inhibitory phosphorylation of the eNOS residue Thr-495. Functionally, 
ectopic expression of PMCA2b or 4b in endothelial cells both resulted in a 
reduction in the production of NO in response to acetylcholine stimulation or 
ionophore (Holton et al, 2010a). 
1.3.7b(iii) Calcineurin
The first indication of an interaction between PMCA and calcineurin was 
reported by Buch et al, 2005 between ectopically expressed PMCA4b and 
calcineurin in HEK293 cells. Functionally, over-expression of PMCA4b resulted 
in up to 60% reduction in the activity of the calcineurin/NFAT pathway 
identifying a new role for PMCA4b as a negative regulator of this pathway (Buch
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et al, 2005). Additionally, PMCAs have been found to interact with calcineurin in
an isoform-dependent manner in breast cancer MCF-7 cells, with calcineurin 
binding predominantly to PMCA2, moderately to PMCA4 and no interaction 
occuring with PMCA1 (Holton et al, 2007). Interestingly, our group has recently 
reported that disruption of the interaction PMCA2/calcineurin in a panel of 
breast cancer cell lines increased calcineurin-mediated apoptosis and 
sensitised the breast cancer cells to paclitaxel-induced cytotoxicity underscoring
the importance of the interaction PMCA2/calcineurin in breast cancer 
progression (Baggott et al, 2012). Additionally, in the cardiovascular system 
endogenous PMCA1, 2 and 4 have also been shown to interact with calcineurin 
in endothelial cells (Holton et al, 2010a) and in cardiomycocytes the interaction 
PMCA4/calcineurin has been shown to play a critical role as a negative 
regulator of pathological cardiac hypertrophy (Wu et al, 2009). Finally in PC12 
neuronal cells PMCAs interaction with calcineurin is isoform dependent and is 
proposed to be a regulator of dopamine secretion by these cells (Kosiorek et al, 
2011). 
1.3.7b(iv) Syntrophin
Mouse α-1 syntrophin has been shown to interact with the large catalytic 
intracellular loop of human PMCA1b and 4b in HEK293 cells and PMCA, 
syntrophin and nNOS have been reported to form a macromolecular complex 
(Williams et al, 2006). The interaction PMCA/syntrophin has been proven to act 
synergistically to inhibit nNOS activity (upto 80% inhibition) (Williams et al, 
2006).    
1.3.7c Protein Interaction With the C-Terminal Domain of PMCA
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Interactions with the C-terminal region of PMCA occur via a Post synaptic 
density protein, Drosophila disc large tumour suppressor and Zonula occludens-
1 protein (PDZ) binding domain. Protein interactions involving the PDZ domain 
require the minimum sequence E-S/T-X-V (where X represents any amino acid)
(DeMarco and Strehler, 2001). PMCAb isoforms contain a PDZ binding domain 
(either ETSL or ETSV for PMCA1/2/3 and PMCA4 respectively) at the C-
terminus allowing their interaction with various PDZ containing partner proteins 
(Fig. 1.3.3) (Kim et al, 1998). 
1.3.7c(i) Membrane Associated Guanylate Kinase (MAGUK)
MAGUKs have a role in the regulation of cellular signalling specifically at the 
membrane (DeMarco and Strehler, 2001) and contain three PDZ domains (Kim 
et al, 1998). One member of this family is the synapse associated protein (SAP)
which is proposed to act as a scaffolding protein at the membrane. There are 
multiple SAPs including SAP90/ post-synaptic density protein of 95 kDa (PSD-
95), SAP93/Chapsyn-110, SAP97/hDlg and SAP102/NE-Dlg (DeMarco and 
Strehler, 2001). PMCA2b and 4b have been shown to interact with a variety of 
SAPs such as SAP90, SAP93 and SAP97, with SAP102 specifically interacting 
with only PMCA4b (DeMarco and Strehler, 2001; Kim et al, 1998). Interstingly 
the PMCA ‘a’ isoforms fail to interact with SAP97 showing an isoform selective 
interaction with SAPs (Kim et al, 1998). In epithelial Madin-Darby Canine 
Kidney (MDCK) cells PMCA4b and SAP97 co-localise to the basolateral 
membrane. It is hypothesised interaction of PMCAs with SAPs may localise the 
pump within signalling complexes at specific sites of the membrane (DeMarco 
and Strehler, 2001).
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1.3.7c(ii) Calcium /Calmodulin Dependent Serine Protein 
           Kinase (CASK)
CASK is also classed as a MAGUK family member and contains a PDZ domain.
Additionally, it contains a guanylate kinase-like domain allowing its interaction 
with Tbr-1, a T-box transcription factor. CASK and Tbr-1 co-localise to the 
nucleus where they induce the transcription of promoters containing T-elements
(Schuh et al, 2003b). Co-immunoprecipitation experiments with both rat brain 
and kidney lysates demonstrated the interaction between endogenous PMCA 
and CASK which results in a significant inhibition of T-element driven reporter 
vectors, indicating that PMCA4b down-regulates CASK activity (Schuh et al, 
2003b).  
1.3.7c(iii) Na+/H+ Exchanger Regulatory Factor 2 (NHERF2)
There are four members within the NHERF family NHERF1-4. In particular 
NHERF2 is known to act as a scaffold of molecular complexes due to its two 
PDZ domains and also an ezrin-radixin-moesin binding domain, allowing its 
interaction with ion channels or receptors and the actin cytoskeleton 
respectively (Kruger et al, 2009). NHERF2 has been found to interact with 
PMCA in an isoform dependent manner associating with PMCA2b but not 4b 
(DeMarco et al, 2002). As PMCA1 and 3 have the same terminal sequence as 
PMCA2b it is hypothesised they will also interact with NHERF2. PMCA2b and 
NHERF2 were shown to co-localise to the apical membrane in MDCK cells 
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(DeMarco et al, 2002). Silencing of NHERF2 results in a decrease in the rate of 
calcium recovery as there is a reduction in calcium removal by PMCA. This was
suggested to be the result of the reduction in PMCA localisation to the plasma 
membrane due to the loss of NHERF2 (Kruger et al, 2009).
1.3.7c(iv) CLP36
Human CLP36 is a 38 kDa protein that contains a PDZ domain within its N-
terminus.  CLP36 also forms a complex with α-actinin-1 and as a result interacts
with actin filaments and therefore the cytoskeleton in both endothelial cells and 
activated platelets (Bauer et al, 2000). CLP36 has also been shown to interact 
with PMCA in resting platelets and were reported to be in a complex with α-
actinin and actin that upon activation of platelets becomes associated with the 
cytoskeleton. It is therefore proposed that PMCAs interaction with CLP36 acts 
to mediate its association with the cytoskeleton (Bozulic et al, 2007).
1.3.7c(v) Neuronal Nitric Oxide Synthase (nNOS/NOS-I)
nNOS is another nitric oxide synthase enzyme that is calcium/calmodulin 
dependent (Förstermann and Sessa, 2012). Immunoprecipitation and pull-down
assays identified the interaction of ectopic PMCA4b and nNOS in HEK293 cells 
via a PDZ domain (Schuh et al, 2001). nNOS activity, measured by cGMP 
production, was inhibited in a dose dependent manner in relation to increasing 
PMCA4b expression in HEK293 cells, indicating the functional significance of 
the interaction between the two proteins (Schuh et al, 2001). It is hypothesised 
PMCAs down- regulation of nNOS activity is due to the calcium extrusion 
activity of the pump. In agreement with this theory a mutant form of PMCA4b at 
residue Asp672 (which significantly reduces calcium removal by the pump) 
67
failed to inhibit nNOS activity to the same extent as the wild-type (Schuh et al, 
2001). Additionally, a PMCA pump with the last 120 residues removed (resulting
in a constitutively active pump with no PDZ binding domain) has no effect on 
nNOS activity compared to the control (Schuh et al, 2001). 
PMCA1 and 4 have also been shown to interact with nNOS in cardiac cells 
(Williams et al, 2006). In the heart, PMCA4 has been proposed to act as a 
scaffold to regulate nNOS activity. The PMCA/nNOS interaction down-regulates
the β-adrenergic contractile response as the mutant pump, PMCA4ct120 which 
has the PDZ domain removed and therefore cannot interact with nNOS, had no 
effect on β-adrenergic contraction. Interestingly, over-expression of PMCA4b 
had no effect on general excitation-contraction coupling as the rate of calcium 
removal was unchanged from the wild-type (Oceandy et al, 2007).
 Furthermore, Schuh et al, 2003a, demonstrated that mice over-expressing 
PMCA4b in vascular smooth muscle cells specifically, had an increase in blood 
pressure in vivo. It was hypothesised this result occurs due to PMCAs 
interaction with and consequently downregulation of nNOS activity which would 
regulate vascular tone. However, over-expression of PMCA4b had no impact on
endothelium dependent relaxation. PMCA4 was therefore suggested to have a 
role not in general contraction, but in signalling pathways which regulate 
contraction, in this case via nNOS (Schuh et al, 2003a). 
1.3.7c(vi) PMCA Interacting Single PDZ Protein (PISP)
PISP is a single PDZ containing protein. All PMCAb splice variants interact with 
PISP (Goellner et al, 2003). PISP does not interact with a truncated mutant of 
PMCA4b missing six amino acids at the C-terminus suggesting that the 
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interaction between the two proteins is via the PDZ binding region (Goellner et 
al, 2003). At present, it is not clear what the functional consequences of the 
interaction PMCA/PISP are. In reconstituted human erythrocyte membranes 
PISP has no effect on PMCA pump activity (Goellner et al, 2003). It is 
hypothesised that PISP may act as a transporter protein for PMCA localisation 
to the membrane, although this has yet to be determined experimentally 
(Goellner et al, 2003).
1.3.7c(vii) Ania-3 
Ania-3 is a member of the Homer protein family. Homer proteins are involved in 
the regulation of the interaction of metabotropic glutamate receptors (mGluR) 
with other receptors such as IP3 which could potentially regulate calcium 
concentration within the cytosol. Ania-3, like all Homer proteins, contains a PDZ
sequence (Sgambato-Faure et al, 2006). In COS-7 cells Ania-3 interacts with all
b splice variants of PMCA1-4. In MDCK epithelial cells PMCA2b and Ania-3 
have been reported to co-localise to the plasma membrane and in rat 
hippocampal neurons the two proteins co-localise in the soma and dendrites. 
The C-terminal region of PMCA was found to be essential for the interaction 
between the two proteins (Sgambato-Faure et al, 2006). More recently it has 
been shown in rat hippocampal neurones knockdown of the Homer 1 protein 
results in a reduction in the calcium removal by PMCAs (Salm and Thayer, 
2012). It is hypothesised Homer 1 proteins mediate their effect on PMCA 
activity by interacting with the C-terminal region and preventing the association 
of the auto-inhibitory domain with its site in the PMCA pump (Salm and Thayer, 
2012).
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Fig. 1.3.3 PMCA and its partner proteins (adapted 
from Di Leva et al, 2008). Interactions with partner proteins occur at three main 
domains of PMCA: the N-terminal, the large cytosolic loop between transmembrane 
(TM) domain 4 and 5 and the C-terminal tail containing a PDZ-binding domain. Only 
one protein to date has been reported to interact with the N-terminal domain which is 
the 14-3-3ϵ protein. Endothelial nitric oxide synthase (eNOS), calcineurin A, ras-
associated factor 1(RASSF1) and syntrophin bind to the second, large intracellular loop
between TM4 and TM5. Syntrophin has been proposed to form a macromolecular 
complex with neuronal nitric oxide synthase (nNOS) which binds to the c-terminal 
region of PMCA via a PDZ motif. Many other PDZ-containing partner proteins such as 
PMCA interacting single PDZ protein (PISP), membrane associated guanylate kinase 








































calcium /calmodulin dependent serine protein kinase (CASK) bind to the PDZ-binding 
region present in the C-terminal end of PMCAb isoforms.  
1.4 Aims and Hypothesis 
It has previously been reported PMCA4 interacts with calcineurin and 
negatively-regulates the calcineurin/NFAT signalling pathway in HEK293 
mammalian cells and cardiomyocytes (Buch et al, 2005; Wu et al, 2009). 
PMCA4 has also been shown to interact with calcineurin in endothelial cells 
(Holton et al, 2010a) The aim of this project was to establish PMCA4s role in 
the regulation of the calcineurin/NFAT signalling pathway specifically in 
endothelial cells. 
As the calcineurin/NFAT pathway has been implicated in the regulation of 
angiogenic processes (Hernández et al, 2001) the effect of PMCA4s regulation 
of the calcineurin/NFAT pathway will also be investigated in relation to 
angiogenesis, by studying the effect of ‘gain of function’ and ‘loss of function’ of 
PMCA4 on processes required for successful angiogenesis such as cell 
migration, tube formation and proliferation.
The finding that the interaction between PMCA and calcineurin is involved in the
inhibitory function of PMCA on the calcineurin/NFAT signalling pathway (Buch 
et al, 2005; Baggott et al, 2012) which is hypothesised to maintain calcineurin in
a low calcium microenvironment (Holton et al, 2010b) prompted us to establish 
the mechanism of PMCA4s regulation of the calcineurin/NFAT pathway and 
angiogenesis by investigating the role of the interaction between the two 
proteins on these processes.
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We hypothesise PMCA4 is an inhibitor of the calcineurin/NFAT pathway in 
endothelial cells and consequently a negative-regulator of calcineurin-
dependent processes involved in angiogenesis. We predict this novel role for 
PMCA4 will be the result of its interaction with calcineurin which is hypothesised
to sequester calcineruin to a microdomain with a low calcium concentration 
generated by the calcium removal function of the pump. This study will 
investigate a novel role for PMCA4 in the regulation of angiogenesis and 
consider its potential therapeutically as a target in the treatment of diseases that
are associated with pathological angiogenesis.
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2. CHAPTER TWO
                              Materials and Methods
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2.1 Tissue culture
All procedures and experiments requiring tissue culture were carried out in 
aseptic conditions using sterile equipment and techniques in a laminar tissue 
culture hood, to prevent the risk of contamination of cells.
2.1.1 Culturing Cells
All solutions required for tissue culture were pre-warmed to room temperature 
before use. Cells in culture were split to maintain and amplify the amount of 
cells for experiments. To do this, cells were washed with 1x phosphate buffered 
saline (PBS1x) and detached with 0.25% trypsin EDTA solution. When the cells 
had successfully detached, fresh complete medium was added to neutralise the
trypsin and cells were centrifuged for 5 minutes at 1200 rpm. Pelleted cells were
resuspended in fresh medium and transferred to tissue culture flasks. Cells 
were then incubated at 37ºC, 5% CO2. The medium was changed every other 
day until cells reached confluency. 
2.1.2 Isolation of Mouse Lung Endothelial Cells (MLEC)
Mouse lungs from 6-8 week old female mice were a generous gift from the 
Cardiovascular Research Group, University of Manchester, Manchester, United 
Kingdom. MLEC were isolated from both wild-type (PMCA4+/+) and PMCA4 
knockout mice (PMCA4-/-). Lungs were washed in ethanol for 5 seconds and 
placed in MLEC medium (see section 2.1.3). Lungs were then minced into a 
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paste and digested in a 10 ml solution of Type I collagenase (Gibco, UK) (440 
units/ml) in PBS1x pre-warmed at 37°C and then incubated for exactly one hour
at 37°C, 5% CO2. Fresh collagenase was prepared for each new round of 
endothelial cell isolation by incubating Type I collagenase in 25 ml PBS1x at 
37ºC, 5% CO2 for 1 hour. After this time an additional 25 ml PBS1x was added 
generating a final concentration of 440 units/ml. This solution was filter sterilised
using a 0.2 µm filter and stored at 4ºC. After one hour incubation an equal 
volume of MLEC medium was added to the lung solution and the whole content 
was poured into a petri dish. Aggregates were disrupted by passing the solution
through a 19 gauge needle four times and subsequent filtering through a 70 μm 
cell strainer into 20 ml of MLEC medium. The resulting cell solution was 
centrifuged for 5 minutes at 1200 rpm, the supernatant was removed and the 
pellet resuspended in 10 ml of MLEC medium and plated onto Primaria™ tissue
culture dishes (BD biosciences, UK) that had been pre-coated for at least two 
hours with 0.1% gelatin, 0.1 mg/ml fibronectin from bovine plasma (SIGMA, UK)
and 0.3 mg/ml collagen solution ultrapure bovine (SIGMA, UK) to aid 
attachment of the cells to the plate. The following day negative selection was 
carried out for the removal of macrophages and other immune cells that display 
the FcγIII/II receptor. The medium was removed and cells were washed with 
PBS1x. Fresh MLEC medium was added and incubated at 4°C for 20 minutes. 
The medium was aspirated off and replaced with 3 ml of a 0.0017 mg/ml 
solution of purified rat anti-mouse, CD16/CD32 (FcγIII/II receptor), antibody (BD
Biosciences, UK) in PBS1x. Cells were incubated for 30 minutes at 4°C with 
regular rotation of the plate. This antibody solution was removed and 3 ml of a 
6.67x106 beads/ml solution of Dynabeads® sheep anti rat IgG (Invitrogen, UK) 
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in MLEC medium was added to the plate and incubated at 4°C for 30 minutes 
with regular turning of the plate. This solution was then removed and the cells 
were washed three times with PBS1x. Cells were trypsinised, and once 
detached from the plate, resuspended in MLEC medium and transferred in a 
centrifuge tube to a magnetic holder. After 5 minutes of allowing the beads to 
attach to the tube the cell solution was pipetted off and put into a pre-coated 
petri dish (see above) and incubated at 37°C, 5% CO2. The beads were 
discarded. Medium was changed on the cells every day until colonies of 
approximately 20 cells were visible, at which point positive selection to isolate 
endothelial cells was carried out using an antibody directed against the 
endothelial cell marker ICAM-2. The same process as that used for negative 
selection was carried out with the following alterations; the antibody solution 
used in this case was 3 ml of a 0.0017 mg/ml CD102 purified rat anti mouse 
(BD Biosciecnes, UK) solution in PBS1x. Additionally, the beads containing 
attached endothelial cells were kept, resuspended in fresh MLEC medium and 
plated onto pre-coated petri dishes. Cells were incubated at 37°C, 5% CO2 with 
the medium being changed every day until plates reached confluency. To 
assure a high percentage of endothelial cells (≥ 95%) in the culture a second 
round of positive selection with α-ICAM-2 was performed before using the cells 
for experiments. To establish the percentage of cells that were endothelial in the
cultures, cells were viewed microscopically and counted. The number of 
endothelial cells, as identified by the attachment of beads, was calculated as a 
percentage of the total number of cells within the field. This was performed for 
several random microscopic fields to calculate an average percentage of 
endothelial cells in the population which we reported to be ≥ 95% in each case. 
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2.1.3 Mouse Lung Endothelial Cells (MLEC) 
Isolated MLEC were plated on pre-coated plates (see section 2.1.2) and grown 
in MLEC medium complete consisting of 400 ml Dulbecco’s Modified Eagle’s 
medium (DMEM) F-12 medium (SIGMA, UK) with additional supplements, 
generating medium containing; 100 ml fetal bovine serum (FBS), 0.096 mg/ml 
heparin sodium salt from porcine intestinal mucosa (SIGMA, UK), 10 ml L-
glutamine (200 mM) and 0.024 mg/ml endothelial cell growth supplement (AbD 
serotec, UK). An antibiotic/antimycotic solution (100x) was added to the medium
resulting in a final concentration of 95.97 units/ml penicillin, 0.096 mg/ml 
streptomycin and 0.24 µg/ml amphotericin B. MLEC cells were used for 
experiments at very low passages (either when the cells reached confluency 
after positive selection (see section 2.1.2) or after one passage.
2.1.4 Human Umbilical Vein Endothelial Cells (HUVEC)
HUVEC supplied by TCS Cellworks, UK or PromoCell, UK were grown in tissue 
culture flasks pre-coated with 0.1% gelatin in endothelial cell growth medium 
(ECGM) complete consisting of 500 ml basal medium with an endothelial cell 
growth medium supplement mix (Promocell, UK) generating medium containing:
2% fetal calf serum, 0.4% endothelial cell growth supplement, 0.1 ng/ml 
epidermal growth factor (recombinant human), 1 ng/ml basic fibroblast growth 
factor (recombinant human), 90 µg/ml heparin and 1 µg/ml hydrocortisone. 
HUVEC cells between passages 7 and 10 were used for experiments.
2.1.5 Human Embryonic Kidney 293A Cells (HEK293A)
77
HEK293A cells were used to amplify the Ad-ID4 virus (see section 2.7.10). Cells
were infected and grown in HEK medium consisting of 500 ml of DMEM 
(SIGMA life sciences, UK) supplemented with; 50 ml FBS, 1.73 mM L-
glutamine, 17.39 mM HEPES buffer (SIGMA, UK), 5 ml non-essential amino 
acids (100x) and 5 ml of an antibiotic/antimycotic solution (100x) resulting in a 
final concentration of 86.96 units/ml penicillin, 0.087 mg/ml streptomycin and 
0.22 µg/ml amphotericin B. 
 2.1.6 Serum Starvation
Where stated experiments required serum starvation. To do this cells were 
washed with PBS1x to completely remove any remaining medium containing 
serum and cells were then incubated in the corresponding medium with no 
growth factors, supplemented with 0.5% additional FBS. Cells were left 
overnight at 37ºC, 5% CO2.
2.1.7 Counting Cells
After detachment of cells (see section 2.1.1) an aliquot of cell suspension was 
taken to count.  This solution was pipetted onto a hemocytometer. The number 
of cells in a 16-square grid of the hemocytometer was then multiplied by 10 000 
to get the number of cells in 1 ml of cell solution. 
2.1.8 Freezing cells
Cells were detached and centrifuged to collect a pellet as stated in section 
2.1.1. The supernatant was discarded and the pellet was re-suspended in 1 ml 
freezing solution (90% FBS and 10% dimethyl sulfoxide (DMSO)) and 
transferred to a freezing vial. Vials were then wrapped in tissue and stored at -
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80ºC for a week to ensure slow freezing. After this time vials were transferred to
liquid nitrogen (-180ºC) for long term storage. 
2.1.9 Thawing cells
Vials were taken from liquid nitrogen and the cells were thawed quickly. Once 
thawed, the cell solution was added in stages to 9 ml of fresh medium complete 
to prevent damage to cells. The cells were centrifuged at 1200 rpm for 5 
minutes to collect a pellet. The supernatant (containing DMSO) was removed 
and cells were re-suspended in fresh medium, transferred to an appropriate 
tissue culture flask and incubated at 37ºC, 5% CO2. 
2.2 Transfection and Infection of Cells
2.2.1 Electroporation Transfection 
Electroporation for transfection of HUVEC with si-RNA non-target (si-NT) 
(Thermoscientific, Germany), that acts as a control as its sequence does not 
correspond to any known target, and si-RNA PMCA4 (Thermoscientific, 
Germany), that has the complementary sequence to PMCA4 (si-PMCA4) and 
knocksdown its expression, was carried out using an AmaxaTM HUVEC 
nucleofectorTM kit (Lonza, UK) following the manufacturer’s instructions. HUVEC
(5 x 105 cells/cuvette) were transfected with the corresponding si-RNA (30 
pmoles/cuvette) in HUVEC NucleofectorTM solution (Lonza, UK) using a 
Nucleofector® II (amaxa biosystems, UK) on programme A-034. Transfected 
cells were resuspended in fresh HUVEC medium complete and plated in 0.1% 
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gelatin pre-coated T-25 tissue culture flasks. The medium was changed after 24
hours incubation and cells used for experiments 48 hours after transfection. 
2.2.2 Adenoviral Infection
All viruses were a generous gift from Dr Delvac Oceandy and Dr Tamer 
Mohamed from the Institute of Cardiovascular Sciences, University of 
Manchester, Manchester Academic Health Sciences Centre, Manchester, UK 
with the exception of the Ad-ID4 virus which we generated as part of this project
(see section 2.6 and 2.7 and results chapter 5 for Ad-ID4 virus production). 
HUVEC were plated in T-75 tissue culture flasks at a density of 2.5 x 106 
cells/flask.  For over-expression studies cells were infected with either Ad-LacZ 
(encoding the β-galactosidase protein) or Ad-PMCA4b (encoding human 
PMCA4b) at a MOI=50, for 72 hours at 37°C, 5% CO2. To check the importance
of the interaction between PMCA4b and calcineurin, HUVEC cells, seeded as 
above, were infected with Ad-LacZ or Ad-ID4 (encoding the region of human 
PMCA4 that interacts with calcineurin (428-651)) at a MOI=150 for 72 hours.
2.3 Protein Determination Assays
2.3.1 Immunoprecipitation (IP)
To determine infection with Ad-PMCA4 resulted in successful ectopic 
expression of PMCA4, HUVEC infected with either Ad-LacZ or Ad-PMCA4 in T-
75 tissue culture flasks (see section 2.2.2) were washed with PBS1x. After the 
complete removal of PBS cells were lysed in 750 μl of radioimmunoprecipitation
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assay (RIPA) buffer (1xPBS, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS 
20 µM phenylmethylsulfanyl fluoride, 500 ng/ml leupeptin, 1.0 µg/ml aprotinin, 
500 ng/ml pepstatin) and incubated on a shaker for 10 minutes at 4°C, after 
which time the lysate was collected using a cell scraper. Cell debris was 
removed by centrifugation at 13000 rpm for 3 minutes and to the supernatant 
100 μl of washed protein A-agarose beads (Roche, UK) were added and 
incubated for 1 hour at 4°C on a rotator to pre-clear the lysates. Samples were 
then centrifuged for 2 minutes at 3000 rpm to remove the beads. Protein 
quantification was carried out using a BCA protein assay kit (Thermo Scientific 
Pierce, UK) following the manufacturer’s instructions. Samples were adjusted to
2 mg/sample with RIPA buffer and 5 μl of 5F10 (an anti-pan PMCA mouse 
monoclonal antibody) (abcam, UK) and 40 μl of protein A-agarose beads were 
added and incubated overnight at 4°C with constant rotation. Beads were 
collected the following day by centrifugation at 3000 rpm for 2 minutes and 
washed in RIPA buffer 3 times.  After complete removal of RIPA buffer, beads 
were resuspended in 2x NuPAGE® LDS sample buffer (Invitrogen, UK) 
including 5% of β-mercaptoethanol and stored at -20°C for western blot (see 
section 2.3.3). 
2.3.2 Analysis of Protein Expression/Activation
Several experiments were carried out to analyse the expression/activation of 
various proteins. These are described as below and in addition summarised in 
Table 1.3 at the end of this section. Numbers in square brackets within the text 
correspond to the numbering of experiments within the table. 
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To determine the successful expression of 3xFlagPMCA4b(428-651) in HUVEC
after infection with Ad-ID4 [1], HUVEC were seeded at a density of 3.5 x 105 
cells/well and after overnight incubation at 37°C, 5% CO2  infected with either 
Ad-LacZ or Ad-ID4 at a MOI=50 for 72 hours. 
To analyse the expression levels of the proteins Cox-1, Cox-2 and RCAN1.4 [2],
HUVEC were plated into 6-well tissue culture plates at a density of 3x105 
cells/well and incubated at 37ºC, 5% CO2, overnight.
The following day cells were infected with either Ad-LacZ or Ad-PMCA4b at a 
MOI=50 for 48 hours. Cells were then serum starved by incubation at 37ºC in 
ECGM (0.5% FBS) without additional growth factors for 16 hours. After serum 
starvation cells were stimulated with human VEGF-A165 (Peprotech, UK) (25 ng/
ml) for 4 hours.
To study the effect of knockdown of PMCA4 on RCAN1.4 expression [3], 
HUVEC were transfected with the corresponding si-RNA (see section 2.2.1) and
plated in a 6-well tissue culture plate. After 24 hours of incubation in medium 
complete, medium was changed for fresh medium and cells were incubated 24 
hours more. The following day cells were serum starved overnight in 0.5% 
serum starvation medium after which time cells were stimulated for 4 hours with
VEGF (25 ng/ml).
 For the analysis of RCAN1.4 expression in MLEC [4], wild-type and knockout 
cells were plated at a density of 3.0 x 105 cells/well in a 6-well tissue culture 
plate.  Cells were serum starved overnight by incubation in MLEC growth 
medium (0.5% FBS) without additional supplements. The following day cells 
were either left unstimulated or stimulated with VEGF (50 ng/ml) for 4 hours.
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To analyse the effect of disrupting the interaction between PMCA4 and 
calcineurin on RCAN1.4 protein expression [5], HUVEC cells were seeded at a 
density of 3.5x105 cells/well in a 6-well tissue culture plate. The following day 
cells were infected with Ad-LacZ or Ad-ID4 at a MOI=100 for 48 hours which 
was followed by overnight serum starvation in 0.5% medium. After this time 
cells were stimulated with VEGF (25 ng/ml) for 4 hours.
For Erk1/2 detection, HUVEC infected with the corresponding adenoviruses [6 
and 7], or, transfected with si-NT or si-PMCA4 [8] were plated into tissue culture
6-well plates, starved in 0.5% serum starvation medium as described and left 
unstimulated or treated with VEGF (25 ng/ml) for 5 minutes. 
In all cases cells were washed with PBS1x after stimulation to remove any 
remaining medium and stimulus, and lysed with 100 µl of 2x NuPAGE® LDS 
sample buffer (Invitrogen, UK) containing 5% of β-mercaptoethanol. Samples 
were heated at 100ºC in a heat block for 15 minutes and stored at -20ºC until 
analysed by western blot.
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2.3.3 Western Blot 
To study protein expression sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was carried out which separates proteins based 
on their molecular weight (MW). The gel consisted of two sections; the stacking 
gel was prepared by mixing: 
- 2.50 ml of stacking gel buffer (0.5 M Tris-HCl, 0.4% SDS, pH6.6) 
(GENEFLOW, UK)
- 1.40 ml of Ultra Pure ProtoGel®  30% (w/v) Acrylamide: 0.8% (w/v) Bis-
Acrylamide (37.5:1) (acrylamide/bis-acrylamide) (GENEFLOW, UK)
- 6.10 ml of dH2O
- 100 µl of 10% ammonium persulfate (APS)
- 60 µl of N,N,N',N'-Tetramethylethylenediamine (TEMED)
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The resolving gel was prepared by adding:
- 3.75 ml of 10x resolving buffer (4x 1.5 M Tris-HCl, 0.4% SDS, pH8.8) 
(GENEFLOW, UK)
- X ml of Ultra Pure ProtoGel®  30% (w/v) Acrylamide: 0.8% (w/v) Bis-
Acrylamide (37.5:1) (acrylamide/bis-acrylamide) (GENEFLOW, UK)
- Y ml of dH2O (up to a final volume of 14.06 ml)
- 100 µl of 10% ammonium persulfate (APS)
- 60 µl of N,N,N',N'-Tetramethylethylenediamine (TEMED)
In general proteins with a MW of less than 50 kDa were run in a 12% gel (5.60 
ml acrylamide/bis-acrylamide and  4.55 ml dH2O), those with a MW between 50 
kDa and 100 kDa were run in an 8% gel (3.73 ml acrylamide/bis-acrylamide and
6.42 ml dH2O) and proteins of 100 kDa or more were run in a 6% gel (2.80 ml 
acrylamide/bis-acrylamide and  7.35 ml dH2O) (see appendix 1 for SDS-PAGE 
gel percentages for specific proteins). The resolving gel was added first into the 
PAGE equipment and butanol was pipetted on top to remove air bubbles and 
create an even surface to the gel. The gel was left to polymerise after which 
time butanol was removed by washing with dH2O. The stacking gel was added 
on top of the resolving gel and left to polymerise. Protein samples were 
denatured by heating at 100ºC for two minutes, briefly incubated on ice to cool 
down and loaded into the gel. 12 µl of SeeBlue® markers (Invitrogen, UK) and 
12 µl ProtoMarkers™ (National Diagnostics, UK) pre-stained proteins were 
included in the gel as markers of protein MW. Gels were run in running buffer 
(0.025 M Tris, 0.192 M Glycine and 0.1% SDS) (GENEFLOW, UK) at 150 volts 
for an hour and a half.
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Proteins were transferred from the gel to a polyvinylidene difluoride (PVDF) 
Immobilon-P transfer membrane (Millipore, UK) for an hour and a half at 35 
volts in transfer buffer (0.025 M Tris, 0.192 M Glycine, 20% methanol). After 
transferring, membranes were incubated for 1 hour, or overnight in the case of 
membranes used to detect 3xFlag, at 4ºC in a 5% w/v solution of skimmed milk 
in tris buffered saline (TBS) 1x to block unspecific binding of antibodies to the 
membrane. Membranes incubated for 1 hour were briefly washed in TBS with 
0.05% Tween 20 (TBS-T) to remove the milk solution and incubated overnight 
at 4ºC with shaking in the appropriate primary antibody solution (see appendix 
1). The following day membranes were washed for 4 minutes, 5 times with TBS-
T to remove any unbound antibody and then incubated at room temperature for 
an hour and a half in the appropriate secondary antibody (see appendix 1) or in 
the case of membranes for the detection of 3xFlag briefly washed with TBS-T 
and incubated in the primary antibody, anti-Flag M2 peroxidase (HRP) 
conjugate antibody (SIGMA, UK), for three hours. In all cases both primary and 
secondary antibodies were diluted in TBS-T. All secondary antibodies and the 
primary anti-Flag antibody were conjugated to the enzyme horseradish 
peroxidase (HRP), for detection using chemiluminescence. After incubation in 
the secondary antibody (or primary antibody in the case of detection of 3xFlag) 
membranes were washed as above and incubated for 1 minute in 
chemiluminescence detection solution prepared by mixing the components of 
an EZ-ECL chemiluminescence detection kit (GENEFLOW, UK) in a 1:1 ratio (1
ml solution A: 1 ml solution B). Chemiluminescence signal was recorded by 
exposure to Kodak BioMax MS auto-radiographic film and subsequent 
development.
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2.4 RNA Determination 
2.4.1 RNA Extraction 
To determine the effect of over-expression of PMCA4 on the RNA levels of 
RCAN1.4 and Cox-2, HUVEC cells were seeded at a density of 3x105 cells/well 
in a 6-well tissue culture plate and incubated at 37°C, 5% CO2. The following 
day cells were infected with Ad-LacZ or Ad-PMCA4b at a MOI=50 for 48 hours, 
after which time cells were serum starved overnight in 0.5% serum. Cells were 
then stimulated with VEGF (25 ng/ml) for 2 hours and RNA was extracted. To 
determine if knockdown of PMCA4 by si-RNA transfection at the RNA level was 
successful transfected cells (see section 2.2.1) were plated in 6-well tissue 
culture plates at a density of 3.5x105 cells/well and the following day RNA was 
extracted. In both cases RNA was isolated using a total RNA purification kit 
(Norgen, UK). All centrifugation steps were carried out for 1 minute at 13000 
rpm unless otherwise stated. The medium was removed and cells were lysed in 
300 μl of lysis buffer after which time 200 μl of ethanol (100%) was added, 
samples were vortexed for 10 seconds, transferred to columns and centrifuged. 
A DNase I solution was prepared by mixing DNase I (Norgen, UK) and enzyme 
incubation buffer in a 1:6.67 ratio (15 μl:100 μl). 100 μl of this solution was 
added per column and centrifuged. The DNase I solution was then pipetted 
back onto the column and left for 15 minutes at room temperature. After this 
time, 400 μl of wash solution was added to the column and centrifuged and this 
step was repeated. Samples were then centrifuged once more to completely 
eliminate the wash buffer. RNA was eluted by addition of 50 μl of RNA elution 
buffer and incubation for 1 minute at room temperature. Samples were then 
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collected by centrifugation for 2 minutes at 2000 rpm followed by centrifugation 
for 1 minute at 13000 rpm after which samples were stored at -80°C.
2.4.2 RNA Quantification
The RNA concentration (ng/μl) of each sample was calculated using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific, UK) by loading 1.5 μl of 
the sample onto the disc. The purity of the sample was also checked by looking 
at the A260/280 and A260/230 ratios. 
2.4.3 Reverse Transcription
Reverse transcription to convert RNA into cDNA was performed using a high 
capacity cDNA reverse transcription kit (Applied Biosystems, UK). After 
quantification, samples were prepared by adjusting all to 500 ng in a final 
volume of 9 μl with nuclease-free water (Promega, UK). Adjusted samples were
heated for 10 minutes at 65°C after which time they were put directly to ice for 
at least 5 minutes. A master mix was prepared containing a final concentration 
per sample of; 1x RT buffer, 1x dNTP mix (4 mM), 1x RT random primers, 
RNase inhibitor (1 unit/μl), MultiScribe reverse transcriptase (5 units/μl) and 
nuclease free water up to a volume of 11 μl. This master mix was added to each
sample generating a final volume of 20 μl. Samples were then put in a thermal 
cycler (Thermo Hybaid, UK) and reverse transcription carried out under the 
following conditions; 42°C for 60 mins, 52°C for 30 mins, 94°C for 3 mins and 
4°C until ready to collect. These samples were then used for real-time 
polymerase chain reaction.
2.4.4 Resuspension of Oligonucleotides
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All oligonucleotides (SIGMA, UK) were resuspended in autoclaved dH2O and 
the concentration (μg/μl) measured in a Jenway Genova machine using the 
photometrics setting at a wavelength of 260 nm. 1OD260 in this case correlates 
to 20 μg as the oligonucleotides were single stranded. Resuspended 
oligonucleotides were then adjusted to a final concentration of 100 ng/μl.
2.4.5 Semi-Quantitative Polymerase Chain Reaction (PCR)
PCR amplification was used to determine the successful knockout of PMCA4 in 
MLEC. MLEC PMCA4+/+ and PMCA4-/- cells were plated at a density of 3x105 
cells/well in pre-coated 6-well tissue culture plates. The following day cells were
washed in PBS1x, lysed in 300 μl of RNA lysis buffer (Norgen, UK) and RNA 
extraction and reverse transcription carried out as previously described (see 
section 2.4.2 and 2.4.3 respectively). Reverse transcription was performed after
adjustment of the samples to 1 μg of RNA. PCR was then carried out on the 
reverse transcribed samples using oligonucleotides for mouse PMCA4 (mRNA).
PMCA1 mRNA was also studied as a control using oligonucleotides for mouse 
PMCA1 (mRNA) and the housekeeping gene, Hprt1 detected as a control using
the mouse Hprt1 (mRNA) oligonucleotides (see appendix 2 for all 
oligonucleotides). All PCR reactions contained the following; PCR template, 
forward oligonucleotide (2 ng/μl), reverse oligonucleotide (2 ng/μl), 1x Roche 
PCR master mix (high fidelity PCR master mix (Roche, UK) and PCR water 
(H2O PCR grade) (Roche, UK) up to a final volume of 50 μl. Samples were then 
amplified using the following cycles: 94ºC for 2 minutes (initial denaturation), 35 
cycles of 94ºC for 1 minute (denaturation), the required annealing temperature 
for 1 minute (see appendix 2) and 72ºC for 1 minute 30 seconds. Samples were
finally incubated at 72ºC for 10 minutes (final elongation). The melting 
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temperatures (Tm) were calculated using the formula Tm= 2(A+T) + 4(G+C). 
Annealing temperatures used were Tm minus 4°C. Bands were then viewed by 
running amplified samples in a DNA agarose gel (see section 2.7.4) (see 
appendix 2 for size of bands and gel percentages).
2.4.6 Real-Time Polymerase Chain Reaction (Real-Time PCR)
To begin cDNA samples from reverse transcription were diluted 1/10 with 
nuclease-free water (Promega, UK). To a MicroAmp® fast optical 96-well 
reaction plate (Applied Biosystems, UK) 5 μl of cDNA sample/well (1.25 ng/μl) 
was added. A master mix was prepared containing a final concentration/well of; 
1x syber green (Primerdesign, UK), 0.25 μM forward primer, 0.25 μM reverse 
primer (see appendix 3 for specific primer sequences) and nuclease free water 
up to a volume of 15 μl, and was added to the samples generating a final 
volume of 20 μl/well. Samples were then run in a Stratagene MX3000 system at
FAM490 wavelength using the following conditions; 95°C for 10 minutes, 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The (cycle 
threshold) Ct value was recorded and normalised using the Ct values for two 
housekeeping genes; Ubiquitin C (UBC) and YWHAZ. These values were then 
used to calculate the fold change of RNA levels using the 2-ΔΔCt method of 
analysis (see section 2.8.2). Melting curves were also carried out to ensure no 
primer dimers had been formed and that specific amplification had occurred. 
2.5 Functional Assays
2.5.1 Calcineurin/NFAT Pathway Activity
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To study the effect of over-expression of PMCA4 on the activity of the 
calcineurin/NFAT signalling pathway HUVEC were seeded at a density of 
3.5x105 cells/well in a 6-well tissue culture plate. Cells were then infected with 
Ad-LacZ or Ad-PMCA4 at a MOI=50 for 24 hours. After this time Ad-NFAT-Luc 
(a NFAT-dependent luciferase-based reporter vector) was added to the cells at 
a MOI=50 and cells were incubated for 24 additional hours. Cells were serum 
starved in 0.5% serum starvation conditions overnight. The following day cells 
were stimulated with VEGF (25 ng/ml) for 6 hours. 
MLEC cells were plated into a 24-well tissue culture plate at a density of 6.5x104
cells/well or in a 6-well plate at a density of 3x105 cells/well. The following day 
cells were infected with Ad-NFAT-Luc at a MOI=50 for 48 hours after which time
cells were serum starved in 0.5% serum overnight. Cells were then stimulated 
with phorbol-12 myristate 13-acetate (PMA) (20 ng/ml) and Ionophore A23487 
(1 μM) for 6 hours.
To study the effect of disruption of the PMCA/calcineurin interaction on NFAT 
activity, HUVEC were plated in 6-well tissue culture plates at a density of 
3.5x105 cells/well. The following day cells were infected with Ad-LacZ or Ad-ID4 
at an MOI=150. After overnight incubation, Ad- NFAT-Luc was added at a 
MOI=25 and cells were incubated at 37°C, 5% CO2 for an additional 24 hours. 
The next day cells were serum starved using 0.5% serum starvation conditions. 
After this time cells were stimulated with VEGF (25 ng/ml) for 6 hours.
 In all cases after stimulation, cells were washed with PBS1x and lysed in 60 μl 
cell culture lysis reagent 1x (Promega, UK) for 10 minutes at room temperature.
Luciferase activity in the samples was determined by measuring 20 μl of the cell
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lysate in a SIRIUS Luminometer V3.1 (Berthold detection systems, UK) that 
injected 100 μl of luciferase assay substrate from a luciferase assay system kit 
(Promega, UK) into the samples and recorded the amount of relative light units 
(RLU) produced after 30 seconds.
2.5.2 Cell Migration
Cell migration assays were carried out using 24-well cell culture cluster plates 
(COSTAR®, UK). Infected cells for over-expression studies (see section 2.2.2) 
were plated at a density of 5 x 104 cells/well and a 0.9 mm gap was created 
using inserts from a CytoselectTM 24-well wound healing assay kit (Cell Biolabs 
Inc, UK). The following day cells corresponding to time zero (t=0) were stained 
with a 0.6% crystal violet/0.025% ammonium oxalate/5% ethyl alcohol solution 
(SIGMA-ALDRICH, UK) for 15 minutes at 37°C. Excess stain was removed by 
washing with PBS1x three times and cells were fixed at room temperature for 
10 minutes using formalin solution, 10% neutral buffered containing 
formaldehyde 4% w/v (SIGMA-ALDRICH, UK). Fixed cells were further washed 
twice with PBS1x and visualised using a microscope Nikon ECLIPSE TS100 at 
4x magnification. Images were recorded using a digital camera (Nikon DSFi1, 
UK). The remaining cells were incubated in ECGM complete supplemented with
VEGF (25 ng/ml) for 24 hours (t=24). After incubation, cells were stained, fixed 
and viewed as above. 
MLEC migration was studied using the same protocol as previously mentioned 
apart from the following alterations; MLEC were directly plated (no virus 
infection) at a density of 1 x 105 cells/well into pre-coated (see section 2.1.2) 24-
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well plates. Cells were also incubated in MLEC medium complete 
supplemented with VEGF (50 ng/ml) for 24 hours.
To calculate the percentage of migration, the unmigrated area was determined 
using the Image J programme and compared to the unmigrated area of time 
zero (taken as 100%). The difference between the total area at time zero and 
the unmigrated area after stimulation with VEGF represents the percentage of 
migration.
2.5.3 Tube Formation
In all cases the appropriate tissue culture plates were pre-coated  with 
Geltrex™ Matrix (low growth factors) (GIBCO®, UK) and incubated at 37ºC for 
30 minutes to allow the gel to set up. 
For over-expression studies, infected cells (see section 2.2.2) were detached, 
centrifuged for 5 minutes at 1200 rpm to pellet cells and washed in Medium 200
(Cascade Biologics™, UK). Cells were pelleted again by centrifugation, re-
suspended in Medium 200 and plated onto geltrex at a density of 1x105 
cells/well in a 24-well tissue culture plate in either Medium 200 with 2% FBS 
(control) or Medium 200 with 2% FBS supplemented with VEGF (50 ng/ml) and 
incubated for 24 hours at 37°C. 
For PMCA4 knockdown studies HUVEC si-RNA transfected cells (see section 
2.2.1) were plated in a pre-coated 96-well tissue culture plate at a density of 
3x104 cells/well in Medium 200 with 2% FBS or 2% FBS plus additional VEGF 
(50 ng/ml) and incubated for 24 hours.
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HUVEC cells infected with Ad-LacZ or Ad-ID-4 (see section 2.2.2) to determine 
the effect of disruption of the interaction between PMCA4 and calcineurin on 
tube formation, were plated in geltrex pre-coated 96-well tissue culture plates at
a density of 3x104 cells in Medium 200 (Cascade BiologicsTM, UK) with 
additional 2% FBS. Cells were then incubated for 24 hours at 37°C, 5% CO2. 
In all cases cells were fixed after the appropriate incubation time with formalin 
solution, 10% neutral buffered containing formaldehyde 4% w/v (SIGMA-
ALDRICH, UK) at 37ºC, 5% CO2 for 15 minutes. The fixative was then removed 
and replaced with PBS1x and cells were viewed using a Nikon ECLIPSE TS100
microscope and Nikon DSFi1digital camera at 4x magnification. The percentage
of tube formation was determined by counting branching points from the images
taken. The value for cells infected with Ad-LacZ and incubated with 2% serum 
was set as 100% and used as the control. Values for all the other conditions 
were calculated as a percentage in relation to the control.
2.5.4 MTT Assay-Proliferation
Infected cells for over-expression studies (see section 2.2.2) were plated at a 
density of 5x103 cells/well in three tissue culture 96-well plates and incubated 
overnight at 37ºC. The following morning cell number at time zero (t=0) was 
determined in one of the plates by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) analysis by adding 50 µl/well of 5 mg/ml MTT 
directly to the culture medium and subsequent incubation for 4 hours in the dark
at 37ºC. After incubation, medium containing MTT was removed and 175 µl of 
DMSO and 25 µl of Sorensen’s glycine buffer (0.1 M glycine and 0.1 M NaCl 
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equilibrated to pH10.5) was added to each well. The absorbance of the resulting
solution was measured at 540 nm in a Multiskan Ascent (ThermoLabsystems, 
UK). In the other two plates, the medium was replaced with medium ECGM 
complete containing VEGF (25 ng/ml) and cells were further incubated at 37ºC, 
5% CO2 and analysed after three days (t=3) by standard MTT assay. The 
medium was changed on the other three plates and analysed after 6 days (t=6) 
as above.
2.6 Microbiology
2.6.1 Preparation of Luria Broth and Antibiotic Plates
Luria broth (LB) was prepared by dissolving 25 g of luria broth (SIGMA life 
sciences, UK) in a final volume of 1000 ml. These were aliquoted into 400 ml 
and autoclaved. LB agar for the production of plates was made by addition of 6 
g of agar (Fluka BioChemika, UK) to freshly prepared (before autoclaving) 400 
ml aliquot of LB generating a final concentration of 0.015 g/ml and then 
autoclaved. Autoclaved agar was melted using a microwave and poured into 
petri dishes 25 ml/plate containing 100 μg/μl of the appropriate antibiotic for 
selection.
2.6.2 Mini-Preparations
Colonies formed after bacterial transformation (see section 2.7.2), were picked 
up and added to 10 ml of LB containing 100 μg/ml of the appropriate antibiotic 
using aseptic conditions and incubated at 37°C with shaking. The following day 
mini-preparations were carried out using a QIAprep® Miniprep kit (QIAGEN, 
UK). All centrifugation steps were carried out at 13000 rpm unless otherwise 
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stated. Cultures were centrifuged for 10 minutes at 4000 rpm and the 
supernatant was discarded. Pellets were resuspended in 250 μl of buffer P1 
(resuspension buffer) and then an equal volume of buffer P2 (lysis buffer) was 
added and mixed by inversion. Additionally, 350 μl of buffer N3 (neutralisation 
buffer) was added and mixed by inversion. Samples were centrifuged for 10 
minutes then the supernatant was transferred to a QIAprep® spin column. 
Centrifugation for 1 minute was followed by addition of 750 μl of buffer PE 
(wash buffer) to the column. Samples were centrifuged for 1 minute then 
centrifuged in the same conditions again to completely eliminate the wash 
buffer. Samples were eluted in 30 μl of buffer EB (elution buffer) by incubation 
for 1 minute at room temperature followed by centrifugation for 2 minutes.
2.6.3 Maxi-Preparations
Before maxi-preparations were preformed starter cultures of plasmid were 
produced containing 10 ml of LB, the required plasmid and 100 μg/ml of the 
appropriate antibiotic and incubated at 37°C with shaking overnight. The 
following morning 1 ml of the starter culture was added to 9 ml of LB with 100 
μg/ml of antibiotic and incubated at 37°C until the evening, to ensure that 
bacteria were in the log phase of growth, and were then inoculated into 400 ml 
bottles of LB plus antibiotic. Inoculated plasmids were incubated overnight with 
shaking at 37°C. The following day maxi-preparations of plasmids were carried 
out using a plasmid maxi kit (Qiagen, UK). Cultures were centrifuged at 4500 
rpm at 4°C. The supernatant was discarded and the pellet was resuspended in 
10 ml buffer P1 (resuspension buffer) containing RNase A. An equal volume of 
buffer P2 (lysis buffer) was added and mixed by inversion. The same was done 
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for buffer P3 (neutralisation buffer). Solutions were centrifuged for 15 minutes at
4500 rpm and columns were prepared by adding 10 ml of buffer QBT 
(equilibration buffer). After centrifugation the supernatant was pipetted into the 
columns and once it had run through, 30 ml of buffer QC (wash buffer) was 
added. An additional 30 ml of wash buffer was added and once this had passed
through the column the column was transferred to a centrifuge tube and the 
plasmid was eluted by addition of 15 ml of buffer QF (elution buffer). After this 
step, 10.6 ml of 2-propanol (Isopropanol) was added and mixed by inversion. 
The plasmid was then centrifuged at 9600 rpm for 1 hour at 4°C. After this time 
the supernatant was discarded and the pellet resuspended in 300 μl of Tris-
EDTA buffer 1x (TE1x). Samples were centrifuged at 13000 rpm for 1 minute to 
remove any debris. The concentration (μg/μl) was calculated by measuring the 
absorbance of the sample at 260 nm using the photometrics setting that 
correlates 1OD260 to 50 μg in a Jenway Genova machine. 
2.7 Cloning 
2.7.1 PCR Amplification
PCR amplification of the human PMCA4b interaction region (428-651) including 
a Methionine start codon and 3 copies of the Flag-epitope was carried out using
the pF-PMCA4b-(428-651) vector previously generated by Buch et al, 2005 as a
template (Buch et al, 2005) and the oligonucleotides BamHIPMCA4b Sense 
and XhoIPMCA4b Anti-sense (see appendix 2 for oligonucleotides). The sense 
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oligonucleotide sequence is complementary to the sequence just upstream of 
the start codon ensuring that the 3xFlag is incorporated in the amplified product 
and also contains a BamHI restriction site. The anti-sense oligonucleotide 
sequence is complementary to the end of the interaction region (428-651), 
includes a stop codon and also a XhoI restriction site. These restriction sites 
were selected as they are not found within the fragment that is being amplified 
and could therefore be used later on in the cloning process. PCR amplification 
reactions were carried out as stated in section 2.4.5 (see appendix 2 for 
annealing temperatures) and run in a DNA agarose gel (see section 2.7.4) 
2.7.2 Transformation
pGEM®-T- 3xFlagPMCA4b(428-651) and pENTRTM 11- 3xFlagPMCA4b(428-
651) were transformed in 200 μl of JM109 competent cells (Promega, UK). After
addition to bacteria, samples were incubated on ice for 30 minutes after which 
they were heat shocked at 42°C for 2 minutes. LB was then added up to a final 
volume of 500 μl and incubated at 37°C with shaking for 1 hour. The pGEM®-T- 
3xFlagPMCA4b(428-651) and  pENTRTM 11- 3xFlagPMCA4b(428-651) samples
were then plated onto ampicillin and kanamycin LB agar (100 μg/ml) plates 
respectively and incubated overnight at 37°C.
2.7.3 Restriction Digests
All restriction digest enzymes and their corresponding buffer were bought from 
Promega, UK apart from PacI and its relating buffer which was from New 
England BioLabs, UK (see appendix 4 for a table of enzymes and the 
appropriate buffer). Reactions were set up as follows, plasmid (sample), 
restriction enzyme, buffer, 1x bovine serum albumin (BSA) (New England 
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BioLabs, UK) and dH2O up to a final volume of 20 μl. Initially only half of the 
required amount of restriction enzyme was added to the sample and incubated 
at 37°C for 2 hours after which time the remaining amount of enzyme was 
added and incubated overnight at 37°C. In the case of mini-preparation digests, 
samples were incubated with the full amount of enzyme for 2.5 hours.
 2.7.4 Agarose Gel Electrophoresis
DNA agarose gels were made to the appropriate percentage dependent on the 
size of the product that was being observed (see appendix 4 for table of 
percentages of gel and size of fragments). In general DNA with a size below 
500 bp was run in a 2% gel, between 500 bp-1000 bp in a 1% gel and those 
above 1000 bp in a 0.7% gel. Gels were made by dissolving the required 
amount of agarose, electrophoresis grade (Invitrogen, UK) in a total volume of 
60 ml Tris-Acetate-EDTA (TAE) 1x buffer (Invitrogen, UK) in a microwave. After 
allowing the gel solution to cool slightly, ethidium bromide (Invitrogen, UK), final 
concentration 5x10-4 mg/ml, was added and poured into the casting gel device. 
15 μl of a 1kb ladder solution (0.17 μg/μl) (Invitrogen, UK) was loaded as a 
marker of DNA size. Gel loading solution 6x was added to the samples at a final
concentration of 1x allowing samples to be loaded and retained in the gel. 
Samples were run at 80 volts for 30 minutes and then viewed using UV light in a
SYNGENE Bio imaging machine (Geneflow, UK). 
2.7.5 Purification of DNA From Agarose Gels
To purify DNA from agaose gels, samples were run in the appropriate 
percentage gel (see appendix 2 and 4) and the required band was viewed and 
selected using UV light on a UV Transilluminator 2000 (BIORAD, UK) and cut 
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from the gel. DNA was extracted and purified from the gel using a QIAquick® gel
extraction kit (QIAGEN, UK). All centrifugation steps were carried out for 1 
minute at 13000 rpm. 3 volumes of buffer QG (solubilisation buffer) was added 
to the samples and they were incubated at 50°C for 10 minutes, with vortexing 
every 2 minutes until the gel had completely dissolved. 1 volume of isopropanol 
was added, inverted to mix and the sample was transferred to a QIAprep® spin 
column and centrifuged. 500 μl of buffer QG was added to the column and 
centrifuged. 750 μl of buffer PE (wash buffer) was added to the column and left 
for 5 minutes followed by centrifugation. Centrifugation was carried out again to 
ensure complete removal of the wash buffer. The DNA was then collected in 30 
μl of buffer EB (elution buffer) by addition of it to the column, 4 minute 
incubation at room temperature and centrifugation. Samples were then stored at
-20°C.
2.7.6 DNA Precipitation
For DNA precipitation reactions, 10% of sodium acetate (NaAc) 3 M solution 
and 2.5 volumes of ice cold ethanol (100%) were added to the sample and 
stored at -20°C overnight. After this time, precipitated DNA was collected by 
centrifugation at 13000 rpm for 15 minutes, the supernatant was removed and 
DNA resuspended in an appropriate buffer. 
2.7.7 Adenylation
Adenylation was used to add the nucleoside, deoxyadenosine, to the 3’ end of 
DNA, in this case the 3xFlagPMCA4b(428-651) fragment to allow cloning into 
the pGEM®-T Easy Vector (Promega, UK) that has 3’ thymidine to ensure 
successful ligation. Precipitated DNA that had been collected and resuspended 
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in 20 μl of PCR water (Roche, UK) was used to set up adenylation reactions 
using the following components; template (precipitated DNA) (0.651 μg), 1x Taq
buffer (Mg free) (Promega, UK), MgCl2 (2.5 nM), dNTPs (0.8 mM each), aTaq 
DNA polymerase (0.1 units/μl) (Promega, UK) and PCR water up to a final 
volume of 50 μl. Reactions were run for 30 minutes at 72°C in a thermal cycler. 
2.7.8 Ligation
Ligation procedures were carried out to join the insert, adenylated 
3xFlagPMCA4b(428-651), into the pGEM®-T Easy Vector (Promega, UK) and to
insert the purified released fragment from the pGEM®-T- 3xFlagPMCA4b(428-
651) into the pENTRTM 11 dual selection vector (Invitrogen, UK) after both had 
been digested with XhoI and BamHI. Ligation reactions were set up as follows; 
vector, insert, T4DNA ligase (400 u/μl) (New England biolabs, UK), 1x ligase 
buffer (New England biolabs, UK) and dH2O up to a final volume of 10 μl. 
Samples were incubated overnight at 15°C in a thermal cycler.
2.7.9 Recombination
The pENTRTM 11-3xFlagPMCA4b(428-651) was recombined into the pAd/CMV/
V5-DESTTM vector (Invitrogen, UK). Reactions were set up as follows; 300 ng of
each plasmid, TE buffer and 2 μl of Gateway® LR ClonaseTM II enzyme mix 
(Invitrogen, UK) up to a final volume of 10 μl. Samples were incubated at 25°C 
for 5 hours after which time the sample was transformed (see section 2.7.2) in 
DH5α competent bacteria. The bacteria were then plated onto ampicillin (100 
μg/ml) LB agar plates and incubated overnight at 37°C.
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2.7.10 Virus Amplification and Collection
Dr Mohamed and Dr Delvac from the Institute of Cardiovascular Sciences, 
University of Manchester, Manchester Academic Health Sciences Centre, 
Manchester, UK, kindly generated and amplified the adenoviruses used in this 
study. The Ad-ID4 virus was generated from adenoviral plasmids digested with 
PacI as stated in Mohamed et al, 2010 with the following exceptions: Tertiary 
stock of the virus was generated by infection of HEK293A cells with the 
secondary stock of virus (30 μl/flask) for 3 days until all cells had become 
rounded and detached. Cells were collected and centrifuged at 1500 rpm for 5 
minutes. The supernatant was discarded and the pellet was washed in 5 ml 
PBS1x with great care. Cells were re-centrifuged at 1500 rpm for 5 minutes, the
supernatant was removed, and the pellet resuspended in 0.5 ml/flask of PBS1x.
Purification of the virus was performed by adding an equivalent volume of 
chloroform and mixing cells continuously by inversion for 5 minutes after which 
time the solution was centrifuged for 15 minutes at 3000 rpm. The top phase 
(containing virus) was collected and stored at -80°C.
2.7.11 Sequencing
The pAd/CMV/V5-DESTTM- pENTRTM 11-3xFlagPMCA4b(428-651) (pAd-ID4) 
plasmid was sequenced by the Department of Vascular Biology and 
Inflammation, Centro Nacional de Investigaciones Cardiovasculares CNIC, 
Madrid, Spain. Sequencing of pAD-ID4 confirmed the fidelity of the PCR 
amplification and the successful recombination and generation of the plasmid 




For analysis of protein expression, the density of bands from western blot 
images was calculated using Image J software. The value obtained for Ad-
PMCA4 tubulin was set as 1 and the density for Ad-LacZ tubulin normalised 
relative to this. Normalisation of the density of the bands for the identified 
proteins was carried out by dividing the density values of the specific protein by 
the corresponding adjusted tubulin values. Ad-LacZ normalised results were 
then set as 100% and normalised data for Ad-PMCA4 calculated as a 
percentage relative to this.
2.8.2 RNA Quantification
To analyse the RNA levels of the gene of interest (GOI), samples were firstly 
normalised to obtain the ΔCt value by subtracting the Ct values for the 
housekeeping genes (HKG) from the Ct values for the equivalent sample 
assayed for the gene of interest (ΔCt = Ct GOI - Ct HKG). The alterations in RNA
levels between samples were then calculated in respect to a reference which 
was si-NT in Fig. 3.3.1 and Ad-LacZ unstimulated (-) in Fig. 4.2.2. To do this the
ΔCt of the reference was subtracted from itself and from the ΔCt of all samples 
giving the ΔΔCt value (ΔΔCt = ΔCt Sample - ΔCt Reference). 2^-ΔΔCt expresses the 
data as the fold change of the samples, as a result the reference gene becomes
1 and all other samples calculated as a fold change relative to the reference 




                                            Results
Role of PMCA4b in the Regulation of the
Calcineurin/NFAT Pathway in Endothelial Cells
3.1 Introduction
It has previously been reported by our group that PMCA4 interacts with 
calcineurin, via PMCAs large intracellular loop between transmembrane 
domains TM4 and TM5, in mammalian HEK293 cells (Buch et al, 2005), breast 
cancer MCF-7 cells (Holton et al, 2007) and endothelial cells (Holton et al, 
2010a). Additionally, ectopic expression of human PMCA4b has been shown to 
down-regulate NFAT activity and therefore act as a negative regulator of the 
calcineurin pathway in HEK293 cells (Buch et al, 2005). Thus our first aim was 
to determine if this effect also occurred in endothelial cells. To do this we 
carried out ‘gain of function experiments’ by over-expressing PMCA4b and 
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determining its effect on the activity of the calcineurin/NFAT pathway. We 
hypothesised that over-expression of PMCA4b would result in inhibition of 
endogenous calcineurin and consequently the activity of the calcineurin/NFAT 
















































Fig. 3.1.1 Hypothesis of PMCAs down-regulation of the calcineurin/NFAT 
pathway and consequently angiogenesis. A) Under physiological conditions 
calcineurin (Cn) is activated by calmodulin (CaM) in response to VEGF binding to its 
receptor (VEGFR) resulting in an increase in the concentration of cytosolic calcium.  
Activated calcineurin then interacts with the nuclear factor of activated T-cells (NFAT) 
resulting in its dephosphorylation and translocation to the nucleus. Here it binds to 
promoters on target genes and initiates their transcription, in this case, those involved 
in angiogenesis resulting in an increase in angiogenic processes. B) With over-
expression of PMCA4 we hypothesise more calcineurin will interact with PMCA4 
resulting in its sequestration in a low calcium microenvironment (represented by the 
grey area at the plasma membrane) and will inhibit its activity. As a consequence 
NFAT will not be dephosphorylated, will not translocate to the nucleus and will not 
activate gene transcription, therefore resulting in inhibition of angiogenesis.
3.2 Over-Expression of PMCA4b Using Adenovirus and its Effect on the   
Calcineurin/NFAT Pathway
To ectopically over-express PMCA4b in endothelial cells, HUVEC were infected
with an adenovirus encoding PMCA4b (Ad-PMCA4) or the control LacZ (Ad-
LacZ). PMCA proteins from infected cells were immunoprecipitated using the 
anti-pan PMCA 5F10 monoclonal antibody. Western blot of the 
immunoprecipitated proteins using an antibody recognising specifically PMCA4 
(Swant, Switzerland) demonstrated PMCA4 over-expression had been 
successful in cells infected with Ad-PMCA4 compared to the control (Fig. 3.2.1, 
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A, upper panel). In addition to this a western blot detecting an anti-PMCA1 
antibody (Swant, Switzerland) was also completed to show that ectopic 
expression of PMCA4 was specific and had no effect on the expression of other
PMCA isoforms (Fig. 3.2.1, A, lower panel). As the ectopic expression of 
PMCA4 in HUVEC had been successful we next went on to study the effect of 
PMCA4 on the regulation of the calcineurin/NFAT pathway. HUVEC cells were 
infected as above in conjunction with an adenovirus encoding NFAT luciferase 
(Ad-NFAT-Luc). Luciferase activity is used as a surrogate measurement of the 
activity of the calcineurin/NFAT pathway. Infected HUVEC were stimulated with 
VEGF (25 ng/ml) for 6 hours to activate the pathway. The presence of ectopic 
PMCA4 resulted in a reduction in the percentage of NFAT activation by 31.92% 
compared to the NFAT activity in control infected cells (Fig. 3.2.1, B). 
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Fig. 3.2.1 VEGF-stimulation of the calcineurin/NFAT pathway is inhibited by 
adenoviral expression of PMCA4 in HUVEC. A) Ectopic expression of PMCA4 by 
adenoviral-mediated infection of HUVEC. HUVEC were infected with either Ad-LacZ or 
Ad-PMCA4b and protein lysates immunoprecipitated with the anti-PMCA 5F10 
antibody analysed by western blot to detect PMCA4 (WB: α-PMCA4) and PMCA1 (WB:
α-PMCA1). B) Ectopic expression of PMCA4 significantly decreased the activity of 
NFAT. Cells were infected as above, in conjunction with Ad-NFAT-Luciferase and 
stimulated with VEGF (25 ng/ml) for 6 hours, after which, luciferase activity was 
measured. Histogram represents mean ± S.E. of 2 independent experiments, n=5 (* p 
≤ 0.05).
3.3 Knockdown and Knockout of PMCA4 and its Effect on the   
Calcineurin/NFAT Pathway
3.3.1 Si-RNA Mediated Knockdown of PMCA4 in HUVEC
In the case of the knockdown, HUVEC were transfected with si-PMCA4 or the 
control si-NT. Successful knockdown of PMCA4 was confirmed by western blot 
with protein lysates obtained from si-PMCA4 transfected cells using the JA3 
anti-PMCA4 monoclonal antibody (Santa Cruz, UK). Protein lysates of HUVEC 
cells transfected with si-NT were used as a control (Fig. 3.3.1, A, upper panel). 
Additionally, an antibody against PMCA1 (Swant, Switzerland) was used to 
show that the knockdown of PMCA4 was isoform specific as expression of 
PMCA1 was not altered by si-PMCA4 transfection (Fig, 3.3.1, A, middle panel). 
A western blot was also run to detect the levels of tubulin using an anti-tubulin 
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antibody (SIGMA-ALDRICH, UK) to determine equivalent loading of samples 
(Fig. 3.3.1, A, lower panel). Additionally, successful knockdown of PMCA4 by si-
RNA transfection was also confirmed at the RNA level by real-time PCR 
analysis. PCRs performed using HUVEC transfected with si-PMCA4 and 
primers specific for PMCA4 (see appendix 3) had a reduction in PMCA4 RNA 
by 78% compared to si-NT transfected cells (Fig. 3.3.1, B). Furthermore, the 
knockdown of PMCA4 in endothelial cells by si-PMCA4 transfection was 
isoform specific as detection of PMCA1 by real-time PCR analysis using 
primers specific for PMCA1 (see appendix 3) resulted in no significant 
difference between the RNA levels of PMCA1 in si-NT or si-PMCA4 transfected 
cells (Fig. 3.3.1, C).
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Fig. 3.3.1 Si-RNA-induced knockdown of PMCA4 at the protein and RNA level in 
HUVEC was successful A) Knockdown of PMCA4 by use of si-RNA in HUVEC. 
HUVEC were transfected with si-RNA specific for PMCA4 (si-PMCA4) or a control non-
targeting si-RNA (si-NT) and protein expression was analysed by western blot using an
antibody against PMCA4 (α-PMCA4), PMCA1 (α-PMCA1) or tubulin (α-tubulin). 
Transfection of HUVEC with si-PMCA4 resulted in a strong reduction in the protein 
expression of PMCA4 as compared to the levels observed in cells transfected with the 
si-NT control (A, upper panel). The expression of PMCA1 was unaffected by 
transfection with si-PMCA4 (A, middle panel) confirming specific knockdown of 
PMCA4. Equal amounts of protein were loaded in each case as equivalent bands were 
seen with both transfections after detection using an anti-tubulin antibody (A, lower 
panel). B) Successful knockdown of PMCA4 at the RNA level.  HUVEC cells 
transfected with si-PMCA4 resulted in a decrease in PMCA4 RNA expression 
compared to si-NT (control) transfected cells when analysed by real-time PCR using 
primers specific for PMCA4. C) PCR analysis with primers specific for PMCA1 showed 
no significant difference between si-NT and si-PMCA4 transfected cells confirming 
isoform specific knockdown of PMCA4. The fold change for si-NT was set as 1 and si-
PMCA4 values normalised to this as described in section 2.8.2. Data plotted as ± S.E. 
of three independent experiments, n=9 (*** p ≤ 0.001). 
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3.3.2 Isolation of Mouse Lung Endothelial Cells Deficient in PMCA4
To demonstrate the successful knockout of PMCA4 in MLEC cells RNA was 
extracted from PMCA4+/+ and PMCA4-/- MLEC, reverse transcribed into cDNA 
and used as a template for PCR amplification. PCR amplification using primers 
specific for PMCA4 (see appendix 2) produced a band of the expected size of 
363bp (Fig. 3.3.2, upper panel) in PMCA4+/+ endothelial cells that was absent in 
PMCA4-/- endothelial cells, confirming knockout of PMCA4 expression in MLEC.
Additionally, primers detecting PMCA1 (see appendix 2) produced a band at the
predicted size of 370bp (Fig. 3.3.2, middle panel) in samples from PMCA4+/+ 
and PMCA4-/- mice demonstrating the RNA levels of PMCA1 are unaffected and
therefore the knockout is isoform specific. To confirm equal amount of total 
cDNA in the PCR reactions from PMCA4+/+ or PMCA4-/- samples, a control PCR 
of the housekeeping gene Hprt1 was also performed. Agarose gel 
electrophoresis of the amplified fragment revealed equivalent amplification 
levels of a unique band of 85bp (Fig. 3.3.2, lower panel).
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Fig. 3.3.2 Successful isolation of MLEC PMCA4+/+ and PMCA4-/- cells. RNA was 
extracted from MLEC isolated from wild-type (PMCA4+/+) or PMCA4 knockout 
(PMCA4-/-) animals and reversed transcribed into cDNA. PCR amplification was then 
performed using primers specific for mouse PMCA4, PMCA1 and Hprt1 (control) and 
products analysed in 2% DNA agarose electrophoresis gels. Absence of PMCA4 
amplification in the PCR reactions carried out with samples reversed-transcribed with 
RNA isolated from PMCA4 -/- MLEC confirmed loss of PMCA4 expression in these cells
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(upper panel). PCR reactions with oligonucleotides specific for PMCA1 showed that 
suppression of PMCA4 did not substantially affect the expression of PMCA1 (middle 
panel). Amplification with oligonucleotides specific for Hprt1confirmed equal amounts of
cDNA in samples from wild-type or knockout MLEC (bottom panel).
3.3.3 Effect of Loss of PMCA4 on the Activity of the 
Calcineurin/NFAT Pathway
To evaluate the effect of PMCA4 suppression on the activity of the 
calcineurin/NFAT pathway, PMCA4+/+ and PMCA4-/- MLEC were infected with 
Ad-NFAT-Luc and the calcineurin/NFAT signalling pathway activated by 
stimulation with PMA (20 ng/ml) and calcium Ionophore A23487 (1 μM) for 6 
hours. Loss of PMCA4 resulted in a significant increase (325.18%, p ≤ 0.05) in 
NFAT activity in the PMCA4-/- compared to the wild-type MLEC (Fig. 3.3.3) 
confirming that PMCA4 has a down-regulatory effect on NFAT activity and 
therefore is a negative-mediator of the calcineurin/NFAT pathway.
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Fig. 3.3.3 Knockout of PMCA4 in MLEC results in an increase in NFAT activity. 
Loss of PMCA4 increases NFAT activity of MLEC in response to PMA and Ionophore 
stimulation. Wild-type (PMCA4+/+) and PMCA4 knockout (PMCA4-/-) MLEC were 
infected with Ad-NFAT-Luc and luciferase activity measured in a luminometer after 6 
hour stimulation with PMA (20 ng/ml) and Ionophore (1 μM). Knockout of PMCA4 
significantly increased NFAT activity compared to the activity in wild-type cells. Data 
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3.4 Discussion
3.4.1 PMCA4 is a Negative-Regulator of the Calcineurin/NFAT 
         Pathway in Endothelial Cells in Response to VEGF-Stimulation
PMCA4 has previously been reported to interact specifically with calcineurin in a
variety of cells including; HEK293 (Buch et al, 2005), MCF-7 breast cancer cells
(Holton et al, 2007), cardiomyocytes (Wu et al, 2009), PC12 cells (Kosiorek et 
al, 2011) and most interestingly, in the scope of this research, endothelial cells 
(Holton et al, 2010a). In HEK293 cells and neonatal rat cardiomyocytes 
PMCA4b down-regulates NFAT activation and has therefore been reported to 
act as an inhibitor of the calcineurin/NFAT pathway (Buch et al, 2005, Wu et al, 
2009). This was also confirmed in vivo by localised over-expression of PMCA4b
in the heart of mice. In response to TAC for two weeks, which induces pressure 
overload, NFAT activity was inhibited in the PMCA4b over-expressing heart 
compared to the control. Attenuation of cardiac hypertrophy in PMCA4b 
transgenic mice correlated with NFAT inhibition although a direct link with 
PMCA4b down-regulation of the calcineurin/NFAT pathway was not 
demonstrated. Interestingly, PMCA4b inhibition of cardiac hypertrophy only 
occurred in response to pathological but not physiological stimuli highlighting 
the potential of PMCA4b as a therapeutic target (Wu et al, 2009). In light of this 
data we focused our study specifically on the PMCA4 isoform although PMCA1 
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and 2 have also been shown to interact with calcineurin in endothelial cells 
(Holton et al, 2010a). PMCA1 would also be of interest to study as it is classed 
as the ‘housekeeping’ isoform (Okunade et al, 2004) and its expression, like 
PMCA4 is ubiquitous, whereas PMCA2 has a more tissue specific distribution 
localised to the brain, hair cells of the inner ear and the lactating mammary 
gland (Strehler and Zacharias, 2001). However, studies with PMCA1 pose 
potential challenges due to the knockout of this protein resulting in embryonic 
lethality (Okunade et al, 2004).
To evaluate the role of PMCA4 in the regulation of the calcineurin/NFAT 
pathway and angiogenesis we generated both ‘gain of function’ and ‘loss of 
function’ models. A successful gain of function model was produced by infection
of HUVEC with an adenovirus that encodes PMCA4b resulting in specific 
ectopic expression of PMCA4. To further elucidate the regulatory role of 
PMCA4 two models for ‘loss of function’ were produced; PMCA4 knockdown, 
achieved by reducing PMCA4 expression in HUVEC using si-RNA and PMCA4 
knockout, by isolating MLEC from PMCA4-/- mice. Furthermore, VEGF-A165 was 
selected as the appropriate stimulus in this study as it is the predominant 
isoform (Liekens et al, 2001) and has been shown in HUVEC to increase NFAT 
activity which is dependent on calcineurin activation (Armesilla et al, 1999).  Our
data confirms the previously reported inhibitory function of PMCA4 on NFAT 
activity (Buch et al, 2005; Wu et al, 2009) also occurs in endothelial cells as 
over-expression of PMCA4 attenuated VEGF-induced NFAT activation 
identifying PMCA4 as a negative-regulator of the calcineurin/NFAT pathway, 
specifically in endothelial cells. In agreement with this, a ‘loss of function’ study 
using the PMCA4 knockout model resulted in a significant increase in NFAT 
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activity in the PMCA4-/- cells compared to the wild-type (PMCA4+/+) in response 
to PMA and ionophore stimulation. This is also in accordance with the findings 
of Wu et al, 2009 who used a si-RNA method of PMCA4b knockdown in rat 
cardiomyocytes which resulted in an up-regulation of NFAT activity in response 
to phenylephrine-stimulation compared to the control (Wu et al, 2009).
3.5 Conclusion
In conclusion, we confirmed successful over-expression, knockdown and 
knockout models of PMCA4 in endothelial cells for use in ‘gain of function’ and 
‘loss of function’ studies to elucidate the involvement of PMCA4 in 
calcineurin/NFAT signalling and angiogenesis. Additionally, this data has shown
ectopic expression of PMCA4 down-regulates NFAT activity which was 
confirmed in the PMCA4 knockdown model establishing PMCA4 as a negative-
regulator of the calcineurin/NFAT pathway in response to VEGF-stimulation in 
endothelial cells. This highlights the potential of PMCA4 as an endogenous 
regulator of this signalling pathway in endothelial cells in a variety of 
physiological and pathological settings, such as angiogenesis, where this 
pathway has been established to be involved (Hernández et al, 2001).  
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4. CHAPTER FOUR
                                            Results




Successful angiogenesis requires several events including basement 
membrane degradation, cell migration, proliferation and tube formation (Liekens
et al, 2001). A number of signalling pathways regulated by the pro-angiogenic 
factor, VEGF, are implicated in processes required for angiogenesis such as; 
p38 MAPK (McMullen et al, 2005), PI3K (Fujio and Walsh, 1999) and of 
particular interest, PLC-γ (Holmes et al, 2010) which activates the 
calcineurin/NFAT pathway (Crabtree and Olson, 2002). Inhibition of calcineurin 
by CsA has been shown to inhibit angiogenesis (Hernández et al, 2001), 
however, use of CsA is associated with severe side effects (Matrínez-Martínez 
and Redondo, 2004) and it would be beneficial to find an endogenous regulator 
of this pathway that could be a potential therapeutic target in the future. We 
hypothesise this molecule could be PMCA as it has previously been reported 
that PMCA4 and PMCA2 are negative-regulators of the calcineurin/NFAT 
pathway in HEK293 cells (Buch et al, 2005; Holton et al, 2007). Our data 
suggests down-regulation of the activity of the calcineurin/NFAT pathway by 
PMCA4 also occurs in endothelial cells (see chapter 3). We therefore 
hypothesise that over-expression of PMCA4 will result in inhibition of angiogenic
processes regulated by the calcineurin/NFAT pathway. To evaluate this 
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hypothesis we have performed PMCA4 ‘gain’ and ‘loss’ of function experiments 
in endothelial cells and analyzed the effect of PMCA4 excess or deficiency on 
the expression of NFAT-dependent, pro-angiogenic genes and on endothelial 
cell migration, tubular morphogenesis (in vitro and in vivo) and proliferation. The
results of these experiments are described in the following sections. 
4.2 PMCA4 Inhibits VEGF-Induced Expression of the Pro-Angiogenic 
Proteins RCAN1.4 and Cox-2 at Both the Protein and mRNA Levels
RCAN1.4 and Cox-2 have been implicated in processes required for successful 
angiogenesis such as cell migration (Iizuka et al, 2004; Holmes et al, 2010; 
Hernández et al, 2001)  and tube formation (Iizuka et al, 2004; Hernández et al, 
2001; Woods et al, 2003). As their expression is regulated by the VEGF-
mediated activation of the calcineurin/NFAT pathway (Iizuka et al, 2004; 
Hernández et al, 2001) these genes were of particular interest as they could 
potentially be regulated by PMCA4. To test this possibility HUVEC were 
infected with adenovirus encoding PMCA4 or LacZ as previously described. 
Cells were serum-starved in 0.5% fetal calf serum and then stimulated with 
VEGF (25 ng/ml) for 4 hours. Protein lysates of infected cells were analysed by 
western blot using antibodies against RCAN1.4 (SIGMA-ALDRICH, UK), Cox-2 
(Alexis® Biochemicals, UK) and Cox-1 (Alexis® Biochemicals, UK) (see appendix
1 and 6 for table of antibodies and all western blot images respectively). Over-
expression of PMCA4 resulted in a significant decrease in RCAN1.4 and Cox-2 
protein expression by 48.42% and 52.1%, p ≤ 0.001, respectively compared to 
the control, whereas Cox-1 levels remained unaffected (Fig. 4.2.1). A western 
blot detecting tubulin was carried out to confirm equal loading of all samples 
(Fig. 4.2.1).
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Fig. 4.2.1 Ectopic expression of PMCA4b attenuates the protein expression 
levels of RCAN1.4 and Cox-2 in HUVEC cells stimulated with VEGF. HUVEC were 
infected for 48 hours with either Ad-LacZ or Ad-PMCA4b. After serum starvation cells 
were stimulated with VEGF (25 ng/ml) for 4 hours and protein expression was analysed
by western blot. A) Representative western blot images of protein expression (see 
appendix 6 for all images). Ectopic expression of PMCA4b reduces the expression 
levels of RCAN1.4 (WB:α-RCAN1.4) and Cox-2 (WB:α-Cox-2) in endothelial cells.  The
levels of Cox-1 (WB:α-Cox-1) remain unaffected and the loading control tubulin (WB:α-
Tubulin) was equivalent in all cases. B, C, D) Histograms showing analysis of western 
blot experiments. The density of bands from  western blot experiments was analysed 
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using Image J software (as stated in section 2.8.1) and the results represented in 
histograms that show data as mean ± S.E. of two independent experiments, n=5 (*** p 
≤ 0.001).  
RNA levels for RCAN1.4 and Cox-2 were also determined by real-time PCR 
analysis using specific primers for each gene (see appendix 3). Both RCAN1.4 
and Cox-2 expression at the RNA level was also found to be reduced in the 
presence of ectopic PMCA4 by 28.84% and 29.44% respectively in HUVEC 
infected cells stimulated with VEGF (25 ng/ml) for 2 hours (Fig. 4.2.2)
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Fig. 4.2.2 Ectopic 
expression of PMCA4b significantly reduces the fold induction of the pro-
angiogenic genes RCAN1.4 and Cox-2. HUVEC cells were infected with Ad-LacZ 
(control) or Ad-PMCA4b. After serum starvation overnight, cells were stimulated with 
VEGF (25 ng/ml) for two hours and RNA extracted. The RNA levels encoding RCAN1.4
and Cox-2 were analysed by quantitative real-time PCR using oligonucleotides specific 
for each gene (see appendix 3). Results were analysed using the 2-∆∆CT method (see 
section 2.8.2). Ad-LacZ unstimulated samples were set as 1 and the fold induction for 
the other conditions calculated relative to this.  A) Expression of PMCA4b significantly 




































































independent experiments, n=6 (** p ≤ 0.01) is shown. B) The VEGF-mediated 
increment in Cox-2 RNA levels was also decreased by over-expression of PMCA4b. 
Mean ± S.E of two independent experiments, n=5 (* p ≤ 0.05) is shown.  
These results demonstrate that PMCA4 over-expression down-regulates the 
expression of the NFAT dependent genes RCAN1.4 and Cox-2 but does not 
exert any influences on the expression of Cox-1 (which is not regulated via 
calcineurin/NFAT) suggesting that PMCA4 attenuates the expression of the pro-
angiogenic genes RCAN1.4 and Cox-2 via inhibition of the calcineurin/NFAT 
pathway.
In support of this data the knockdown of PMCA4 conversely yielded an increase
in RCAN1.4 protein expression. HUVEC were transfected with si-RNA 
corresponding to PMCA4 (si-PMCA4) or the control non-target (si-NT) and 
stimulated with VEGF as above. Silencing of PMCA4 resulted in a significant 
increase in the protein expression of RCAN1.4 compared to the control 
(Fig.4.2.3, A). Interestingly, knockdown of PMCA4 increased RCAN1.4 protein 
expression both at the basal level and in response to VEGF-stimulation with an 
up-regulation of 91% and 29.97% respectively compared to the control (si-NT) 
(Fig.4.2.3, B). 
Similar results were observed in western blot analysis of PMCA4+/+ and 
PMCA4-/- MLEC after 4 hour stimulation with VEGF (50 ng/ml) using an antibody
against RCAN1.4 (Fig. 4.2.4) although this variable was not quantified by 
densitometry. In both cases western blots detecting tubulin were carried out to 
ensure equal loading of all samples (Fig. 4.2.3 and Fig. 4.4.4).
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Fig.4.2.3 Knockdown of PMCA4b in HUVEC significantly increases RCAN1.4 
protein expression both at the basal level and in response to VEGF-stimulation. 
HUVEC were transfected with si-RNA corresponding to PMCA4 (si-PMCA4) or the 
control non-target (si-NT), stimulated with VEGF (25 ng/ml) for 4 hours and analysed 
by western blot. A) Representative western blot images (see appendix 7 for all images)
showing that loss of PMCA4 increases the protein expression of RCAN1.4 (α-
RCAN1.4). A western blot detecting tubulin (α-Tubulin) confirmed equal amounts of 
protein in the samples. B) Histogram shows analysis of western blot images using 
Image J software. Knockdown of PMCA4 increases RCAN1.4 protein expression both 
in the absence and presence of the VEGF-stimulus. Data plotted as mean ± S.E. of two
independent experiments, n=3 (* p ≤ 0.05).  
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Fig. 4.2.4 Knockout of PMCA4 in MLEC increases RCAN1.4 protein expression in 
response to VEGF-stimulation. Isolated wild-type MLEC (PMCA4+/+) and PMCA4 
knockout (PMCA4-/-) were stimulated with VEGF (50 ng/ml) after serum starvation and 
analysed by western blot using an antibody against RCAN1.4 (α-RCAN1.4). In all 
cases a western blot detecting tubulin (α-tubulin) was carried out to check protein 
concentration in different samples. PMCA4-/- resulted in an increase in the VEGF-
induced protein expression of RCAN1.4 compared to PMCA4+/+ in three independent 
experiments, n=4. 
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4.3 VEGF-Induced Endothelial Cell Migration is Inhibited in the Presence 
of Ectopic PMCA4b
As we had shown PMCA4 was a negative regulator of the pro-angiogenic 
factors RCAN1.4 and Cox-2 we wanted to determine if this had a knock on 
effect on the processes they have been reported to be involved in such as cell 
migration (Iizuka et al, 2004; Holmes et al, 2010; Hernández et al, 2001). 
HUVEC cells were infected with adenovirus as previously mentioned and a 0.9 
mm gap created using a gap generator from a wound healing assay kit (Cell 
Biolabs Inc, UK). At time zero and after 24 hours of incubation with VEGF (25 
ng/ml) cells were stained and fixed. Endothelial cell migration was found to be 
significantly reduced (39.80% reduction, p ≤ 0.05) by ectopic expression of 
PMCA4b compared to the migration of control cells infected with Ad-LacZ (Fig. 
4.3.1), highlighting PMCA4s role as a negative-regulator of endothelial cell 
migration in response to VEGF. 
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Fig. 4.3.1 Ectopic expression of PMCA4b prevents cell migration of endothelial 
cells stimulated with VEGF. Infected HUVEC (Ad-LacZ or Ad-PMCA4b) were fixed at 
time zero or after incubation in ECGM supplemented with VEGF (25 ng/ml) for 24 
hours. (A) VEGF-induced endothelial cell migration was significantly attenuated with 
ectopic expression of PMCA4b. Images are representative of endothelial cell migration 
assays after HUVEC infection with Ad-LacZ or Ad-PMCA4. B) The amount of migration
was calculated from all images (see appendix 8 for all images used in quantification) by
calculating the unmigrated area (the area shown by red boxes that contain no cells) as 
a percentage in relation to the value for the total area in the corresponding time zero 
image (set as 100%) (again represented by red boxes). Subtraction of the unmigrated 
value from 100% gave the percentage of migration. Data plotted as mean ± S.E. of 




























To substantiate this observation, we studied the effect of PMCA4 knockout on 
endothelial cell migration. MLEC PMCA4+/+ and PMCA4-/- cells were plated as 
above and analysed at time zero and after 24 hours of stimulation with VEGF 
(50 ng/ml). PMCA4 deletion resulted in a significant increase in VEGF-induced 
endothelial cell migration by 66.62%, p ≤ 0.01, compared to the migration of 
wild-type MLEC (PMCA4+/+) (Fig. 4.3.2) reassuring our hypothesis of PMCA4 
function as a down-regulator of endothelial cell migration, one of the essential 
processes required for successful angiogenesis.
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Fig. 4.3.2 Knockout of PMCA4 augments VEGF-induced endothelial cell 
migration. Isolated MLEC from wild-type (PMCA4+/+) and PMCA4 knockout (PMCA4-/-) 
mice were plated in the presence of a gap creator which was subsequently removed 
allowing cell migration into the wound. Migration was measured at time zero and after 
24 hours of incubation of cells in MLEC growth medium complete supplemented with 
VEGF (50 ng/ml). A) Images were used to calculate the migrated area as mentioned in 
the over-expression study (see appendix 9 for all images). B) Loss of PMCA4 in 
PMCA4-/- endothelial cells resulted in a significant increase in cell migration in response
to VEGF-stimulation compared to that in the wild-type cells PMCA4+/+. Data plotted as 
mean ± S.E. of two independent experiments n=4 and n=6 for PMCA4+/+ and PMCA4-/- 
respectively (** p ≤ 0.01).  
4.4 In Vitro Tube Formation in Response to VEGF-Stimulation is 


































Tube formation is another process required for successful angiogenesis 
(Carmeliet, 2000). RCAN1.4 and Cox-2 have been implicated in the stimulation 
of tube formation (Iizuka et al, 2004; Hernández et al, 2001; Woods et al, 2003) 
therefore we decided next to investigate the role of PMCA4 as a regulator of 
tubular morphogenesis by endothelial cells. To study the effect of PMCA4 over-
expression on tube formation, HUVEC cells were infected with Ad-LacZ or Ad-
PMCA4b and plated onto a layer of growth-factor reduced matrigel. Cells were 
then incubated in medium 200 including 2% FBS or 2% FBS with additional 
VEGF (50 ng/ml) for 24 hours. After this time cells were fixed and images taken 
by microscopic examination (see appendix 10 for full set of images). The 
number of tubes in unstimulated cells infected with Ad-LacZ were taken as a 
reference and assigned a value of 100%. Tube formation in the other conditions
was calculated as a percentage relative to this control. Interestingly, ectopic 
expression of PMCA4b attenuated tube formation both in response to VEGF 
and also in the absence of the stimulus by 49.01% and 34.29% respectively 
(Fig. 4.4.1). These results suggest that PMCA4 is a negative-regulator of 
endothelial tube formation.  
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Fig. 4.4.1 In vitro tube formation of endothelial cells in response to VEGF-
stimulation is reduced by over-expression of PMCA4b. Infected HUVEC (Ad-LacZ 
or Ad-PMCA4b) were incubated with 2% FBS (control) (-) or 2% FBS with additional 
VEGF (50 ng/ml) for 24 hours (+). (A) A representation of images used for the 
calculation of the percentage of tube formation (see appendix 10 for all images). (B) 
Ectopic expression of PMCA4b significantly reduced both the basal and VEGF-induced
tube formation of endothelial cells. Data plotted as mean ± S.E. of two independent 
experiments, n=at least five (* p ≤ 0.05).  
To confirm this observation we analysed the effect of PMCA4 knockdown on 
endothelial cell tube formation. HUVEC cells were transfected with si-PMCA4 or
the non-target control (si-NT) as previously mentioned. Cells were plated onto 
matrigel and incubated in 2% FBS (control) or 2% FBS supplemented with 
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VEGF (50 ng/ml) for 24 hours. Loss of PMCA4 significantly increased tube 
formation by HUVEC in the absence and presence of VEGF compared to the 
control by 23.07% and 22.05%, p ≤ 0.01, respectively (Fig. 4.4.2), reassuring the
role of PMCA4 as a down-regulator of tube formation.
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Fig. 4.4.2 Knockdown of PMCA4 significantly increases tube formation of 
endothelial cells in vitro in both the absence and presence of VEGF.  HUVEC 
transfected with the control non-target (si-NT) or si-RNA corresponding to PMCA4 (si-
PMCA4) were plated onto growth factor-reduced matrigel and stimulated with 2% FBS 
(control) (-) or 2% FBS supplemented with VEGF (50 ng/ml) for 24 hours (+). (A) A 
representation of images used for the calculation of the percentage of tube formation. 
Non-target (si-NT) was set as 100% and the percentage of tube formation in the other 
conditions calculated from this value (see appendix 11 for all images). (B) Loss of 
PMCA4 significantly increased tube formation at the basal level and in response to 
VEGF-stimulation. Histogram represents mean ± S.E. of two independent experiments,
n=7 (* p ≤ 0.05) (** p ≤ 0.01).  
4.5 In Vivo Over-Expression of PMCA4b Down-Regulates the Formation of 
Functional Vessels in Response to VEGF-Stimulation
We are collaborating in this project with Professor Redondo’s research group 
(at the Department of Vascular Biology and Inflammation, Centro Nacional de 
Investigaciones Cardiovasculares CNIC, Madrid, Spain) to analyse the effect of 
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PMCA4 over-expression in an in vivo model of angiogenesis. Professor 
Redondo’s group implanted a mixture of growth factor-reduced matrigel 
containing VEGF (500 ng/ml), heparin (376 μg/ml) and 2x109 pfu of the 
corresponding adenovirus (Ad-LacZ or Ad-PMCA4), subcutaneously in 4 week 
old anesthetised mice. Seven days later the plugs were removed and half was 
used to measure haemoglobin content, by colorimetric assay at 540nm, and the
other half embedded in paraffin, sliced and stained with haematoxylin and eosin
to detect the number of vessel like structures containing red blood cells. Over-
expression of PMCA4 significantly reduced both the haemoglobin content and 
the number of vessels containing blood by 47.1% and 58.19%, p ≤ 0.05, 
respectively compared to the control (Fig. 4.5.1, B and C). Professor Redondo 
has very kindly granted permission to present these results in this thesis. 
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Fig. 4.5.1 VEGF-induced tube formation in vivo is inhibited with ectopic 
expression of PMCA4b. Matrigel plugs containing VEGF and Ad-LacZ or Ad-PMCA4 
were injected subcutaneously into mice. One week later plugs were analysed for 
haemoglobin content and the number of blood vessels. The matrigel plug containing 
PMCA4 had significantly fewer functional vessels than the control. A) Plugs were 
stained with haematoxylin to detect endothelial cells (blue) or eosin to identify red blood
cells (pink). Plugs formed in the presence of Ad-LacZ present numerous vessel-like 
structures containing red blood cells. In comparison, in plugs containing Ad-PMCA4 
most of the vessel like structures appear empty. B) The haemoglobin content 
measured at 540nm wavelength is significantly reduced in the matrigel plugs containing
PMCA4. Data plotted as mean ± S.E. of three independent experiments with at least 
seven animals per group in each experiment (* p ≤ 0.05). C) The number of blood 
vessels was also significantly attenuated in PMCA4 containing plugs. Histogram 
represents mean ± S.E. of three independent experiments (* p ≤ 0.05). 
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4.6 Over-Expression of PMCA4b has no Effect on VEGF-Induced 
Proliferation of Endothelial Cells or the Activation of Erk1/2 MAPK
Proliferation is another process required for angiogenesis (Liekens et al, 2001). 
To study the effect of PMCA4 over-expression on endothelial cell proliferation 
HUVEC were infected with Ad-LacZ or Ad-PMCA4b and proliferation measured 
by standard MTT assay after 3 and 6 days of incubation in ECGM complete 
supplemented with additional VEGF (25 ng/ml). Ectopic expression of PMCA4b 
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had no significant effect on endothelial cell proliferation compared to the 
proliferation in control cells infected with Ad-LacZ, suggesting that PMCA4 is 
































Fig. 4.6.1 Ectopic expression of PMCA4b has no effect on endothelial cell 
proliferation. Endothelial cell proliferation for cells infected with Ad-LacZ (control) or 
Ad-PMCA4b were measured by standard MTT assay at time zero and after three and 
six days of incubation in ECGM complete supplemented with 25 ng/ml VEGF. Over-
expression of PMCA4b resulted in no significant differences in cell proliferation 
compared to the control. Histogram shows data as mean ± S.E. of three independent 
experiments, n=6.
To confirm the above result the phosphorylation (activation) status of Erk1/2 
MAPK was analysed as it has been reported that Erk1/2 are implicated in 
VEGF-induced cell proliferation of HUVEC (Yu and Sato, 1999). HUVEC cells 
were infected as above and left unstimulated or stimulated with VEGF (25 
ng/ml) for 5 minutes. Western blot analysis using an antibody against 
phosphorylated Erk (Cell Signalling, UK) showed no significant difference in the 
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phosphorylation status, and therefore activation of Erk, in cells over-expressing 
PMCA4b or control cells infected with Ad-LacZ. Total levels of Erk were also 
detected using an antibody against total Erk (Cell Signalling, UK) to normalise 
the phosphorylated values (Fig. 4.6.2).
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Fig. 4.6.2 VEGF-induced phosphorylation of endothelial Erk1/2 is unaffected by 
ectopic expression of PMCA4b. Endothelial cells infected with Ad-LacZ or Ad-
PMCA4b were left unstimulated (-) or stimulated (+) with VEGF (25 ng/ml) for 5 
minutes. (A) Western blots detecting phosphorylated Erk1/2 (WB:α-Phospho-Erk1/2) 
and total Erk1/2 (WB:α-Total-Erk1/2) showed no significant difference between control 
cells or those over-expressing PMCA4 (see appendix 12 for all images). (B) Histogram 
shows data as mean ± S.E. of two independent experiments, n=6. In each case the 
density of the bands for phosphorylated Erk1/2 were normalised to the density of the 
corresponding band for total Erk1/2. 
This result was further supported by observing the effect of knockdown of 
PMCA4 on the phosphorylation of Erk1/2. HUVEC were transfected with si-RNA
specific for PMCA4 (si-PMCA4) or non-target (si-NT) and treated as above. 
PMCA4 knockdown or over-expression yielded similar results, in that no 
significant difference in the phosphorylation and therefore activation of Erk1/2 
occurred (Fig. 4.6.3). Altogether, these data indicate that PMCA4 is not a 
regulator of endothelial cell proliferation in response to VEGF-stimulation.
142
143
Fig. 4.6.3 Knockdown of PMCA4 has no significant effect on the phosphorylation 
of Erk1/2 in response to VEGF-stimulation. HUVEC cells were transfected with si-
RNA specific for PMCA4 or non-targeting control and stimulated with VEGF (25 ng/ml) 
for 5 minutes (+) or left unstimulated (-). A) Samples were analysed by western blot 
using an antibody against phosphorylated Erk (WB:α- Phospho-Erk1/2) showing no 
significant difference between the phosphorylation (activation) of Erk1/2 in control cells 
or those where PMCA4 was silenced. A western blot detecting total Erk1/2 (WB:α-
Total-Erk1/2) was also performed as a control (see appendix 13 for all images used in 
quantification). (B) The density of bands for phosphorylated Erk1/2 were normalised to 
the value obtained for total Erk1/2 (α-Total Erk1/2) and plotted as mean ± S.E. of two 
independent experiments, n=3.
4.7 Discussion
As angiogenesis is associated with over 70 diseases it highlights an important 
aspect of disease progression and therefore regulation of angiogenesis by 
therapeutic targeting would be advantageous in a plethora of illnesses 
(Carmeliet, 2005). Successful angiogenesis requires several events such as, 
proliferation, cell migration and tube formation (Carmeliet, 2000). Numerous 
pathways are involved in the regulation of these processes but of particular 
interest is the calcineurin/NFAT signalling pathway which has been shown to 
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regulate a number of these events (Hernández et al, 2001). We identified 
PMCA4 as an inhibitor of this pathway in endothelial cells (see chapter 3) and 
therefore aimed to establish if PMCA4 could also regulate calcineurin/NFAT 
dependent angiogenic processes.
4.7.1 The Protein Expression and mRNA Levels of the Pro-
Angiogenic Factors RCAN1.4 and Cox-2 are Negatively-
Regulated by PMCA4
It has previously been reported that the expression and activation of RCAN1.4 
and Cox-2 in response to VEGF-stimulation is regulated by the 
calcineurin/NFAT pathway and both have been shown to be pro-angiogenic 
proteins by regulating processes required for angiogenesis such as cell 
migration and tube formation (Iizuka et al, 2004; Hernández et al, 2001). As we 
have previously demonstrated that PMCA4 is a negative-regulator of the 
calcineurin/NFAT pathway in endothelial cells we wanted to identify if PMCA4 
could also regulate these NFAT-dependent proteins. 
RCAN1 RNA levels have been shown to increase in HUVEC in response to 
VEGF-signalling (Hesser et al, 2004). Specifically, RCAN1.4 mRNA is elevated 
in response to VEGF-stimulation in endothelial cells, such as HUVEC, in a 
calcineurin-dependent mechanism, whereas RCAN1.1 levels remain the same 
(Yao and Duh, 2004; Holmes et al, 2010; Minami et al, 2004). Additionally, the 
presence of RCAN1.4, but no other isoforms, was identified in VEGF-induced 
HUVEC (Iizuka et al, 2004). The conditions used in our study, such as VEGF165-
stimulation and HUVEC, suggest we are studying in particular the RCAN1.4 
isoform.
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We found ectopic expression of PMCA4b in VEGF-induced HUVEC significantly
attenuated both the protein and RNA levels of RCAN1.4. In support of this 
finding, knockdown of PMCA4 significantly increased the protein expression of 
RCAN1.4 both in the absence and presence of VEGF compared to the control. 
Similarly to RCAN1.4, Cox-2 protein and mRNA expression has been reported 
to be increased in HUVEC in response to VEGF-stimulation and is inhibited by 
CsA, showing a calcineurin-dependent mechanism of expression (Hernández et
al, 2001). We also established ectopic expression of PMCA4 significantly 
inhibited the protein and mRNA levels of Cox-2 in VEGF-induced HUVEC 
compared to the control. This data demonstrates PMCA4 is a negative-regulator
of the calcineurin/NFAT dependent proteins RCAN1.4 and Cox-2 in endothelial 
cells.
Cox-1 has been reported to be a pro-angiogenic protein involved in processes 
such as tube formation in HUVEC cells (Tsujii et al, 1998). However, Cox-1 
knockout mice showed no significant effect on the rate of tumour growth 
compared to the control therefore suggesting Cox-1 is not the predominant Cox 
isoform in angiogenesis (Williams et al, 2000). In contrast to Cox-2, its 
expression is constitutive and independent of calcineurin and VEGF-signalling 
in HUVEC (Hernández et al, 2001) and its expression was therefore studied as 
a control. We established over-expression of PMCA4 had no effect on the 
protein expression of Cox-1 compared to the control in response to VEGF-
stimulation in HUVEC supporting the findings of Hernández et al, 2001, that 
Cox-2 but not Cox-1 is induced by VEGF in endothelial cells and is regulated by
calcineurin signalling. Additionally, it also shows that the inhibitory role of 
PMCA4 is specific for processes regulated by the calcineurin/NFAT pathway. It 
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should be taken into consideration that a paper by Bryant et al, 1998, showed in
HUVEC that Cox-1 levels, although constitutively expressed, were increased in 
response to VEGF-stimulation whereas Cox-2 expression was unaffected 
(Bryant et al, 1998). The variation in these results compared to Hernández et al,
2001 could possibly be due to the differences in VEGF concentration used as 
Bryant used a low concentration (10ng/ml) (Bryant et al, 1998) whereas 
Hernández used a higher concentration (50 ng/ml) (Hernández et al, 2001).
4.7.2 VEGF-Induced Cell Migration is Attenuated by Ectopic 
Expression of PMCA4
Endothelial cell migration is one of the processes required for successful 
angiogenesis (Carmeliet, 2000). VEGF-stimulation of HUVEC induces cell 
migration which is down-regulated by the calcineurin inhibitor CsA, suggesting 
this process is controlled by the calcineurin/NFAT pathway (Hernández et al, 
2001). Additionally, RCAN1.4 and Cox-2 have been reported to be involved in 
the regulation of cell migration (Iizuka et al, 2004; Holmes et al, 2010; 
Hernández et al, 2001). As we previously established PMCA4 to be a negative-
regulator of the calcineurin/NFAT pathway and consequently RCAN1.4 and 
Cox-2 expression, we wanted to investigate if this resulted in a concomitant 
reduction in cell migration. 
Ectopic expression of PMCA4 in HUVEC resulted in a significant down-
regulation of VEGF-induced cell migration. In comparison, loss of PMCA4 
(PMCA4-/-) resulted in an increase in cell migration compared to the wild-type 
(PMCA4+/+), verifying that PMCA4 is a negative-regulator of VEGF-stimulated 
endothelial cell migration. The inhibition of migration observed in this study 
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could potentially be a result of the PMCA4-mediated down-regulation of 
RCAN1.4 and Cox-2 expression previously reported in this thesis. In support of 
this hypothesis two studies detected reduced endothelial cell migration in 
response to VEGF-signalling with knockdown of RCAN1.4 (Iizuka et al, 2004, 
Holmes et al, 2010). Additionally, PMA-induced migration of HDMEC and 
human renal microvascular endothelial cells was inhibited in the presence of a 
variety of Cox-2 inhibitors (Woods et al, 2003; Daniel et al, 1999). Furthermore, 
inhibition of VEGF-induced HDMEC migration by CsA is reversed with addition 
of PGE2 (Hernández et al, 2001), a product of Cox-2 activity (Pai et al, 2001).  
It should also be taken into consideration that PGE2 produced by Cox-2 is 
involved in the activation of angiogenesis. It was reported in rat gastric 
microvascular endothelial cells (RGMEC) that PGE2 stimulation results in an 
increase in the expression of VEGF at both the mRNA and protein level (Pai et 
al, 2001). VEGF has been shown to be a pro-angiogenic factor (Liekens et al, 
2001). Therefore in light of this data, the inhibition of cell migration observed 
with ectopic expression of PMCA4 in this study could potentially also be 
attributed to the reduction in prostaglandin formation as a result of PMCA4s 
inhibition of Cox-2 expression at the protein and mRNA level that would 
consequently decrease the levels of endocrine VEGF, preventing propagation 
of the angiogenic response. 
All the studies mentioned above demonstrate that down-regulation of the 
expression or activity of the pro-angiogenic proteins RCAN1.4 and Cox-2 
consequently results in reduced endothelial cell migration. Our data is in 
support of this as we too saw inhibition of VEGF-induced HUVEC migration and
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have demonstrated PMCA4 to be a negative-regulator of the expression of 
these two proteins.
4.7.3 VEGF-Induced In Vitro and In Vivo Tube Formation is Inhibited 
by Over-Expression of PMCA4
Tube formation is an additional event required for successful angiogenesis 
(Carmeliet, 2000). It has been reported that VEGF-induced in vitro tube 
formation of  HUVEC plated onto matrigel is inhibited by CsA, suggesting a 
calcineurin/NFAT pathway dependent mechanism (Hernández et al, 2001) and 
has also been shown to be regulated by RCAN1.4 (Iizuka et al, 2004) and Cox-
2 (Hernández et al, 2001; Woods et al, 2003). In light of this data and our 
previous findings in this study, of PMCA4s role in the inhibition of the 
calcineurin/NFAT pathway and consequently RCAN1.4 and Cox-2 expression, 
we hypothesised that tube formation could also potentially be regulated by 
PMCA4.
We began by studying in vitro tube formation of HUVEC which was found to be 
significantly attenuated with ectopic expression of PMCA4 compared to the 
control when seeded onto matrigel. Interestingly, this occurred both at the basal
level and in response to VEGF-stimulation, establishing PMCA4 as a negative-
regulator of tube formation. This was confirmed by knockdown of PMCA4 with 
si-RNA which conversely initiated an increase in tube formation that was again 
observed both in the absence and presence of VEGF. Similar to the hypothesis 
made in the case of migration, it is possible this down-regulation of tube 
formation with over-expression of PMCA4 is a result of inhibition of RCAN1.4 
and Cox-2 expression by this membrane pump, previously reported in this 
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project. In support of this theory knockdown of RCAN1.4 in HDMEC resulted in 
inhibition of VEGF-induced tube formation in a collagen based assay, as 
measured by total cellular junctions and organisation (Holmes et al, 2010) while 
inhibition of Cox-2 activity by the selective Cox-2 inhibitor, rofecoxib, attenuated 
PMA-induced tube formation in a matrigel assay (Woods et al, 2003). 
Furthermore, addition of a Cox-2 inhibitor, NS-398, resulted in equivalent down-
regulation of VEGF-induced tube formation of HUVEC to that seen in the 
presence of CsA which had been shown to be reversed with the addition of 
PGE2, implying the involvement of Cox-2 in successful tube formation 
(Hernández et al, 2001). 
However it should be noted, in contrast to our results where we observe a 
decrease in tube formation with ectopic expression of PMCA4, which we have 
reported also inhibits RCAN1.4 expression, a study by Minami et al, 2004 found
over-expression of RCAN1 in HUVEC down-regulates VEGF- induced tube 
formation in a collagen gel assay (Minami et al, 2004). The discrepancy in 
results between the studies may in part be due to the experimental procedures 
carried out. For example, we studied tube formation after 24 hours stimulation 
with VEGF in comparison to 48 hours in their study. In support of this all studies
mentioned above that our data is in accordance with observed tube formation 
between 12 and 20 hours which is similar to the time we ended the experiment 
in our study.
When aiming to establish the significance of a protein or molecule in a 
physiological or pathological setting, it is of relevance to complete in vivo 
studies where possible. In collaboration with the Department of Vascular 
Biology and Inflammation, Centro Nacional de Investigaciones 
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Cardiovasculares CNIC, Madrid, Spain, Professor Redondo’s group kindly 
investigated in vivo functional vessel formation and allowed the results to be 
included in this thesis. VEGF-induced in vivo tube formation was attenuated in 
matrigel containing Ad-PMCA4 compared to the control Ad-LacZ, as measured 
by a significant decrease in both haemoglobin content and the number of 
vessels containing blood. The data obtained in this in vivo study is in agreement
with that observed for the equivalent in vitro experiments, further confirming 
PMCA4 as a negative-regulator of tube formation and is of particular relevance 
for the potential of PMCA4 as a future therapeutic target.
Interestingly, studies by Iizuka et al, 2004 and Hernández et al, 2001 have 
established a role for RCAN1.4 and Cox-2 in in vivo angiogenesis. Matrigel 
containing VEGF and oligonucleotides for the knockdown of RCAN1was shown 
to attenuate the number of vessels observed (Iizuka et al, 2004) while implants 
containing VEGF inserted into the corneas of mice resulted in reduced 
angiogenesis when treated with CsA, with equivalent inhibition observed in the 
presence of the Cox-2 inhibitor, NS-398. Additionally, negative-regulation of 
angiogenesis seen in the presence of CsA was reversed by treatment with 
PGE2 (Hernández et al, 2001). This data could be used in part to explain the 
inhibition we observe in in vivo vessel formation with ectopic expression of 
PMCA4, as we have demonstrated this protein to be a down-regulator of the 
expression of the pro-angiogenic proteins RCAN1.4 and Cox-2.
However, in contrast to our own results, Qin et al, 2006 observed a decrease in 
in vivo angiogenesis when RCAN1.4 was over-expressed, but no effect when 
RCAN1.4 was knocked down in a matrigel assay (Qin et al, 2006). Minami et al,
2004 similarly found over-expression of RCAN1 reduced the vascularisation 
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and haemoglobin content of matrigel plugs containing VEGF (Minami et al, 
2004).
The discrepancy in the data between these studies and our own could be due to
a variation in methods used. For example, Qin et al, 2006 did not add VEGF but
instead used a VEGF expressing tumour cell while Minami et al, 2004 used a 
lower concentration of VEGF (50 ng/plug of matrigel) compared to that used in 
our study (100 ng/plug of matrigel). Furthermore, the time course of 
experiments also varied, with Qin et al, 2006 observing in vivo tube formation 
after only 3 days while Minami et al, obtained data on day 14 after implantation, 
compared to the 7 days performed in this thesis. Studies that our results 
correlate with, previously mentioned above, such as Iizuka et al, 2004 and 
Hernández et al, 2001 observed angiogenesis at similar time points to our 
investigation such as 5 and 6 days respectively.  
4.7.4 VEGF-Induced Proliferation is Unaffected by PMCA4 
         Expression
Successful angiogenesis also requires the proliferation of endothelial cells 
(Liekens et al, 2001). VEGF has been established to induce proliferation of 
HUVEC (Bryant et al, 1998), which is reported to occur via a calcineurin/NFAT 
independent pathway, as CsA has no effect on proliferation of HUVEC in 
response to VEGF-signalling (Hernández et al, 2001). Therefore we 
hypothesised from our previous data that identified PMCA4 as an inhibitor of 
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calcineurin activity, that PMCA4 will not regulate this angiogenic process as it is 
not calcineurin-dependent. In support of this we ascertained the proliferation of 
HUVEC after 3 or 6 days of stimulation with VEGF was unaffected with ectopic 
expression of PMCA4 compared to the control.
The MAP kinase Erk1/2 has been established as an inducer of HUVEC 
proliferation in response to VEGF-signalling. Furthermore, Erk1/2 
phosphorylation and activity is increased in HUVEC in response to VEGF-
stimulation (Yu and Sato, 1999). Therefore to confirm the above result we 
additionally studied the phosphorylation (activation) status of the Erk1/2 protein.
Over-expression or knockdown of PMCA4 had no effect on the phosphorylation 
and therefore activation of Erk1/2 in response to VEGF-signalling compared to 
the control, concluding that PMCA4 does not regulate VEGF-induced Erk1/2 
signalling in endothelial cells. This supports our original hypothesis and is in 
accordance with the findings of Hernández et al, 2001, that showed a 
calcineurin inhibitor did not affect proliferation of endothelial cells. As we have 
identified PMCA4 as an endogenous inhibitor of calcineurin and also observed 
no effect of PMCA4 on cell proliferation it suggests this process does not occur 
via signalling through the calcineurin/NFAT pathway. This data also highlights 
the specificity of PMCA4s inhibitory effect by seemingly only down-regulating 
processes regulated by calcineurin.
Interestingly, RCAN1.4 has been studied in relation to proliferation with 
conflicting results. For example, knockdown of RCAN1.4 in HUVEC and 
HDMEC has been shown to have no effect on VEGF-induced proliferation 
(Iizuka et al, 2004; Holmes et al, 2010) or phosphorylation of Erk1/2 in HDMEC 
(Holmes et al, 2010). Our data is in agreement with these findings as over-
153
expression of PMCA4 inhibits RCAN1.4 expression but has no effect on 
proliferation or Erk1/2 phosphorylation in response to VEGF-stimulation in 
HUVEC. However, a study by Qin et al, 2006 showed RCAN1.4 over-
expression in HUVEC resulted in inhibition of proliferation with the opposite 
result occurring in the presence of knockdown of RCAN1.4 in response to 
VEGF-stimulation (Qin et al, 2006). Additionally, Baek et al, 2009 demonstrated 
VEGF-induced proliferation of endothelial cells isolated from RCAN1 over-
expressing mice was also inhibited (Baek et al, 2009). The discrepancy 
between studies could be due to the methods adopted in each case. For 
example, Iizuka et al, 2004 and Holmes et al, 2010 both studied proliferation 
after 72 hours (one of the time points used in our experiment) whereas Qin et 
al, 2006 measured proliferation after only 24 hours and also used a lower 
concentration of VEGF (10 ng/ml) compared to 50 ng/ml used in other studies. 
Furthermore, Iizuka et al, 2004 and Holmes et al, 2010 both used methods that 
measure proliferation in proportion to mitochondrial activity (MTT and 
luminescent based cell-titre glo assay respectively). As we also used an MTT 
assay for measurement of proliferation this could explain the similarity between 
our results and their studies. In comparison Qin et al, 2006 measured 
proliferation using a thymidine incorporation assay which measures DNA 
synthesis in S phase and although Baek et al, 2009 measured proliferation after
72 hours the cells used were isolated from RCAN1 transgenic mice which could
potentially identify a reason for the differences in data obtained.
4.7.5 Potential of PMCA4 as a Future Therapeutic Target
Angiogenesis is associated with a multitude of pathological phenotypes 
(Liekens et al, 2001) and is often targeted therapeutically in the treatment of a 
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number of these diseases (Carmeliet, 2005). As we have identified PMCA4 as 
an endogenous inhibitor of endothelial cell angiogenesis in this thesis, it is 
tempting to speculate the potential relevance of PMCA4 as a future therapeutic 
target in the regulation of these pathological conditions.
4.7.5a Tumour Angiogenesis
Angiogenesis is required for the propagation and survival of tumours by 
supplying oxygen and nutrients (Papetti and Herman, 2002) and also increases 
the potential of metastases (Jain, 2005). Interestingly, anti-angiogenic drugs 
that inhibit VEGF-signalling by either binding to VEGF such as bevacizumab or 
to VEGF receptors (for example Sunitinib) are being used in the treatment of 
colorectal cancer (Ferrara et al, 2004) and renal cell carcinomas (Motzer et al, 
2006) respectively, which is hypothesised to occur due to a reduction in 
angiogenesis (Willet et al, 2004; Motzer et al, 2006). This data therefore 
highlights the advantageous blockage of VEGF-signalling in the therapeutic 
treatment of tumours. As we have demonstrated PMCA4 to be an endogenous 
inhibitor of VEGF-induced angiogenesis by reducing processes such as cell 
migration, tube formation and the expression of pro-angiogenic proteins our 
findings imply a potential role for over-expression of PMCA4 in the treatment of 
tumours that are VEGF-dependent, consequently inhibiting VEGF-signalling, 
angiogenesis and tumour growth.
It should be taken into consideration that current anti-angiogenic treatments do 
not directly target the tumour and are not capable of causing complete tumour 
regression but instead reduce and prevent further growth (Shih and Lindley, 
2006). Therefore, anti-angiogenic therapies such as bevacizumab are often 
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administered in conjunction with chemotherapeutic agents that directly target 
the tumour (Hurwitz et al, 2004). As we have demonstrated PMCA4 to be an 
anti-angiogenic protein it suggests PMCA4 could be a potential therapeutic 
target in tumour treatment although it would need to be administered as a 
combined therapy for optimal treatment.
Additionally, Cox-2 has also been reported to be over-expressed in certain 
cancers such as cervical cancer (Kulkarni et al, 2001) and its expression is 
negatively correlated with survival and disease free survival in radiotherapy 
treated cervix carcinomas (Gaffney et al, 2001). Furthermore, xenografts of 
colorectal cancer cells resistant to chemotherapy treatment have an up-
regulation of Cox-2 expression and tumour size compared to sensitive cells 
(Rahman et al, 2012). Lewis lung carcinomas implanted into Cox-2-/- mice have 
reduced tumour growth, vascular density and VEGF expression compared to 
wild-type, implying Cox-2 has a role in the vascularisation of tumours which is 
required for their growth (Williams et al, 2000). In support of this, Caco-2 colon 
cancer cells over-expressing Cox-2 had an increased rate of growth when 
implanted into mice compared to the control (Tsujii et al, 1998). Cox-2 selective 
inhibitors, such as Celecoxib and NS-398, have also been successfully used in 
the reduction of tumour growth in a variety of xenograft mouse models (Tsujii et
al, 1998; Williams et al, 2000). Moreover, treatment with Celecoxib decreased 
tumour growth rate of chemotherapeutic resistant colorectal cancer cells in 
combination with chemotherapeutic agents compared to either treatment 
individually, which was thought to be due to an increase in apoptosis and 
therefore re-sensitisation of cells to treatment (Rahman et al, 2012).
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As the above results show a beneficial role of inhibiting Cox-2 in the therapy of 
tumours this further implies an advantageous function of PMCA4 as a target in 
the treatment of tumours, as we have demonstrated PMCA4 to be a negative-
regulator of Cox-2 expression. 
RCAN1 has also been reported to have a role in tumour progression although 
its exact function varies in different cells. For example, tumour formation 
resulting from injection of B16 melanoma cells into mice is attenuated with 
adenoviral infection of RCAN1 due to a reduction in blood vessel density 
(Minami et al, 2004). Similarly, over-expression of RCAN1 in transgenic mice 
inhibited the growth of Lewis lung carcinoma and B15F10 melanoma cells 
which again was thought to be due to a reduction in microvessel density (Baek 
et al, 2009). Both these studies suggest a negative feedback role of RCAN1 on 
angiogenesis. The data obtained in this thesis is not in accordance with these 
studies as we demonstrated PMCA4 to be a down-regulator of RCAN1.4 
expression and consequently angiogenic processes are inhibited. Interestingly, 
renal carcinoma cells injected into RCAN1-/- mice have reduced growth and 
microvessel density compared to the wild-type (Ryeom et al, 2008). Even 
though our results seem to support this study, in that a reduction in RCAN1.4 
expression by PMCA4 consequently inhibited angiogenic processes such as 
tube formation, they hypothesise the negative regulation they observe is again 
due to a loss of negative feedback inhibition resulting in hyperactivation of 
calcineurin and consequently activation of apoptosis, resulting in reduced 
tumour growth (Ryeom et al, 2008), whereas we have demonstrated PMCA4 to 
be a negative-regulator of both RCAN1.4 expression and calcineurin activity in 
this project.
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Therefore, further studies would need to be carried out to determine the 
beneficial or detrimental effect of RCAN1.4 inhibition by PMCA4 on tumour 
growth as the above studies suggest down-regulation of RCAN1.4 by over-
expression of PMCA4 would increase tumour angiogenesis. However, we did 
not identify RCAN1.4 to be a negative feedback inhibitor of calcineurin and 
consequently calcineurin/NFAT dependent angiogenesis, therefore, there is a 
possibility inhibition of RCAN1.4 by PMCA4 could be used to therapeutically 
inhibit tumour progression.
4.7.5b Limb Ischemia
Limb ischemia occurs due to occlusion of vessels, for example due to 
atherosclerotic plaque formation in limbs. This can lead to adverse events such 
as gangrene, amputation, cardiovascular complications and in severe cases 
mortality. Current treatments include surgery to bypass the occlusion although 
this is not always successful or an option for patients. Therefore, angiogenesis 
has become a target in therapy of this pathology to increase perfusion of 
ischemic limbs (Annex, 2013).
A mouse model of limb ischemia generated by ligating the femoral artery and 
removing it later, demonstrated the relevance of VEGF in this pathology. VEGF 
expression was identified to be increased at 7 and 14 days after induction of 
ischemia and reduced again after this time point. Interestingly, at 7 days, blood 
flow through the limb was initiated and continued to recover up to 35 days after 
initial surgery. An increase in capillary density was also observed. Furthermore, 
treatment with either an angiogenic inhibitor (platelet factor-4 (PF-4)) or an 
antibody against VEGF resulted in equivalent inhibition of blood flow recovery, 
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endothelial cell proliferation, capillary density and consequently 
neovascularisation in the ischemic limb of mice (Couffinhal et al, 1998). 
Additionally, a study in NOD mice reported a significant attenuation of blood 
flow recovery and capillary density in the ischemic limb which could be reversed
by treatment with an adenovirus encoding VEGF injected intramuscularly 
(Rivard et al, 1999). This data therefore demonstrates the relevance of VEGF 
signalling in the successful re-perfusion of ischemic limbs and its potential use 
in therapy for this disease (Couffinhal et al, 1998). 
It has previously been reported in a rabbit model of limb ischemia, VEGF-A165 
treatment via intra-arterial injection directly upstream of the occlusion results in 
an increase in collateral vessels compared to the control (Takeshita et al, 1994).
Additionally, a study on one patient with limb ischemia showed treatment with 
plasmid DNA encoding VEGF-A165 resulted in an increase in collateral vessels 
and consequently up regulation of blood flow in vivo after 1 month of treatment. 
However, one side effect observed was oedema due to an increase in the 
permeability of the vessels and it should be noted the treatment was not able to 
reverse gangrene and amputation was required (Isner et al, 1996).
Furthermore, Cox-2 has been reported to have a functional role in the re-
perfusion of ischemic limbs. Cox-2 expression is increased in response to 
induction of ischemia in wild-type mice 14 days after surgery (Ohashi et al, 
2009). Conversely, mice containing knockout of Cox-2 (Cox-2-/-) specifically in 
endothelial cells had impaired recovery of blood flow and capillary density in the
ischemic limb compared to the control mice (Ohashi et al, 2009).
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As we have demonstrated PMCA4 to be an inhibitor or VEGF-signalling, Cox-2 
expression and consequently angiogenesis, this data suggests up regulation of 
VEGF activity or Cox-2 expression could be used successfully to re-perfuse 
ischemic limbs. In this thesis we have reported that disruption of the interaction 
between PMCA4 and calcineurin or knockdown/knockout of PMCA4 increases 
both VEGF-induced angiogenic processes and Cox-2 expression and could 
therefore be used therapeutically to enhance vascularisation in ischemic limbs. 
4.7.5c Endometriosis
Endometriosis is characterised by ectopic sites of endometrium that due to 
angiogenesis continue to grow outside of the uterus (Hull et al, 2003). The 
severity of the disease correlates with the expression levels of VEGF (Shifren et
al, 1996) and it has been reported treatment with sFlt-1 (a soluble form of the 
VEGFR-1 receptor) or an antibody against VEGF, which both prevent VEGF-
signalling, resulted in reduced ectopic lesion formation in a mouse model of 
endometriosis (Hull et al, 2003). Hull et al, 2003 proposed this down-regulation 
of endometriosis by inhibition of VEGF could potentially be due to an increase in
apoptosis or conversely a decrease in proliferation. It should be noted, in this 
thesis we have not established if PMCA4 has any role in the regulation of 
apoptosis and therefore we cannot speculate how PMCA4 would affect this 
process in relation to the treatment of endometriosis. Additionally, even though 
we have shown PMCA4 to be a negative-regulator of VEGF-induced angiogenic
processes, we established PMCA4 does not regulate endothelial cell 
proliferation in response to VEGF-signalling which would suggest if the 
improvement seen in the pathophysiology of endometriosis with inhibitors of 
VEGF, reported in Hull et al, 2003 study, was a result of inhibition of 
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proliferation, PMCA4 may not be the optimum therapeutic target for the 
treatment of endometriosis.
On the other hand, Cox-2 has also been implicated to have a role in the 
progression of endometriosis. Cox-2 expression was reported to be higher in 
eutopic endometrial stromal cells from patients suffering with endometriosis 
compared to the control, especially during the secretory phase of the menstrual 
cycle (Matsuzaki et al, 2004b) and has also been shown to be increased in 
ectopic compared to eutpoic endometrium tissue. It is proposed an increase in 
PGE2 expression, due to an up-regulation of Cox-2, leads to propagation of the 
disease phenotype (Chishima et al, 2002). Additionally, treatment with a Cox-2 
inhibitor, celecoxib, in a rat model of endometriosis resulted in reduced size of 
ectopic implants suggesting the importance of Cox-2 in propagation and 
maintenance of pathological endometriosis (Matsuzaki et al, 2004a). 
Furthermore, the levels of Cox-2 have also been reported to be associated with 
the level of dysmenorrhea (menstrual pain) with higher expression of Cox-2 
correlating with more severe pain (Matsuzaki et al, 2004b). This suggests 
treatment by over-expression of PMCA4, which will consequently reduce Cox-2 
expression as previously reported in this thesis, could be used to reduce growth
of ectopic sites and also alleviate the pain associated with the pathology of this 
disease, therefore highlighting the potential of PMCA4 in the regulation of the 
symptoms and severity of this illness. 
4.7.5d Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an inflammatory disease of the joint. The synovium 
increases in size and develops a leading edge termed the pannus that is highly 
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vascularised and results in destruction of cartilage and bone. The quantity of 
synovial fluid also increases leading to inflammation, swelling and consequently
joint pain (Paleolog, 2002). Due to the increase in proliferation required to 
increase mass (Maruotti et al, 2006) the synovia becomes hypoxic and to 
provide oxygen and nutrients for this additional growth angiogenesis is 
stimulated (Paleolog, 2002; Maruotti et al, 2006). It is therefore hypothesised 
inhibition of angiogenesis will alleviate symptoms of RA (Paleolog, 2002). It has 
been proposed that anti-angiogenic therapies successfully used for the 
treatment of tumours could potentially be utilized in RA due to similarities in 
angiogenic features between both diseases (Semerano et al, 2011). 
In a mouse model of collagen induced RA, treatment with an antibody against 
VEGF reduced the severity of the phenotype of RA joints and postponed the 
onset of the disease although all mice developed arthritis (Sone et al, 2001a). 
An improvement in disease phenotype was also observed if treatment was 
given after symptoms of RA had already occurred (Sone et al, 2001a). 
However, in the same mouse model, one study saw an improvement in 
inflammation and reduced damage to bone and cartilage in the presence of an 
anti-VEGF antibody administered in early stages of the disease, but had no 
effect when given in the later stages after disease onset (Lu et al, 2000). The 
discrepancy in the efficacy of VEGF treatment after the onset of disease could 
be due to the time points studied as Sone et al, 2001a and Lu et al, 2000 both 
observed the effect of VEGF after the onset of disease but at 46 days or 50-58 
days after primary immunisation respectively. In this study we have established 
PMCA4 to be a mediator of VEGF-induced angiogenesis by negatively-
regulating processes required for angiogenesis such as cell migration and tube 
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formation. Therefore, over-expression of PMCA4 in this disease phenotype may
relieve some of the symptoms observed, although its potential use after the 
onset of the disease or in its later stages is currently controversial. 
Additionally, Cox-2 mRNA, protein expression and consequently PGE2 
production is elevated, whereas, Cox-1 levels remain the same in the paws of 
adjuvant-induced RA mouse models. Furthermore, paw oedema, number of 
osteoclasts and consequently bone resorption, inflammation and most 
interestingly Cox-2 expression is reduced in the presence of a Cox-2 selective 
inhibitor, SC-58125, which is a result of the reduction of PGE2 formation. This 
was similar to Indomethacin, a non-selective non-steroidal anti-inflammatory 
drug (NSAID) that inhibits both Cox-1 and Cox-2 activity (Anderson et al, 1996).
This data implies a role for Cox-2 but not Cox-1 in the propagation of RA. As we
have demonstrated PMCA4 to be an endogenous inhibitor of Cox-2 expression,
and therefore PGE2 production (although we did not demonstrate this in this 
study) it suggests PMCA4 could also potentially be used successfully in the 
treatment of RA. It has been suggested that using a selective Cox-2 inhibitor 
instead of a general Cox inhibitor (that inhibits both Cox-1 and Cox-2) will 
reduce the adverse side effects seen with the non-selective NSAIDs (Anderson 
et al, 1996). Specifically, it has been shown in patients suffering with 
osteoarthritis that treatment with a selective Cox-2 inhibitor, Rofecoxib, rather 
than a non-selective NSAID that attenuates both Cox-1 and Cox-2 activity, 
resulted in reduced gastrointestinal damage often seen as a side effect when 
the activity of both Cox isoforms are inhibited (Langman et al, 1999). This 
further implies a beneficial use of PMCA4 in the treatment of pathological 
disorders as we have demonstrated PMCA4 down-regulates Cox-2 expression 
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but has no effect on the expression of Cox-1, therefore the reduction in severe 
side effects observed in the presence of Cox-2 selective inhibitors should also 
occur with ectopic expression of PMCA4 if used as a treatment for pathological 
angiogenesis.  
Moreover, in an adjuvant-induced rat model of arthritis, PMCA activity was 
shown to be reduced and PGE2 levels increased in lymphocytes from arthritic 
rats compared to the control, with the opposite result occurring after pulsed 
electromagnetic field (PEMF) treatment which was shown to alleviate the 
symptoms of RA (Selvam et al, 2007). This finding is highly interesting in 
relation to our data as we have shown an increase in PMCA4 expression 
decreases angiogenesis and consequently Cox-2 expression, which would 
reduce PGE2 levels, and suggests the alleviation of RA symptoms which 
correlates with an increase in PMCA4 expression seen in Selvam et al, 2007 
study is due to the anti-angiogenic properties of PMCA4 we have previously 
demonstrated in this study and further supports the potential of PMCA4 as a 
therapeutic target in the down-regulation of RA pathology. 
However, in the study by Selvam et al, 2007 lymphocytes were studied whereas
we used endothelial cells and PMCA activity was recorded as a whole and the 
involvement of individual isoforms in this case was not established. It would 
therefore be of relevance to distinguish the significance of the PMCA4 isoform 
specifically in their study as it is possible the different cells used in each study 
could have a different PMCA isoform involved in the result observed in each 
case.
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It should be noted for the treatment of tumours, combined therapy such as 
chemotherapy and the anti-angiogenic drug bevacizumab is most beneficial to 
patients, targeting not only the tumour itself but also angiogenesis (Hurwitz et 
al, 2004). It is therefore hypothesised the same will apply to RA, with anti-
angiogenic therapies being given in conjunction with treatments to target other 
significant features of RA progression such as inflammation (Semerano et al, 
2011).
4.7.5e Psoriasis
Psoriasis is an inflammatory disease of the skin leading to hyperplasia of the 
epidermis (Singh et al, 2013). It is hypothesised angiogenesis is initiated in the 
psoriasis sites to cope with the high demand of oxygen and nutrients required 
by the increase in the number of cells (Detmar et al, 1994). In human psoriasis 
skin samples, both VEGF and the receptors VEGFR-1 and 2 have been 
reported to be over-expressed (Detmar et al, 1994) and blood and lymphatic 
vessels have been shown to be enlarged (Kunstfeld et al, 2004). Interestingly, 
treatment with an anti-VEGF antibody in a psoriasis mouse model resulted in 
inhibition of the psoriasis phenotype as observed by alleviation of swelling, 
inflammation and scaly skin on the paw, ear or tails, reduced quantity of 
inflammatory cells such as lymphocytes and macrophages, down-regulation of 
proliferation of keratinocytes and reduced number and size of blood vessels 
(Schonthaler et al, 2009), while treatment with antibodies against VEGFR-1 and
2 simultaneously, reduced inflammation and the size of lymphatic vessels in 
wild-type mice that had induced inflammation (Kunstfeld et al, 2004). 
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Interestingly, in a patient suffering with colon cancer and psoriasis, treatment 
with chemotherapeutic agents and the FDA approved anti-angiogenic drug 
bevacizumab, resulted in remission of psoriasis which was thought to be due to 
bevacizumab (Akman et al, 2008). Even though this finding is promising further 
investigations need to be carried out to confirm this result as only one subject 
was studied. 
As the above data establishes inhibition of VEGF-signalling and consequently 
angiogenesis alleviates the symptom of psoriasis it suggests over-expression of
PMCA4 could possibly be used in the treatment of this pathological disorder as 
we have demonstrated ectopic expression of PMCA4 to be a negative-regulator
of the VEGF-induced angiogenic processes. 
4.7.5f Retinopathies 
There are a number of retinopathies associated with an increase in 
angiogenesis that leads to severe vision loss such as age related macular 
degeneration (AMD) (Kourlas and Abrams, 2007; Zhou and Wang, 2006) and 
diabetic retinopathy (Cheung et al, 2010). Both diseases result in vessel hyper-
permeability, and in severe cases retinal detachment (Kourlas and Abrams, 
2007; Cheung et al, 2010).
Interestingly, VEGF expression has been reported to be up-regulated in retinal 
endothelial cells in cases of diabetic retinopathy (Cheung et al, 2010) which 
have also been shown to have an increase in the vitreous levels of VEGF 
(Adamis et al, 1994). Therefore, anti-VEGF treatments have been used to 
alleviate adverse symptoms of retinopathies. For example, ranibizumab that 
inhibits all isoforms of VEGF (Kourlas and Abrams, 2007) has been reported in 
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patients with AMD to increase visual acuity and cause a decrease in choroidal 
neovascularisation and leakage (Brown et al, 2006).
 Additionally, a VEGF-A165 selective inhibitor, pegaptanib has been successfully 
used to treat AMD resulting in reduced vessel permeability and 
neovascularisation. Advantageously, fewer adverse effects were associated 
with this treatment (Gragoudas et al, 2004).
As we have established PMCA4 as an inhibitor of VEGF-induced angiogenesis 
it proposes a role for PMCA4 in the therapeutic treatment of retinopathies. 
Over-expression of PMCA4 within the eye could potentially down-regulate 
angiogenesis and consequently alleviate the phenotype of both AMD and 
diabetic retinopathy. As we have reported PMCA4 to specifically inhibit the 
calcineurin/NFAT pathway in response to VEGF-stimulation it is possible fewer 
adverse effects will be observed if used therapeutically, as not all VEGF-
signalling pathways will be down-regulated. Therefore, we hypothesise the 
benefits observed with the use of the isoform specific (VEGF-A165) pegaptanib 
could also potentially occur in the presence of PMCA4.       
Additionally, Cox-2 expression has been shown to be increased in the nerve 
fibre layer (NFL) of diabetic patients and in endothelial cells of the NFL in a 
mouse model of retinopathy of prematurity (ROP) in the ischemic phase. 
Interestingly, the use of selective Cox-2 inhibitors, APHS and etodolac 
attenuated preretinal neovascularisation in mouse and rat models respectively, 
of ischemic proliferative retinopathy, which could be reversed in the presence of
PGE2 (Sennlaub et al, 2003). Furthermore, Rofecoxib also reduced 
angiogenesis in a mouse model of ROP as determined by a reduction in the 
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number of blood vessels observed in the inner retina (Wilkinson-Berka et al, 
2003). As we have demonstrated PMCA4 to be an inhibitor of Cox-2 expression
in this study it suggests another potential axis of PMCA4 regulation of diabetic 
or AMD retinopathies. Hypothetically, over-expression of PMCA4 could be used
to alleviate the phenotype of retinopathies such as that seen in the presence of 
Cox-2 inhibitors. However, it should be taken into consideration, Sennlaub et al,
2003, suggested the reduction in angiogenesis observed in the presence of a 
Cox-2 inhibitor was not related to VEGF-signalling (Sennlaub et al, 2003). As 
we have only demonstrated PMCA4 to be a negative regulator of VEGF-
induced angiogenesis, PMCA4 may not be suitable for the inhibition of Cox-2 
and consequently treatment of retinopathies. Furthermore, Cox-2 was reported 
to be present in both physiological and pathological retinal blood vessels and 
therefore inhibition of Cox-2 expression by PMCA4 may potentially be 
detrimental as it will not be able to distinguish between pathological and 
physiological vessels (Wilkinson-Berka et al, 2003). Therefore, the use of 
PMCA4 as an endogenous regulator of angiogenesis in the treatment of 
retinopathies in relation to Cox-2 is unclear and more studies would need to be 
carried out to determine the benefits.
4.7.6 Comparison of Potential PMCA4 Treatment to Current Anti-
Angiogenic Therapy
Many anti-angiogenic therapies currently in use, such as bevacizumab or 
pegaptanib successfully utilized for the treatment of tumours (Ferrara et al, 
2004) or AMD respectively (Zhou and Wang, 2006), function by inhibiting 
VEGF-signalling pathways and consequently angiogenesis (Willet et al, 2004; 
Gragoudas et al, 2004). As we have demonstrated PMCA4 to be an 
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endogenous inhibitor of VEGF-signalling via the calcineurin/NFAT pathway and 
consequently a down-regulator of angiogenesis, it proposes PMCA4 as a 
potential therapeutic target for pathological disorders requiring angiogenesis for 
progression, although the benefits and adverse effects of this treatment in 
comparison to current therapies can only be hypothesised at this time.
It has been suggested pathological angiogenesis is specifically targeted by anti-
VEGF therapy as these vessels do not form correctly. One abnormality of these 
immature vessels compared to physiological ones is the absence of attached 
pericytes which makes them responsive to VEGF-signalling whereas 
physiological vasculature is not (Hull et al, 2003). As we have identified PMCA4 
to be a negative-regulator of angiogenesis in response to VEGF-stimulation it 
suggests if PMCA4 is used therapeutically it would also be selective for 
pathological rather than physiological vasculature as these abnormal vessels 
are sensitive to alterations in VEGF-signalling.  
We have also identified PMCA4 as an endogenous negative-regulator of the 
calcineurin/NFAT pathway. Inhibitors of this pathway such as CsA or FK506 
have successfully been used in transplants to prevent rejection (Crabtree and 
Olson, 2002). However, its use in the treatment of other disease, such as 
cardiac hypertrophy in mouse models, have been less successful due to the 
high dosage of FK506 required that leads to severe side effects such as kidney 
damage (Crabtree, 1999). Therefore, PMCA4 could potentially be a superior 
inhibitor of calcineurin/NFAT signalling as we have identified it to be an 
endogenous negative-regulator of calcineurin and could possibly have less toxic
effects and side effects to that seen in the presence of excess CsA or FK506. 
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One of the most frequent side effects observed with VEGF inhibitors is 
hypertension. Hypertension is thought to occur due to inhibition of NO 
production by eNOS as a result of down-regulation of VEGF-signalling 
consequently increasing blood pressure (Kamba and McDonald, 2007). As 
ectopic expression of PMCA4 has previously been reported to inhibit eNOS 
activity and consequently NO production (Holton et al, 2010a) it suggest 
hypertension could still be a serious adverse effect observed if PMCA4 is used 
therapeutically to inhibit angiogenesis. 
A significant problem posed with current anti-angiogenic treatments is the risk of
systemic adverse effects (Simó and Hernández, 2008). For example, in the 
case of retinopathies, such as diabetic retinopathy, anti-VEGF treatments are 
intravitrealy injected and therefore therapy is initially localised, however, 
treatment can reach the circulation and could potentially cause adverse 
systemic effects. Possible side effects include hypertension, proteinuria, 
cardiovascular complications and impaired wound healing (Simó and 
Hernández, 2008) with some being reported to occur as side effects of current 
anti-VEGF treatments, such as bevacizumab in the therapy of colorectal 
cancers, which then additionally also need to be treated (Hurwitz et al, 2004). 
Potentially, if PMCA4 over-expression could be localised to a specific tissue or 
organ involved in the particular pathology, for example by gene therapy 
delivered by a viral vector harbouring a tissue specific, selective promoter, 
angiogenesis could be inhibited with a reduction in systemic side effects 
possible with current anti-VEGF treatments.  
VEGF has been reported to activate a variety of signalling pathways (Fig.1.1.3) 
such as the calcineurin/NFAT pathway (Armesilla et al, 1999), p38 MAPK (Yu 
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and Sato, 1999), Erk1/2 (Yu and Sato, 1999) and PI3K (Yu and Sato, 1999) 
leading to an increase in angiogenic processes such as cell migration and tube 
formation, reduced apoptosis and increased proliferation (Hernández et al, 
2001; Yu and Sato, 1999). Current anti-angiogenic treatments such as 
bevacizumab prevent VEGF from binding to its receptor (Shih et al, 2006), 
therefore inhibiting VEGF-signalling and consequently all pathways regulated by
VEGF. In comparison PMCA4 inhibits calcineurin and therefore specifically the 
calcineurin/NFAT pathway after stimulation with VEGF. As a result not all 
pathways regulated by VEGF will be inhibited, which was confirmed in this 
study, as we demonstrated PMCA4 had no effect on endothelial cell 
proliferation via the Erk1/2 signalling pathway in response to VEGF-stimulation. 
Interestingly, inhibition of VEGF by anti-angiogenic therapies can reduce cell 
proliferation and survival which is associated with some side effects such as 
haemorrhaging or thrombosis (Kamba and McDonald, 2007). We have reported
in this thesis, VEGF-induced proliferation is unaffected by PMCA4 and therefore
suggests one benefit of PMCA4 as a therapeutic target, as it would be able to 
inhibit pathological angiogenesis without compromising cell survival which could
additionally reduce side effects observed with the use of current anti-VEGF 
treatments.    
4.8 Conclusion
Overall we have identified a novel role of PMCA4 as a negative-regulator of 
VEGF-induced calcineurin/NFAT-dependent angiogenesis. Specifically, ectopic 
expression of PMCA4 inhibited the expression of pro-angiogenic proteins 
RCAN1.4 and Cox-2, cell migration and in vitro and in vivo tubular 
morphogenesis. Interestingly, PMCA4 expression had no effect on endothelial 
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cell proliferation suggesting PMCA4 could inhibit angiogenesis without 
compromising cell survival. Considering the number of diseases that involve 
angiogenesis for progression the finding in this study of PMCA4 as an 
endogenous negative-regulator of angiogenesis is far reaching particularly in 





Characterisation of the Molecular Mechanism of
PMCA4s Inhibition of the Calcineurin/NFAT Pathway
and Angiogenesis
5.1 Introduction
Previous work by our group has mapped the interaction between PMCA4 and 
calcineurin to the region encompassing amino acids 428 to 651 of PMCA4b 
(Buch et al, 2005). We hypothesise that PMCA4b inhibits the VEGF-mediated 
activation of the calcineurin/NFAT pathway via interaction with calcineurin. 
Over-expression of an excess of the region 428-651 of PMCA4b should 
compete with the endogenous PMCA4 protein in the interaction with calcineurin,
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leading to disruption of the PMCA4/calcineurin interaction and therefore an 
increase in the activity of the calcineurin/NFAT pathway (Fig. 5.1.1).
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Fig. 5.1.1 Hypothesis of the effect of ectopic expression of 3xFlag-PMCA4b(428-
651) (Ad-ID4) on the interaction between endogenous PMCA4b and calcineurin 
and consequently the calcineurin/NFAT pathway. A) In physiological conditions 
PMCA4b and calcineurin (Cn) interact with each other. It is believed that this interaction
maintains a percentage of calcineurin in a low calcium micro-environment (represented
as the grey area at the membrane) which will inhibit calcineurin activity and therefore 
prevent NFAT translocation into the nucleus (Holton et al, 2010b) and consequently 
angiogenesis will be reduced. B) Over-expression of the region of PMCA4 that 
interacts with calcineurin, 3xFlag-PMCA4b(428-651) (represented as ID4 in the figure) 
will out-compete endogenous PMCA4b for calcineurin and therefore will prevent the 
interaction between the two proteins resulting in release of calcineurin from the 
inhibitory low-calcium microdomain, activation of calcineurin, NFAT translocation and a 
concomitant up-regulation of angiogenesis. 
5.2 Generation of an Adenovirus Encoding the Region 428-651 of PMCA4b
As a first step to test this hypothesis we generated an adenoviral vector Ad-
3xFlag-PMCA4b(428-651) (Ad-ID4) that encodes a flag-tagged version of the 
region 428-651 of human PMCA4b, to allow us to investigate whether the 
interaction between the two proteins is essential for the inhibitory effect exerted 
by PMCA4b on calcineurin in VEGF-stimulated cells.
The region of human PMCA4b encompassing amino acids 428-651 (numbering 
according to gene bank accession number: NM_001684) was amplified as 
described in methods using plasmid pF-PMCA4b-(428-651) as a template. 
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Target Gene
Amplification was carried out in such a way that the amplified fragment encodes
three copies of the Flag epitope fused to the region 428-651 of PMCA4b.
To ensure the PCR amplification was successful and the correct fragment had 
been amplified PCR products were analysed by DNA electrophoresis using a 
1% agarose gel. The gel showed a unique band of the expected size (797bp) 
suggesting that the correct region of PMCA4b had been amplified (+) (Fig. 
5.2.1). A control PCR was run containing dH2O (-) in place of the plasmid to 
ensure no unspecific amplification occurred in the PCR reactions (Fig. 5.2.1). 
Oligonucleotides forward and reverse used in the PCR reaction contained 












Fig. 5.2.1 Agarose gel electrophoresis of the PCR amplification of pF-PMCA4b-
(428-651). DNA electrophoresis of PCR reactions performed using dH2O (-) (negative 
control) or the plasmid pF-PMCA4b-(428-651) (+) (Buch et al, 2005) reveals a unique 
amplification product of the expected size (797bp) suggesting the interaction region of 
PMCA4 (428-651) has been amplified. A 1Kb ladder (Invitrogen, UK) was used as a 
marker for DNA length.
The amplified fragment was then precipitated, adenylated and ligated into the 
pGEM®-T Easy Vector (Promega, UK). The resulting plasmid was transformed 
into JM109 competent E.coli cells. Bacterial colonies were selected on LB-agar 
plates supplemented with 100 μg/ml ampicillin. Plasmid DNA was isolated by 
the DNA mini-preparation method from overnight cultured bacterial colonies and
analysed for the presence of the fragment by restriction digestion using BamHI 
and XhoI enzymes. Digested samples were subsequently run in a 1% DNA 
agarose gel resulting in two separate bands;  an upper one of 3015bp 
corresponding to the pGEM®-T Easy Vector and a lower one of 797bp relating 
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to the insert (3xFlag-PMCA4b(428-651)) (Fig. 5.2.2) All clones were positive 
showing successful incorporation of the insert into the vector (Fig. 5.2.2). Clone 
number 1 was sequenced by the Department of Vascular Biology and 
Inflammation, Centro Nacional de Investigaciones Cardiovasculares CNIC, 
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Fig. 5.2.2 Electrophoresis gel of the plasmid pGEM®-T- 3xFlag-PMCA4b(428-651) 
digested with BamHI and XhoI. Digestion with BamHI and XhoI of the plasmid 
pGEM®-T- 3xFlag-PMCA4b(428-651) with plasmid DNA obtained by DNA mini-
preparation from several bacterial colonies grown overnight. Restriction digestion of the
plasmid resulted in the presence of two distinct bands when run in a 1% DNA agarose 
gel; one of 3015bp and one of 797bp corresponding to the pGEM®-T Easy Vector and 
the insert (3xFlag-PMCA4b(428-651)) respectively, suggesting that the ligation 
procedure was successful and the vector contains the fragment. Clone 1 was sent for 
sequencing to confirm the fidelity of the amplified fragment and was therefore used for 
further cloning experiments.
The resulting plasmid was named pGEM®-T-3xFlag-PMCA4b(428-651) (Fig. 5. 
2.3). Mini-preparations were then performed using clone 1 and digested with 
BamHI and XhoI to release the insert. The fragment BamHI- 3xFlag-
PMCA4b(428-651)-XhoI (797bp) was isolated and purified after running in a 1%
electrophoresis gel in preparation for its ligation with the pENTRTM 11 dual 




















Fig. 5.2.3 Schematic diagram of the pGEM®-T- 3xFlag-PMCA4b(428-651) plasmid. 
The plasmid pGEM®-T- 3xFlag-PMCA4b(428-651) of 3812bp generated by the ligation 
of the pGEM®-T Easy Vector and the insert (3xFlag-PMCA4b(428-651)). This plasmid 
contains the amplified fragment of PMCA4 that interacts with calcineurin (428-651) and
contains a Flag tag for identification in infected cells (represented in purple in the 
diagram). This fragment was adenylated (A) by addition of adenosine to the 3’ends. 
The pGEM®-T Easy Vector contains Thymidine 3’ overhangs (T) allowing efficient 
ligation of the vector and insert. The pGEM®-T Easy Vector contains ampicillin 
resistance (represented by the green band) allowing transformation and amplification of
the plasmid in ampicillin (100 μg/ml) selective media and plates.
To generate an adenovirus encoding the region of PMCA4b (428-651) that 
interacts with calcineurin, the fragment required ligation into the pENTRTM 11 
dual selection vector for incorporation into the destination vector, pAd/CMV/V5-
DESTTM (Invitrogen, UK). To prepare the pENTRTM 11 dual selection vector for 
ligation with the fragment (3xFlag-PMCA4b(428-651)) it was digested with the 
enzymes BamHI and XhoI to produce complementary sticky ends to that of the 
insert. The vector was initially cut with XhoI and run in a 0.7% electrophoresis 
gel to determine successful digestion. As there is only one XhoI restriction site 
the vector becomes linear. Figure 5.2.4 shows a distinct band at the expected 
size of 3800bp when cut with XhoI. The uncut is also a single band but travels 
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agarose gel of pENTRTM 11 dual selection vector cut with XhoI. The pENTRTM 11 
dual selection vector was either uncut (control) or cut with XhoI and run in a 0.7% 
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electrophoresis gel. Digestion with XhoI resulted in a band of the predicted size of 
3800bp. In comparison the uncut also generates an individual band that travels further 
in the gel due to supercoiling. 
The digested vector was then precipitated, cut with BamHI and run in a 0.7% 
agarose gel. The vector contains three BamHI sites generating 3 fragments 
represented as an upper band of 2313bp and one lower band corresponding to 
fragments 693bp and 702bp which are unable to be resolved as two distinct 
bands due to the similarity in their size (Fig. 5.2.5). Additionally, a 92bp 
fragment which is between a BamHI and the XhoI restriction site would have 
been produced due to the previous digestion with XhoI, however, this band is 
not visible in the gel as the fragment is too small. The successfully digested 
pENTRTM 11 dual selection vector was then dephosphorylated to prevent self-
ligation and purified after running in a 0.7% gel. The purification was successful 




Fig. 5.2.5 Electrophoresis DNA gel of pENTRTM 11 dual selection vector 
previously cut with XhoI and digested with BamHI and dephosphorylation of this 
vector. Previously XhoI digested pENTRTM 11 vector was cut with BamHI generating 
two distinct bands at the expected position of 2313bp and a lower one corresponding to
two fragments of 693bp and 702bp. The digestion was dephosphorylated and purified 
from a 0.7% gel which resulted in the presence of one band at the predicted position of 
2313bp showing successful isolation of the digested vector that now has 
complementary sticky ends to the insert.     
The digested and dephosphorylated vector was then ligated to the fragment 
3xFlag-PMCA4b(428-651) that was also cut with BamHI and XhoI (see above), 
generating the plasmid pENTRTM 11-3xFlag-PMCA4b(428-651) (Fig. 5.2.6), 
transformed in JM109 competent cells and positive colonies selected on 
kanamycin (100 μg/ml) LB plates. Mini-preparations were carried out using 
successful clones and digested with BamHI and XhoI to check the insert was 
present. Cut samples were run in a 1% DNA agarose gel and produced two 
bands one corresponding to the vector (2313bp) and to the insert (797bp) 
showing that the ligation had been successful (Fig. 5.2.7)     
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Fig. 5.2.6 Schematic diagram of the 
plasmid pENTRTM 11-3xFlag- PMCA4b(428-651). The plasmid of 3110bp 
resulting from the ligation of the pENTRTM 11 dual selection vector and the insert, 







































have complementary sticky ends. The plasmid contains kanamycin resistance for 
selective propagation of the plasmid.
  
Fig. 5.2.7 Mini-preparations of the plasmid pENTRTM 11-3xFlag-PMCA4b(428-651) 
digested with BamHI and XhoI and run in a 1% agaose gel. The pENTRTM 11 vector
and the fragment 3xFlag-PMCA4b(428-651) both digested with BamHI and XhoI were 
ligated and transformed in JM109 E.coli cells. Positive colonies were selected on 
kanamycin (100 μg/ml) plates and mini-preparations carried out using these colonies. 
Digestion of these preparations and subsequent running in a 1% electrophoresis gel 
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resulted in 2 separate bands; an upper one of 2313bp corresponding to the vector and 
a lower one of 797bp relating to the insert therefore showing ligation had been 
successful and the vector contained the fragment. Clone 5 was selected for further use 
in the cloning procedure.  
Clone 5 was selected for maxi-preparations and further digestion experiments 
carried out with HindIII and EcoRI to confirm the vector contains the 3xFlag-
PMCA4b(428-651) insert. The pENTRTM 11-3xFlag-PMCA4b(428-651) plasmid 
contains two HindIII restriction sites resulting in two individual bands 
corresponding to the plasmid (2935bp) and the HindIII fragment (175bp) after 
running in a 2% DNA agarose gel (Fig. 5.2.8). The uncut sample ran as one 
unique band showing the digestion was specific (Fig. 5.2.8). 
In comparison only one EcoRI site is present in the plasmid. Running of the 
EcoRI digested plasmid in a 0.7% gel resulted in one isolated band at the 
expected size of 3110bp as the plasmid becomes linear, whereas the uncut, 
although still one single band, travelled further through the gel due to super 
coiling (Fig. 5.2.9). These digestions therefore confirm the pENTRTM 11 vector 
contains the insert 3xFlag-PMCA4b(428-651).
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Fig. 5.2.8 A 2% DNA agarose gel of the pENTRTM 11-3xFlag-PMCA4b(428-651) 
plasmid cut with HindIII. Maxi-preparations of the plasmid pENTRTM 11-3xFlag-
PMCA4b(428-651) were digested with HindIII and subsequently run in an 
electrophoresis gel (2%) resulting in two isolated bands of 2935bp and 175bp as a 
result of the position of the two HindIII restriction sites whereas the uncut plasmid 
contains one isolated band showing the digestion was specific. This therefore suggests

















Fig.5.2.9 Digestion of the plasmid pENTRTM 11-3xFlag-PMCA4b(428-651) with 
EcoRI. The plasmid pENTRTM 11-3xFlag-PMCA4b(428-651) was either uncut or cut 
with EcoRI and run in a 0.7% electrophoresis gel. Digestion of the plasmid resulted in a
unique band as expected at 3110bp due to the presence of only one EcoRI restriction 
site in the plasmid, therefore making it linear. The uncut plasmid travels slightly further 











The pENTRTM 11-3xFlag-PMCA4b(428-651) was then recombined into the pAd/
CMV/V5-DESTTM (Invitrogen, UK) using the Gateway® LR ClonaseTM II enzyme 
mix (Invitrogen, UK), transformed and positive colonies selected on ampicillin 
(100 μg/ml) LB plates. The resulting plasmid was called ID4. Mini-preparations 
of the plasmid were digested with PacI to allow propagation of the virus in 
HEK293A cells. Running of the digested sample in a 0.7% electrophoresis gel 
resulted in two bands of the expected sizes 33257bp and 2074bp due to the two
PacI restriction sites therefore confirming successful cutting with the enzyme 
(Fig. 5.2.10). The uncut sample had only one band showing specific digestion in
the presence of the enzyme (Fig. 5.2.10). Clone 1 was sent for sequencing, 
confirming the presence of the insert (see appendix 5) and was therefore used 
for further cloning procedures. 
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Fig. 5.2.10 Electrophoresis gel (0.7%) of the plasmid ID4 digested with PacI. Mini-
preparations of the plasmid ID4 (pENTRTM 11-3xFlag-PMCA4b(428-651) recombined 

















Selected sample for 
further cloning
fragments at the expected size of 33257bp (upper band) and 2074bp (lower band). The
uncut (control) only had one distinct band showing the digestion was specific. Clone 1 
was sequenced and confirmed to have the insert therefore this sample was used to 
generate the virus.
Plasmid digested with PacI was precipitated and used for the production of the 
primary stock of adenovirus (Ad-ID4) encoding the 3xFlag-PMCA4b(428-651) 
by transfection into HEK293A cells. Secondary and tertiary stocks were further 
obtained by infection of HEK293A with the previous stock and subsequent 
chloroform purification. For infection of HUVEC the tertiary stock of Ad-ID4 was 
used at a MOI=50 and cells were incubated for 72 hours. Due to the presence 
of the Flag-tag on the region of PMCA4b(428-651) that binds with calcineurin, 
successful infection of cells with ID4 could be demonstrated by western blot 
analysis using an antibody against Flag (SIGMA, UK). Infection of HUVEC with 
Ad-ID4 resulted in the detection of the Flag epitope by using an anti-Flag 
antibody. As expected no Flag recombinant protein was observed in cells 
infected with Ad-LacZ (Fig 5.2.11, upper panel). This result confirmed the 
successful generation of an adenovirus that induces the expression of the 
3xFlag-PMCA4b(428-651) region that can be used to disrupt the interaction 
between PMCA4 and calcineurin in HUVEC. Western blots detecting PMCA4 
was also carried out as a control to ensure the protein expression of the pump 
was not altered by transfection with the Ad-ID4 virus. Western blot using 
antibodies for PMCA4 (Fig. 5.2.11, middle panel) showed equivalent levels of 
PMCA4 protein in Ad-ID4 and Ad-LacZ infected HUVEC suggesting infection 
with the ID4 virus does not affect the expression of PMCA4. A western blot 
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detecting tubulin was also carried out to confirm equal loading of the samples 
(Fig. 5.2.11, lower panel).
Fig. 5.2.11 Expression of 3xFlag-PMCA4b(428-651) in HUVEC. HUVEC were 
infected with Ad-ID4 or Ad-LacZ (control) at a MOI= 50 for 72 hours. Samples were 
analysed by western blot using an antibody against Flag (α-Flag). Flag was detected in 
endothelial cells infected with ID4 (first panel) but absent in Ad-LacZ infected cells. The
expression of PMCA4 was unaffected by infection with Ad-ID4 as detected using an 
anti-PMCA4 antibody (α-PMCA4) compared to the control. In all cases a western blot 
detecting tubulin (α-Tubulin) was carried out to confirm equal amounts of protein in the 
samples. 
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5.3 Investigation of the Molecular Mechanism Involved in PMCA4-
Dependent Inhibition of VEGF-Induced Calcineurin/NFAT Activity     
and Angiogenesis
Due to the successful generation of an adenovirus that induces the expression 
of the 3xFlag-PMCA4b(428-651) (Ad-ID4) corresponding to the region of 
PMCA4 that interacts with calcineurin we next wanted to investigate if the 
inhibition of the calcineurin/NFAT pathway and angiogenic processes by 
PMCA4 (seen in chapter 3 and 4) was a result of the interaction between the 
two proteins. As stated in chapter 5.1 (Fig 5.1.1) we hypothesise that 
expression of the interaction domain of PMCA4(428-651) in excess by infection 
of HUVEC with the Ad-ID4 virus will prevent the binding of calcineurin to the 
endogenous PMCA4 pump resulting in a lack of calcineurin inhibition. 
Therefore, we propose that disrupting the interaction between the two proteins 
will reverse the inhibitory effect observed on the calcineurin/NFAT pathway and 
subsequent angiogenic processes regulated by this pathway which we have 
seen in chapters 3 and 4.  
5.3.1 The Interaction PMCA4b/Calcineurin is Essential for PMCA4 
          Dependent Inhibition of the Calcineurin/NFAT Pathway
We have previously demonstrated that over-expression of PMCA4 inhibits the 
calcineurin/NFAT pathway in endothelial cells. If this is a result of the interaction
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between the two proteins, PMCA4 and calcineurin, then over-expression of the 
interaction region of PMCA4 (that is likely to disrupt the association between the
two proteins) would prevent the inhibition observed. To test this theory HUVEC 
were co-infected with Ad-NFAT-Luc and either Ad-LacZ or Ad-ID4. Infected 
cells were then stimulated with VEGF (25 ng/ml) for 6 hours after overnight 
serum starvation and NFAT activity measured in a luminometer. Over-
expression of the interaction region (ID4) by infection with Ad-ID4 resulted in a 
significant increase of 101.62%, p ≤ 0.01, in NFAT activation compared to the 
control Ad-LacZ (Fig 5.3.1). This result supports our hypothesis that putative 
disruption of the interaction between PMCA4 and calcineurin can reverse the 
inhibition observed in PMCA4 over-expressing cells and therefore highlights the
importance of the interaction in the mechanism of PMCA4-downregulation of 
the calcineurin/NFAT signalling pathway.
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Fig. 5.3.1 Ectopic expression of the interaction domain of PMCA4 that interacts 
with calcineurin (428-651) increases the activation of NFAT in response to VEGF-
stimulation. A) Expression of the region of PMCA4b (428-651) that interacts with 
calcineurin significantly increases the activity of NFAT. HUVEC were infected with Ad-
LacZ or Ad-ID4. Cells were then additionally infected with Ad-NFAT-Luc, stimulated 
with VEGF (25 ng/ml) for 6 hours and NFAT activity measured in a luminometer. Data 





























5.3.2 Ectopic Expression of the PMCA4 Interaction Domain 
         Significantly Enhances RCAN1.4 Protein Expression in   
         Response to VEGF-Stimulation
As we had previously identified a role for PMCA4 in the inhibition of the protein 
expression of the pro-angiogenic protein RCAN1.4, we wanted to determine if 
this inhibition could be attenuated by ectopic expression of ID4. HUVEC were 
infected with Ad-LacZ or Ad-ID4, serum starved overnight and analysed by 
western blot after 4 hours stimulation with VEGF (25 ng/ml). Western blot 
analysis using an antibody against RCAN1.4 (SIGMA-ALDRICH, UK) showed a 
significant increase of 120.24%, p ≤ 0.001 in the expression of RCAN1.4 in cells 
expressing the interaction domain of PMCA4 compared to the control LacZ (Fig.
5.3.2) Equal loading of protein was confirmed by the use of an antibody against 
tubulin (SIGMA-ALDRICH, UK) (Fig. 5.3.2). This data also supports the theory 
that the interaction of PMCA4 with calcineurin results in inhibition of the 
calcineurin regulated expression of RCAN1.4 which can be reversed by putative
disruption of the interaction between the two proteins. 
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Fig. 5.3.2 Ectopic expression of the interaction region of PMCA4b, residues 428-
651 (ID4), increases VEGF-induced RCAN1.4 protein expression in endothelial 
cells. HUVEC cells infected with Ad-LacZ or Ad-ID4 were serum starved overnight, 
stimulated with VEGF (25 ng/ml) for 4 hours and analysed by western blot. A) Over-
expression of ID4 increases endothelial cell protein expression of RCAN1.4 (α-
RCAN1.4) in response to VEGF-stimulation compared to the control LacZ. In all cases 
western blots detecting tubulin were carried out (α-tubulin) to show the differences 
observed in RCAN1.4 protein expression were not due to different amounts of protein 
in the samples (see appendix 14 for all western blot images used in quantification). B) 
Histogram shows data as mean ± S.E. of two independent experiments, n=5. Western 
blots were analysed using image J software (*** p ≤ 0.001).  
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5.3.3 Tube Formation of Endothelial Cells is Augmented by Ectopic 
          Expression of ID4
Tube formation both in the presence and absence of VEGF-stimulation was 
shown to be regulated by PMCA4. We therefore wanted to study if the inhibition
in tube formation observed in the presence of PMCA4 could be reversed by 
preventing the interaction between endogenous PMCA4 and calcineurin by 
over-expression of ID4.  HUVEC were infected with Ad-LacZ or Ad-ID4 and 
plated onto matrigel in medium 200 containing additional 2% FBS. Cells were 
incubated for 24 hours after which time they were fixed and images taken. The 
number of tubes in Ad-LacZ infected cells was set as 100% and the amount of 
tube formation in Ad-ID4 infected cells calculated as a percentage relative to 
this. Ectopic expression of ID4 significantly increased the amount of tube 
formation of endothelial cells by 23.23%, p ≤ 0.001 compared to the control (Fig. 
5.3.3) suggesting PMCA4 inhibition of tube formation is a result of its interaction
with calcineurin. 
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Fig. 5.3.3 Endothelial cell tube formation is increased by disruption of the 
interaction between PMCA4 and calcineurin. HUVEC were infected with Ad-LacZ or 
Ad-ID4 and plated onto matrigel in medium 200 supplemented with 2% FBS. Cells 
were incubated for 24 hours after which time images were taken and tube formation 
analysed using the Image J programme. Infection with Ad-ID4 significantly increased 
the number of tubes compared to the control LacZ. A) Representation of images taken 
and used for quantification (see appendix 15 for all images). B) Data plotted as mean ±
S.E. of two independent experiments, n=8 (*** p ≤ 0.001).  
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5.3.4 Over-Expression of ID4 Has No Effect on VEGF-Induced Erk1/2
         Activation 
Phosphorylation of Erk1/2, a MAPK protein involved in proliferation (Yu and 
Sato, 1999), was shown to be unaffected by over-expression or knockdown of 
PMCA4. We next wanted to confirm that the interaction between PMCA4 and 
calcineurin is not involved in the regulation of Erk1/2 activation and therefore 
proliferation. HUVEC were infected with Ad-LacZ or Ad-ID4 and after overnight 
serum starvation either left unstimulated or simulated with VEGF (25 ng/ml) for 
5 minutes. Western blot analysis using an antibody against phosphorylated 
Erk1/2 showed no significant difference between control and Ad-ID4 infected 
cells suggesting the interaction between PMCA4 and calcineurin has no effect 
on the activation of Erk1/2 and consequently proliferation (Fig. 5.3.4). Western 
blots detecting total levels of Erk1/2 were carried out to normalise the 
phosphorylated Erk1/2 values (Fig. 5.3.4). This data confirms the finding from 
the over-expression and knockdown studies that PMCA4 is not a regulator of 
Erk1/2 phosphorylation in response to VEGF-stimulation. 
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Fig. 5.3.4 VEGF-induced Erk1/2 phosphorylation is unaffected by over-
expression of the interaction domain of PMCA4 (428-651) (ID4). HUVEC cells were
infected with Ad-LacZ or Ad-ID4 and either unstimulated (-) or stimulated (+) with 
VEGF (25 ng/ml) for 5 minutes after overnight serum starvation. Western blot analysis 
using an antibody that detects phosphorylated Erk1/2 (WB: α-Phospho-Erk1/2) showed
no significant difference between control infected (LacZ) and cells over-expressing the 
interaction domain of PMCA4b that interacts with calcineurin (ID4) after normalisation 
to the value obtained for the density of bands for western blots detecting total Erk1/2 
(WB:α-Total-Erk1/2). A) Representative image of western blots used for analysis (see 




It has previously been reported that PMCA4 and calcineurin interact in HEK293 
cells. The interaction domain has further been mapped to the region 428-651 of 
PMCA4b, located in the large catalytic intracellular loop between 
transmembrane domain 4 and 5 (Buch et al, 2005). Additionally, in mammalian 
cells, in vitro over-expression of PMCA4 results in re-localisation of calcineurin 
from the cytoplasm to the membrane (Buch et al, 2005) and in neonatal rat 
cardiomyocytes increases the interaction with calcineurin in response to 
endothelin-1 (ET-1) stimulation. Furthermore, in vivo, an increase in association
between PMCA4 and calcineurin occurs in hearts of PMCA4 over-expressing 
mice in response to TAC stimulation (Wu et al, 2009). In human breast cancer 
MCF-7 cells PMCA2 has also been reported to interact with calcineurin via 
residues 462-684 of PMCA2, the equivalent domain to 428-651 in PMCA4 
(Holton et al, 2007). 
The functionality of the association between PMCA4 and calcineurin has been 
demonstrated in mammalian cells. Over-expression of the interaction domain of 
PMCA4 (428-651) reversed the inhibition of NFAT activity seen by PMCA4 
over-expression in HEK293 cells (Buch et al, 2005). Likewise, an increase in 
NFAT activity was observed in PMA/Ionophore-stimulated ZR-75-1 breast 
cancer cells with over-expression of the PMCA2 interaction region (462-684) 
(Baggott et al, 2012). This data implicates the interaction between the two 
proteins is essential for PMCAs inhibitory function of the calcineurin/NFAT 
pathway in mammalian cells.
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It should also be noted that PMCA4 and 2 interact with other proteins such as 
eNOS in endothelial cells. In mammalian cells the region of association has 
been mapped to the same residues as those involved in the interaction with 
calcineurin (462-684 and 428-651 for PMCA2 and PMCA4 respectively) (Holton
et al, 2010a). Over-expression of either PMCA4 or PMCA2 in endothelial cells 
resulted in inhibition of eNOS activity which could be reversed in the presence 
of the corresponding interaction domain for each PMCA isoform. However, it is 
not known if this is a result of disruption of the interaction with eNOS or 
calcineurin as they both bind to the same region of PMCA and calcineurin has 
been reported to be a regulator of eNOS activity (Holton et al, 2010a). In either 
case, it further demonstrates the role of the interaction in PMCAs regulation of 
partner proteins and their subsequent signalling pathways in mammalian cells.
In light of this data we decided to investigate the mechanism of PMCA4s 
inhibitory effect observed in this study on the calcineurin/NFAT pathway and 
VEGF-induced angiogenesis in endothelial cells by determining the relevance of
the interaction between PMCA4 and calcineurin on these processes. To do this 
we generated an adenovirus that successfully expressed the interaction domain
of PMCA4 (3xFlag-PMCA4b(428-651)) (ID4) in endothelial cells. Ectopic 
expression of the equivalent region of PMCA2b (462-684) in ZR-75-1 breast 
cancer cells results in reduction of membrane associated calcineurin, 
demonstrating the association of the two endogenous proteins is disrupted by 
this domain (Baggott et al, 2012), therefore, 3xFlag-PMCA4b(428-651) should 
disrupt the PMCA4/calcineurin interaction in endothelial cells. We found over-
expression of ID4 and consequent putative disruption of the interaction 
PMCA4b/calcineurin resulted in an up-regulation of NFAT-dependent reporter 
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activity. This data suggests PMCA4s inhibitory function of the calcineurin/NFAT 
pathway is via its interaction with calcineurin. In accordance with this data 
ectopic expression of ID4 also increased RCAN1.4 protein expression and tube 
formation which are both regulated by the calcineurin/NFAT pathway (Iizuka et 
al, 2004), implying the inhibition we observe in these processes in the presence 
of ectopic PMCA4 is a result of its interaction with calcineurin. Interestingly, 
Erk1/2 phosphorylation was unaffected by over-expression of ID4 which was 
similar to the results observed with ectopic expression and knockdown of 
PMCA4, further confirming this process is not regulated by PMCA4.
Our data indicates the calcineurin inhibition observed with ectopic PMCA4 is not
due to general calcium removal from the cytoplasm by the pump as the 
interaction domain acts as a competitor, binding to calcineurin but not 
interacting with wild-type PMCA4, therefore, it is unlikely to affect the calcium 
extrusion function of the endogenous pump and has no known calcium ejection 
properties itself (Baggott et al, 2012). If PMCA4-mediated down-regulation of 
calcineurin was due to general calcium clearance from the cell, inhibition of 
NFAT activation would still be seen in the presence of the interaction domain, 
however, we observe an increase in activity.  It should be noted, that in the case
of this study, even though we have demonstrated the interaction between 
PMCA4 and calcineurin to be essential for the inhibitory mechanism of PMCA4 
on calcineurin activity and angiogenesis in endothelial cells we have not 
identified the exact function of the association. For example, PMCA4 could 
prevent the interaction between calcineurin and NFAT by retaining calcineurin 
at the membrane maintaining it out of spatial contact with NFAT (Wu et al, 
2009) therefore attenuating NFAT dephosphorylation and further signalling via 
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this pathway. On the other hand, it has been hypothesised that the calcium 
extrusion function of PMCAs generates calcium microdomains at the 
membrane. Due to the association of the two proteins the calcium/calmodulin 
dependent calcineurin would be sequestered in a low calcium microenvironment
and its activity would consequently be inhibited (Holton et al, 2010b). In support 
of the calcium micro-environment model rather than the spatial separation 
hypothesis, NFAT activation in response to a constitutively active calcineurin, 
whose activity is independent of calcium/calmodulin, was not inhibited by 
ectopic expression of PMCA4b (Buch et al, 2005). Furthermore, Wu et al, 2009 
expressed a mutant PMCA4 pump that maintains only 15% of its calcium 
extrusion function in rat neonatal cardiomyocytes. This mutant only slightly 
reduced NFAT activity in response to phenylephrine-stimulation whereas over-
expression of the wild-type pump resulted in significant inhibition (Wu et al, 
2009). Both of these studies provide support for the calcium microdomain 
hypothesis as they demonstrate the importance of calcium sensitivity of the 
partner protein and the calcium removal function of PMCA4 for its inhibitory 
effect on the calcium-dependent interacting protein and consequently their 
signalling pathways. Even in the light of this data, our study does not definitively
demonstrate that the inhibition we observe on calcineurin activity is a result of 
its maintenance in a low calcium microenvironment generated by PMCA4. 
Further work would be of interest to elucidate the exact mechanism of PMCA4 




We have concluded that the interaction between PMCA4 and calcineurin is 
essential for its inhibitory effect on calcineurin/NFAT signalling and 
consequently the pro-angiogenic processes of angiogenesis regulated by this 
pathway, although we have not identified the exact role of the interaction. These
results are potentially far reaching in the further understanding of the regulation 
of angiogenesis and the potential of PMCA4 as a therapeutic target in 
pathological angiogenesis, as disruption of the interaction can alter the 





6.1 Further Investigation Into the Regulation of Angiogenesis by PMCA4b
In this study we have identified PMCA4 as an inhibitor of VEGF-induced 
calcineurin/NFAT signalling and consequently angiogenic processes regulated 
by this pathway in endothelial cells. The importance of this finding is far 
reaching due to the plethora of diseases that involve an angiogenic mechanism 
for progression. Future investigation into the role of PMCA4 in angiogenesis, 
such as studies in in vivo angiogenic models, would be extremely beneficial to 
further determine the relevance of PMCA4 and its potential as a therapeutic 
target for pathological angiogenesis. 
6.1.1 Role of PMCA4 in In Vivo Angiogenesis
This project contains an in vivo matrigel study kindly carried out by Professor 
Redondo’s research group at the Department of Vascular Biology and 
Inflammation, Centro Nacional de Investigaciones Cardiovasculares CNIC, 
Madrid, Spain and demonstrated the inhibitory function of PMCA4 over-
expression on in vivo VEGF-induced functional blood vessel formation. It would 
be of relevance to carry out a similar experiment in PMCA4 knockout mice to 
confirm this result. It is hypothesised injection of VEGF-containing matrigel into 
PMCA4-/- will result in an increase in functional blood vessel formation 
compared to the wild-type (the opposite result to that reported in this thesis for 
matrigel over-expressing PMCA4).
Additionally, it would be highly beneficial to study the effect of PMCA4 on 
pathological in vivo angiogenic models which are of clinical relevance and will 
further ascertain the therapeutic potential of PMCA4. The two in vivo 
angiogenesis models that are currently established and could be used to 
210
substantiate the significance of PMCA4 in pathological angiogenesis are; the 
induced diabetic retinopathy and hind limb ischemia models which represent 
pathologies where the formation of blood vessels is altered by excessive and 
insufficient angiogenesis respectively. As we have demonstrated in this study 
PMCA4 is a negative-regulator of angiogenesis, we hypothesise over-
expression of PMCA4 would reduce angiogenesis and therefore alleviate 
pathogenesis in the diabetic retinopathy model. Over-expression of PMCA4 
could be achieved by local delivery of an adenovirus encoding the PMCA4 
protein under the regulation of an endothelial specific promoter. 
In the case of the hind limb ischemia model it would be interesting to reduce 
PMCA4 activity as we have shown in this project knockdown or knockout of 
PMCA4 enhances angiogenesis. The same result can be achieved by 
disruption of the interaction between endogenous PMCA4 and calcineurin by 
ectopic expression of the PMCA4 interaction region (428-651). 
6.1.2 Recovery Experiments with PMCA4
We have demonstrated that knockout of PMCA4 in MLEC or expression of the 
interaction domain of PMCA4 (to reduce its association with calcineurin) in 
HUVEC results in an increase in RCAN1.4 protein expression in response to 
VEGF-stimulation. It has been reported in ZR-75-1 cells expression of the 
interaction region of PMCA2 reduces cell viability which can be recovered when
PMCA2 is co-ectopically expressed to re-establish its interaction with 
calcineurin and therefore inhibit its activity (Baggott et al, 2012).
To further confirm that PMCA4 is an inhibitor of angiogenesis, recovery 
experiments similar to the one carried out by Baggott et al, 2012 can be used in 
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the above two models by adenovirus-mediated over-expression of PMCA4 to 
ascertain if we restore inhibition of RCAN1.4 protein expression. We predict that
transfection of PMCA4-/- MLEC with an adenovirus encoding PMCA4 or co-
expression of the interaction domain and PMCA4 in HUVEC will recover 
inhibition of VEGF-induced RCAN1.4 protein expression. 
6.2 Investigating the Significance of Other PMCA Isoforms in the   
Regulation of Calcineurin/NFAT-Dependent Angiogenesis
It has previously been shown PMCA4 is expressed and interacts with 
calcineurin in endothelial cells (Holton et al, 2010a).We have demonstrated in 
this thesis that PMCA4 is a negative-regulator of calcineurin and the calcineurin/
NFAT pathway. This results in concomitant down-regulation of angiogenic 
processes regulated by this pathway. Other PMCA isoforms such as PMCA1 
are expressed and also interact with calcineurin in endothelial cells (Holton et 
al, 2010a). Therefore, further work in ascertaining the significance of other 
isoforms in the regulation of calcineurin and consequently angiogenesis is of 
particular interest. 
Dr Armesilla’s laboratory is currently investigating the effect of PMCA1 
knockdown on the regulation of the calcineurin/NFAT pathway and 
angiogenesis. It has been suggested that the presence of more than one 
isoform of PMCA can result in redundancy in the role of a single isoform as an 
inhibitor. For example, Holton et al, 2010a established knockdown of PMCA4 in 
endothelial cells by shRNA had no effect on basal or acetylcholine-induced NO 
production suggesting loss of one isoform of PMCA is compensated for by the 
presence of alternative isoforms (Holton et al, 2010a). In relation to our data, 
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knockdown or knockout of PMCA4 resulted in an increase in angiogenic 
processes, however, it is unknown if other isoforms present are partially 
compensating for the absence of PMCA4. Knockdown of multiple isoforms 
could potentially further enhance the increase in angiogenesis we observed with
loss of PMCA4 expression alone.PMCA1 and 4 are the major isoforms 
expressed in endothelial cells, therefore the role of PMCA1 in the regulation of 
VEGF-induced angiogenesis needs to be established. This can be 
accomplished by knockdown studies similar to that carried out for PMCA4. If 
PMCA1 is shown to be a regulator of the calcineurin/NFAT pathway and 
consequently angiogenesis it would be interesting to study simultaneous 
knockdown of PMCA1 and PMCA4. Unfortunately PMCA1 knockout studies and
therefore in vivo models pose a challenge as loss of PMCA1 is embryonic 
lethal. A conditional knockout of PMCA1 would need to be generated. It should 
be taken into consideration that the localisation of PMCAs has been shown to 
vary at the membrane. For example, it has been reported in pig cerebellum 
synaptic plasma membranes that only the PMCA4 isoform localises to lipid rafts
(Sepúlveda et al, 2006). As lipid rafts have been proposed to be the site of 
signalling complex formation (Simons and Toomre, 2000) it suggests PMCA4 
could regulate signalling complexes produced here. In support of this a recent 
study has reported disruption of lipid rafts in HEK293 cells prevented the 
interaction between PMCA4 and nNOS (Duan et al, 2013). Schuh et al, 2001 
have previously shown that the interaction between the two proteins inhibits 
nNOS activity (Schuh et al, 2001). Together this data implies the localisation of 
PMCA4s in lipid raft fractions of the membrane is required for its regulation of 
signalling pathways such as nNOS. As PMCA1 has been shown to not localise 
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in lipid rafts (Sepúlveda et al, 2006) there is the possibility it may not be a 
regulator of signalling pathways. Therefore it would be very interesting to 
determine the exact involvement of PMCA1 in the regulation of the calcineurin/
NFAT pathway and consequently angiogenesis in endothelial cells. 
6.3 Conclusion
The findings of this study are far reaching, not only demonstrating PMCA4 as a 
regulator of signalling pathways in endothelial cells, but also identifying a novel 
role for this protein in the regulation of angiogenesis. Further study into the role 
of PMCA4 and potentially other isoforms in the regulation of signalling pathways
in endothelial cells, provides a potential endogenous therapeutic target for the 
regulation of pathological angiogenesis that could benefit the treatment of a 
multitude of diseases. 
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Concluding Remarks
This thesis has clearly established the following:
1- PMCA4 is a negative-regulator of the calcineurin/NFAT pathway in 
endothelial cells in response to VEGF-stimulation.
2- PMCA4 inhibits the calcineurin/NFAT dependent pro-angiogenic proteins
RCAN1.4 and Cox-2 at both the protein and mRNA expression levels 
after stimulation with VEGF, but does not affect the constitutively 
expressed and calcineurin-independent Cox-1 protein.
3- Endothelial cell migration is inhibited by ectopic expression of PMCA4 
and upregulated by suppression of PMCA4 expression.
4- In vitro and in vivo endothelial cell tube formation is inhibited by over-
expression of PMCA4 in response to VEGF-signalling.
5- VEGF- induced endothelial cell proliferation is unaffected by ectopic 
expression of PMCA4.
6- Over-expression or knockdown of PMCA4 does not affect the 
phosphorylation of Erk1/2.
7- Disruption of the interaction between PMCA4 and calcineurin in 
endothelial cells by over-expression of the interaction region of PMCA4b 
(428-651) (ID4), increases calcineurin/NFAT signalling and consequently
RCAN1.4 protein expression and in vitro tube formation, in response to 
VEGF-stimulation.
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Homo sapiens ATPase, Ca++ transporting, plasma membrane 4 (ATP2B4), transcript 
variant 2, mRNA 
Sequence ID: ref|NM_001684.4|Length: 8753Number of Matches: 1
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Gene-associated gene details
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Range 1: 2179 to 2852GenBank  Graphics   Next Match Previous Match First Match 
Alignment statistics for match #1
Score Expect Identities Gaps Strand Frame
1245 bits(674) 0.0() 674/674(100%) 0/674(0%) Plus/Plus
Features: 
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             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  2179  GCTGTCACCATCTCACTGGCCTACTCTGTGAAGAAAATGATGAAAGACAATAACCTAGTA  2238
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    103 ATG GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAC ATC GAT TAC AAG GAT GAC 
      1 Met Asp Tyr Lys Asp His Asp Gly Asp Tyr Lys Asp His Asp Ile Asp Tyr Lys Asp Asp 
    163 GAT GAC AAG CTT GCG GCC GCG AAT TCC GCT GTC ACC ATC TCA CTG GCC TAC TCT GTG AAG 
     21 Asp Asp Lys Leu Ala Ala Ala Asn Ser Ala Val Thr Ile Ser Leu Ala Tyr Ser Val Lys 
    223 AAA ATG ATG AAA GAC AAT AAC CTA GTA CGG CAC TTG GAT GCT TGT GAG ACC ATG GGC AAC 
     41 Lys Met Met Lys Asp Asn Asn Leu Val Arg His Leu Asp Ala Cys Glu Thr Met Gly Asn 
    283 GCC ACC GCC ATC TGC TCT GAT AAG ACA GGC ACG TTG ACC ATG AAC CGC ATG ACT GTG GTA 
     61 Ala Thr Ala Ile Cys Ser Asp Lys Thr Gly Thr Leu Thr Met Asn Arg Met Thr Val Val 
    343 CAA GCT TAT ATT GGG GGC ATC CAT TAC CGT CAA ATC CCA AGC CCT GAT GTC TTC CTG CCC 
261
     81 Gln Ala Tyr Ile Gly Gly Ile His Tyr Arg Gln Ile Pro Ser Pro Asp Val Phe Leu Pro 
    403 AAA GTC CTG GAC CTC ATT GTC AAT GGC ATT TCT ATC AAC AGT GCT TAT ACC TCC AAG ATT 
    101 Lys Val Leu Asp Leu Ile Val Asn Gly Ile Ser Ile Asn Ser Ala Tyr Thr Ser Lys Ile 
    463 CTG CCT CCA GAG AAG GAG GGA GGC CTG CCT CGG CAG GTG GGC AAC AAG ACC GAG TGT GCT 
    121 Leu Pro Pro Glu Lys Glu Gly Gly Leu Pro Arg Gln Val Gly Asn Lys Thr Glu Cys Ala 
    523 CTG CTA GGC TTT GTC ACA GAT CTG AAG CAG GAT TAT CAG GCT GTG CGT AAT GAA GTG CCC 
    141 Leu Leu Gly Phe Val Thr Asp Leu Lys Gln Asp Tyr Gln Ala Val Arg Asn Glu Val Pro 
    583 GAG GAG AAG CTC TAC AAG GTG TAC ACC TTT AAC TCA GTG CGC AAG TCA ATG AGC ACC GTC 
    161 Glu Glu Lys Leu Tyr Lys Val Tyr Thr Phe Asn Ser Val Arg Lys Ser Met Ser Thr Val 
    643 ATC AGG AAT CCC AAC GGT GGC TTC CGT ATG TAC AGC AAG GGC GCC TCT GAG ATC ATC TTG 
    181 Ile Arg Asn Pro Asn Gly Gly Phe Arg Met Tyr Ser Lys Gly Ala Ser Glu Ile Ile Leu 
    703 CGC AAG TGT AAT CGA ATC CTG GAC CGG AAA GGG GAA GCA GTG CCA TTC AAG AAT AAA GAC 
    201 Arg Lys Cys Asn Arg Ile Leu Asp Arg Lys Gly Glu Ala Val Pro Phe Lys Asn Lys Asp 
    763 AGA GAT GAT ATG GTA CGC ACT GTC ATC GAG CCC ATG GCC TGT GAT GGA CTC CGG ACT ATC 
    221 Arg Asp Asp Met Val Arg Thr Val Ile Glu Pro Met Ala Cys Asp Gly Leu Arg Thr Ile 
    823 TGC ATA GCT TAC CGG GAC TTC GAT GAC ACA GAG CCC TCT TGA 
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APPENDIX 11: Images used to quantify the amount of tube formation with 
knockdown of PMCA4. HUVEC were transfected with si-RNA corresponding to 
PMCA4 (si-PMCA4) or non-target (si-NT), plated onto matrigel and stimulated with 2% 
FBS or 2% FBS with VEGF (50 ng/ml). Images were taken after 24 hours incubation 
and the number of tubes counted. The value obtained for si-NT 2% FBS (control) was 
set as 100% and all other values calculated as a percentage relative to this value. 
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APPENDIX 15: Images 
used
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Experiment 5 Experiment 6
Ad-ID4Ad-LacZAd-ID4Ad-LacZ
to quantify the amount of tube formation with over-expression of the interaction 
domain of PMCA4 (428-651) (ID4). HUVEC were infected with Ad-LacZ or Ad-ID4 and
seeded onto matrigel in 2% serum. After 24 hours cells were fixed and images taken. 
The amount of tube formation was calculated by counting branching points and the 
value obtained for Ad-LacZ set as 100%. Other values were calculated as a 
percentage relative to this control.  
266
